---
document_datetime: 2025-12-18 09:21:04
document_pages: 132
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/breyanzi-vr-0000265024-epar-assessment-report-variation_en.pdf
document_name: breyanzi-vr-0000265024-epar-assessment-report-variation_en.pdf
version: success
processing_time: 185.0908167
conversion_datetime: 2025-12-27 22:31:36.998369
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
Address for visits and deliveries

<!-- image -->

16 October 2025 EMADOC-1700519818-2456442 Committee for Advanced Therapies (CAT) Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Breyanzi

International non-proprietary name: Lisocabtagene maraleucel / Lisocabtagene maraleucel

Procedure No. EMA/VR/0000265024

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

●

●

Refer to www.ema.europa.eu/how-to-find-us

Send us a question

Go to www.ema.europa.eu/contact

Telephone

+31 (0)88 781 6000

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                            | ............................................. 8                                                         |
|-----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ..................................................................................8  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product                                                                    | .......................................................8                                                |
| 2. Scientific discussion                                                                                              | ............................................................................... 9                       |
| 2.1. Introduction                                                                                                     | ......................................................................................................9 |
| 2.1.1. Problem statement                                                                                              | ..........................................................................................9             |
| 2.1.2. About the product                                                                                              | .........................................................................................11             |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                             | advice .....11                                                                                          |
| 2.1.4. General comments on compliance with GCP                                                                        | ......................................................12                                                |
| 2.2. Quality aspects                                                                                                  | ................................................................................................12      |
| 2.3. Non-clinical aspects..........................................................................................14 |                                                                                                         |
| 2.3.1. Ecotoxicity/environmental risk assessment........................................................14            |                                                                                                         |
| 2.4. Clinical aspects                                                                                                 | ................................................................................................14      |
| 2.4.1. Introduction                                                                                                   | .................................................................................................14     |
| 2.4.2. Pharmacokinetics                                                                                               | ..........................................................................................15            |
| 2.4.3. Pharmacodynamics........................................................................................27     |                                                                                                         |
| 2.4.4. Discussion on clinical pharmacology                                                                            | .................................................................29                                     |
| 2.4.5. Conclusions on clinical pharmacology                                                                           | ...............................................................31                                       |
| 2.5. Clinical efficacy                                                                                                | ................................................................................................31      |
| 2.5.1. Dose response study(ies)                                                                                       | ...............................................................................31                       |
| 2.5.2. Main study                                                                                                     | ...................................................................................................32   |
| 2.5.3. Discussion on clinical efficacy                                                                                | ..........................................................................87                            |
| 2.5.4. Conclusions on the clinical efficacy...................................................................94      |                                                                                                         |
| 2.6. Clinical safety                                                                                                  | ..................................................................................................94    |
| 2.6.1. Discussion on clinical safety ..........................................................................       | 114                                                                                                     |
| 2.6.2. Conclusions on clinical safety ........................................................................        | 117                                                                                                     |
| 2.6.3. PSUR cycle .................................................................................................   | 118                                                                                                     |
| 2.7. Risk management plan....................................................................................         | 118                                                                                                     |
| 2.8. Update of the Product information ....................................................................           | 126                                                                                                     |
| 2.8.1. User consultation.........................................................................................     | 126                                                                                                     |
| 3. Benefit-Risk Balance............................................................................127                |                                                                                                         |
| 3.1. Therapeutic Context .......................................................................................      | 127                                                                                                     |
| 3.1.1. Disease or condition.....................................................................................      | 127                                                                                                     |
| 3.1.2. Available therapies and unmet medical need                                                                     | ................................................... 127                                                 |
| 3.1.3. Main clinical studies .....................................................................................    | 128                                                                                                     |
| 3.2. Favourable effects..........................................................................................     | 128                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects                                                           | ......................................... 128                                                           |
| 3.4. Unfavourable effects.......................................................................................      | 129                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                         | ...................................... 129                                                              |
| 3.6. Effects Table                                                                                                    | ................................................................................................. 130   |
| 3.7. Benefit-risk assessment and discussion                                                                           | ............................................................. 131                                       |
| 3.7.1. Importance of favourable and unfavourable effects                                                              | .......................................... 131                                                          |
| 3.7.2. Balance of benefits and risks.........................................................................         | 131                                                                                                     |
| 3.7.3. Additional considerations on the benefit-risk balance                                                          | ........................................ 131                                                            |

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions  ................................................................................................... 131 4. Recommendations ...............................................................................131 5. EPAR changes  ......................................................................................132

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                                                                     |
|----------------|----------------------------------------------------------------------------------------------------------------|
| 1L             | having received no prior therapy for the disease under study (first-line treatment)                            |
| 2L             | having received one line of prior therapy for the disease under study (second-line treatment)                  |
| 2L+            | having received 1 or more lines of prior therapy for the disease under study (second-line or later treatment)  |
| 3L             | having received two lines of prior therapy for the disease under study (third-line treatment)                  |
| 3L+            | having received two or more lines of prior therapy for the disease under study (third-line or later treatment) |
| 4L             | having received three lines of prior therapy for the disease under study (fourth-line treatment)               |
| ADR(s)         | adverse drug reaction(s)                                                                                       |
| AE(s)          | adverse event(s)                                                                                               |
| AESI(s)        | adverse event(s) of special interest                                                                           |
| ATA            | anti-therapeutic antibody                                                                                      |
| AUC(0-28)      | area under the blood concentration-time curve from time zero to 28 days after dosing                           |
| BMS            | Bristol-Myers Squibb Company                                                                                   |
| BOR            | best overall response                                                                                          |
| BTKi           | Bruton's tyrosine kinase inhibitor                                                                             |
| CAR            | chimeric antigen receptor                                                                                      |
| CAT            | Committee for Advanced Therapies                                                                               |
| CHMP           | Committee for Medicinal Products for Human Use                                                                 |
| CI             | confidence interval                                                                                            |
| Cmax           | maximum (or peak) concentration                                                                                |
| CNS            | central nervous system                                                                                         |
| COVID-19       | coronavirus disease of 2019                                                                                    |
| CR             | complete response                                                                                              |
| CrCl           | creatinine clearance                                                                                           |
| CRP            | C-reactive protein                                                                                             |
| CRS            | cytokine release syndrome                                                                                      |
| CSR            | clinical study report                                                                                          |
| CT             | computed tomography                                                                                            |
| CV%            | geometric mean                                                                                                 |
| Cy             | cyclophosphamide                                                                                               |
| DBL            | Data Base Lock                                                                                                 |
| DL(1, 2, 3)    | dose level (1, 2, 3)                                                                                           |
| DL1D           | dose level 1 (50 × 10 6 CAR+ T cells) 2-dose regimen                                                           |
| DL1S           | dose level 1 (50 × 10 6 CAR+ T cells) single-dose regimen                                                      |
| DL2S           | dose level 2 (100 × 10 6 CAR+ T cells) single-dose regimen                                                     |
| DLBCL          | diffuse large B cell lymphoma                                                                                  |
| DLT            | dose limiting toxicity                                                                                         |
| DOR            | duration of response                                                                                           |
| EAS            | (Liso-cel-treated) efficacy analysis set                                                                       |
| eCOA           | electronic clinical outcomes assessment                                                                        |
| ECOG PS        | Eastern Cooperative Oncology Group Performance Status (score)                                                  |

<div style=\"page-break-after: always\"></div>

| Abbreviation     | Definition                                                                 |
|------------------|----------------------------------------------------------------------------|
| eCRF             | electronic Case Report Form                                                |
| EGFRt            | truncated epidermal growth factor receptor                                 |
| EMA              | European Medicines Agency                                                  |
| EORTC            | European Organization for Research and Treatment of Cancer                 |
| EOS              | end of study                                                               |
| EQ-5D-5L         | EuroQol 5-Dimension 5-Level (health-related quality of life questionnaire) |
| ESMO             | European Society for Medical Oncology                                      |
| EU               | European Union                                                             |
| EuroQol          | an instrument for measuring quality of life                                |
| FL               | follicular lymphoma                                                        |
| FL3B             | follicular lymphoma Grade 3B                                               |
| GCP              | Good Clinical Practice                                                     |
| GM-CSF           | granulocyte-macrophage colony-stimulating factor                           |
| GVHD             | graft-versus-host disease                                                  |
| HEOR             | Health Economics and Outcomes Research                                     |
| HGBCL            | high-grade B-cell lymphoma                                                 |
| HLH              | hemophagocytic lymphohistiocytosis                                         |
| HR               | hazard ratio                                                               |
| HRQoL            | health-related quality of life                                             |
| HSCT             | hematopoietic stem cell transplantation                                    |
| ICANS            | immune cell-associated neurotoxicity syndrome                              |
| ICH              | International Council for Harmonisation                                    |
| ICU              | intensive care unit                                                        |
| IEC              | Independent Ethics Committee                                               |
| IFN- γ           | interferon-gamma                                                           |
| IgG4             | immunoglobulin G4                                                          |
| iiNT             | investigator identified neurotoxicity                                      |
| IL- (2, 4, 5, 6) | interleukin- (2, 4, 5, 6)                                                  |
| IRB              | Institutional Review Board                                                 |
| IRC              | Independent Review Committee                                               |
| IRR              | infusion-related reaction                                                  |
| ITT              | intention-to-treat (analysis population)                                   |
| IV               | intravenous                                                                |
| K-M              | Kaplan-Meier (time-to-event estimation method)                             |
| LBCL             | large B-cell lymphoma                                                      |
| LDC              | lymphodepleting chemotherapy                                               |
| LDH              | lactate dehydrogenase                                                      |
| LLOD             | lower limit of detection                                                   |
| LPLV             | last patient last visit                                                    |
| LTFU             | long-term follow-up                                                        |
| LVEF             | left ventricular ejection fraction                                         |
| MAIC             | matching-adjusted indirect comparison                                      |
| MAS              | macrophage activation syndrome                                             |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                                                                  |
|----------------|---------------------------------------------------------------------------------------------|
| MCL            | mantle cell lymphoma                                                                        |
| mCRM           | modified continuous reassessment method                                                     |
| MDS            | myelodysplastic syndrome                                                                    |
| NA             | not available                                                                               |
| NHL            | non-Hodgkin lymphoma                                                                        |
| NOS            | not otherwise specified                                                                     |
| NR             | not reached                                                                                 |
| NT             | neurotoxicity                                                                               |
| OR             | odds ratio                                                                                  |
| ORR            | overall response rate                                                                       |
| OS             | overall survival                                                                            |
| PAS            | primary analysis set (analysis population)                                                  |
| PD             | progressive disease or disease progression                                                  |
| PET            | positron emission tomography                                                                |
| PFS            | progression-free survival                                                                   |
| PK             | pharmacokinetic(s)                                                                          |
| PMBCL          | primary mediastinal B-cell lymphoma                                                         |
| PR             | partial response                                                                            |
| PRO            | patient-reported outcome                                                                    |
| PT             | preferred term                                                                              |
| QLQ-C30        | (EORTC) Quality of Life Questionnaire - Core measure 30 Items                               |
| QoL            | quality of life                                                                             |
| qPCR           | quantitative polymerase chain reaction                                                      |
| R/R            | relapsed or refractory                                                                      |
| R-BAC          | rituximab, bendamustine, and cytarabine (combination regimen)                               |
| R-CHOP         | rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (combination regimen) |
| SAA            | serum amyloid A                                                                             |
| SAE(s)         | serious adverse event(s)                                                                    |
| SAP            | statistical analysis plan                                                                   |
| SCE            | Summary of Clinical Efficacy                                                                |
| scFv           | single-chain variable fragment                                                              |
| SCP            | Summary of Clinical Pharmacolgy                                                             |
| SCS            | Summary of Clinical Safety                                                                  |
| SD             | standard deviation                                                                          |
| SLR            | systematic literature review                                                                |
| sMIPI          | simplified MCL International Prognostic Index                                               |
| smPC           | Summary of Product Characteristics                                                          |
| SOC            | system organ class                                                                          |
| SPD            | sum of the products of the perpendicular diameters                                          |
| SPM            | second primary malignancy                                                                   |
| T2V            | type 2 variation                                                                            |
| TEAE(s)        | treatment emergent adverse event(s)                                                         |
| tFL            | DLBCL transformed from follicular lymphoma                                                  |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                        |
|----------------|---------------------------------------------------|
| TLS            | tumor lysis syndrome                              |
| Tmax           | time at which maximum concentration (Cmax) occurs |
| TNE            | transplant non-eligible                           |
| UK             | United Kingdom                                    |
| US             | United States                                     |
| VAS            | visual analog scale                               |
| WHO            | World Health Organization                         |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 07 April 2025 an application for a group of variations.

The following changes were proposed:

| Variation(s) requested   | Variation(s) requested                                                              | Type              |
|--------------------------|-------------------------------------------------------------------------------------|-------------------|
| B.II.d.1.e               | B.II.d.1.e Change outside the approved specifications limits range                  | Variation type II |
| C.I.6.a                  | C.I.6.a Addition of a new therapeutic indication or modification of an approved one | Variation type II |

A grouped application comprised of two Type II variations, as follows:

- Type II (C.I.6): Extension of indication to include the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor for BREYANZI, based on results from the pivotal Study 017001 MCL Cohort (TRANSCEND-NHL-001); this is a Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL). As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package leaflet is updated in accordance. Version 7.0 of the RMP was also submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the list of local representatives in the Package Leaflet.
- Type II (B.II.d.1.e): To modify a specification limit for the CD8+ drug product component, Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0448/2023 on the granting of a (product-specific) waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Scientific advice

The MAH did not seek Scientific Advice from the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Concetta Quintarelli

Co-Rapporteur:  Claire Beuneu

EMADOC-1700519818-2456442

<div style=\"page-break-after: always\"></div>

| Timetable                                                                              | Actual dates      |
|----------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                        | 7 April 2025      |
| Start of procedure:                                                                    | 26 April 2025     |
| CAT Rapporteur's preliminary assessment report circulated on                           | 20 June 2025      |
| PRAC Co-Rapporteur's preliminary assessment report circulated on                       | 26 June 2025      |
| CAT Co-Rapporteur's preliminary assessment circulated on                               | 2 July 2025       |
| Joint Rapporteurs' updated assessment report circulated on                             | 15 July 2025      |
| Request for supplementary information and extension of timetable adopted by the CAT on | 18 July 2025      |
| MAH's responses submitted to the CAT/CHMP on                                           | 11 August 2025    |
| CAT Rapporteurs' preliminary assessment report on the MAH's responses circulated on    | 17 September 2025 |
| Joint Rapporteur's updated assessment report on the MAH's responses circulated on      | 6 October 2025    |
| CAT opinion                                                                            | 9 October 2025    |
| CHMP opinion                                                                           | 16 October 2025   |
| The CAT/CHMP adopted a report on similarity of Breyanzi with Tecartus on               | 9/16 October 2025 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Mantle cell lymphoma (MCL) is an aggressive and relatively uncommon form of non-Hodgkin lymphoma (NHL). MCL is considered incurable with standard chemotherapy and is characterised by relapsing/remitting disease course, with progressive chemoresistance and poor long-term survival (see e.g. Armitage JO et al, NEJM 2022). Results from clinical trials showed that the median duration of remission from initial diagnosis is approximately 5 years, with median OS ranging from 3 to 10 years (see e.g. Vico C et al, Br J Haematol 2019).

## Claimed therapeutic indication

Breyanzi is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.

## Epidemiology

MCL accounts for 3% to 7% of malignant non-Hodgkin lymphomas in Western Europe. The annual incidence of MCL has increased in recent decades to 1-2 cases per 100,000 individuals, occurring more commonly among older adults (median age at diagnosis is 67-68 years). MCL is characterised by a

<div style=\"page-break-after: always\"></div>

striking sex imbalance, with approximately 70% of all cases reported in men, and is more common in ethnic white individuals compared to individuals of African ancestry (see Teras LR et al, CA Caner j Clin 2016; Sant M et al, Blood 2010; Smith A et al, Br J Cancer 2011).

## Biologic features

MCL is characterized by a specific chromosomal translocation, t(11;14), that results in Cyclin D1 overexpression in pre-B cells, and the transcription factor SOX11 is expressed in more than 90% of all cases. MCL cells exhibit increased replication rates and resistance to apoptosis, driven, respectively, by Cyclin D1 and Bcl-2 overexpression. Cytologic subtypes of nodular MCL include classic, pleomorphic and the blastoid MCL. The pleomorphic and blastoid morphologies are characterised by an aggressive clinical behaviour. Other high-risk biological features associated with a negative impact on prognosis are the presence of TP53 mutations/del17p, high tumor proliferation index (measured by Ki-67), high sMIPI scores, refractoriness to upfront therapy, and secondary CNS involvement.

## Clinical presentation, diagnosis prognosis

The clinical presentation of MCL is heterogeneous and can include the presence of enlarged and painless superficial lymph nodes and lymphocytosis at routine analysis; sometimes, large (mostly asymptomatic) abdominal masses may occur, while the presence of constitutional symptoms is less frequent compared to other aggressive forms of NHL. MCL is usually widely disseminated at the time of diagnosis and could involve the spleen or the bone marrow. Involvement of other 'extra-lymphatic' organs is not uncommon, with the gastrointestinal tract and the kidney being preferential sites. Involvement of the central nervous system may also occur, especially in aggressive forms.

A leukemic, non-nodal form of MCL with little or no expression of SOX11 has also been described. Nonnodal MCL is generally asymptomatic and is mainly characterised by the involvement of peripheral blood, bone marrow and spleen. Compared to nodal MCL, non-nodal MCL has an indolent clinical behaviour and favourable prognosis.

## Management

No curative options exist for patients with R/R MCL, with the exception of allogeneic haematopoietic stem cell transplant, which is limited to a subset of younger and fitter patients with a suitable donor. Most patients require multiple lines of salvage therapy in their lifetime. Outcomes progressively worsen after each line of therapy, with a median PFS and OS of 4.0 years and 9.7 years, respectively, in the 1 line of therapy, and 5.0 months and 14.4 months, respectively, in the 4th line of therapy.

As per ESMO guidelines, the Bruton tyrosine kinase inhibitors (BTKis) are the preferred option after failure of upfront treatment in MCL. Ibrutinib, treatment with the covalent BTKi ibrutinib, initially approved in the EU on the basis of results from a single-arm Phase 2 study, showed PFS superiority vs. temsirolimus (HR 0.43 [95% CI: 0.32, 0.58]; P &lt; 0∙0001), with a median PFS of 14.6 months (95% CI 10.4,NE) vs 6.2 months (95% CI: 4.2, 7.9) with temsirolimus. The ORR assessed by IRC was also significantly higher for ibrutinib (72%) than for temsirolimus (40%, P &lt;0.0001). Ibrutinib and additional covalent BTKi have shown to improve outcomes in R/R MCL; however, development of resistance or intolerance to covalent BTKi therapies is common, typically occurring within 18 to 24 months.

There is no single standard-of-care in the post-BTKi setting, the optimal approach/sequence to treat R/R MCL is yet to be defined and there is lack of data comparing the available treatment options in a randomized controlled fashion. The treatment choice for R/R MCL patients is guided by age, performance status, comorbidities, and prior therapy. Treatment options in the EU include

<div style=\"page-break-after: always\"></div>

temsirolimus, lenalidomide and bortezomib. Both temsirolimus and lenalidomide are approved for the treatment of R/R MCL but showed limited efficacy (ORR in the range 22.2% to 40.0%, CRR in the range 3% to 4.7%).  Bortezomib is indicated in combination with rituximab, cyclophosphamide, doxorubicin and prednisone in patients with untreated MCL and those who are unsuitable for haematopoietic stem cell transplant (HSCT), based on its superiority vs R-CHOP, but has limited efficacy as monotherapy in the R/R setting (ORR 33%, CR rate 8%). Temsirolimus, lenalidomide and bortezomib were all licensed before covalent BTKi entered clinical practice, and therefore limited data are available on their efficacy in the post-BTKi setting. Chemoimmunotherapy regimens (e.g. rituximab bendamustine ± cytarabine) are also options that have been associated with high response rates (up to 83%) but toxicity remains critical and survival improvements are limited.

Recently, 2 additional agents have been granted conditional marketing authorizations (CMA) in EU for the treatment of R/R MCL in the post-BTKi setting:

- Brexucabtagene autoleucel (KTE-X19; Tecartus; brexu-cel), an autologous CD19-directed CAR T-cell therapy that received a conditional marketing authorization in EU on 14-Dec-2020 for the treatment of R/R MCL after ≥ 2 lines of systemic therapy, including a BTKi, based on the single-arm ZUMA-2 study. Treatment with brexu-cel resulted in high rates of deep and durable responses (ORR 91%, CRR 68%, median DOR 28.2 months), yet non-negligible toxicity was also observed (Grade ≥3 AEs 98.5%; Grade ≥3 CRS 13%, Grade ≥3 CART -related encephalopathy syndrome 32%, Grade ≥3 infections 30%).
- Pirtobrutinib (Jaypirca), a non-covalent BTKi, was granted a conditional marketing authorization in EU on 31-Oct-2023 for the treatment of adults with R/R MCL who have been previously treated with a BTKi, based on the single-arm BRUIN study. Results from the registrational trial showed an ORR of 56.7% (CRR 18.9%) and a median DoR of 17.61 months.

## 2.1.2. About the product

Lisocabtagene maraleucel (Breyanzi; JCAR017; liso-cel) is an advanced therapy medicinal product consisting of autologous CD4+ and CD8+ T cells that have been transduced using a replicationincompetent, self-inactivating lentiviral vector encoding a CD19-specific chimeric antigen receptor (CAR). The CD19-specific CAR contains a murine single chain variable fragment binding domain (FMC63) and the 41BB and CD3ζ chain signalling domains. Breyanzi is administered as separate infusions consisting of a 1:1 ratio of CD4+ and CD8+ cell components.

Breyanzi is already approved in the EU for the treatment of adult patients with:

- DLBCL, HGBCL, PMBCL and FL3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy
- relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy
- relapsed or refractory R/R FL after 2 or more lines of systematic therapy.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Liso-cel is being developed for the treatment of patients with B-cell malignancies as monotherapy and in combination with other anticancer agents. In particular, the primary efficacy and safety data to support the proposed indication in R/R MCL are from the pivotal Study 017001 MCL Cohort.

<div style=\"page-break-after: always\"></div>

Study 017001 is complete. The Final Analysis of the MCL Cohort is based on the LPLV on 16 -May-2024 data cutoff, which provides 24-months of follow-up with all subjects who completed the study or discontinued earlier.

No scientific advice was requested to the CHMP for the development of liso-cel in the MCL indication.

## 2.1.4. General comments on compliance with GCP

The MAH stated that clinical trials included in this submission were performed in accordance with the principles of Good Clinical Practice, as defined by the International Conference on Harmonization (ICH). The clinical trials carried out outside the European Union meet the ethical requirements of Directive 2001/20/EC.

## 2.2. Quality aspects

## Introduction

The purpose of this grouping of two Type II variations is to support a label expansion to mantle cell lymphoma (MCL) therapy and additionally, to modify a specification limit for the CD8+ drug product component. The proposed update to the acceptance criteria is based on the data analysis of the approved and proposed indication. No changes are proposed for the specification of CD4+ drug product component.

All clinical trial materials supporting the label expansion were manufactured per the approved manufacturing process (v4) and at commercially approved manufacturing sites. No changes are being proposed to the manufacturing process.

The vector RNA sequence encoding the amino acid sequence of the CD19-targeted CAR for the mantle cell lymphoma (MCL) cohort in Study 017001 (referred to hereafter as 'MCL Cohort 017001') is identical to that of the 3L+ LBCL cohort in Study 017001 (referred to hereafter as 'DLBCL Cohort 017001'). Thus, CAR structure and function and the DP mechanism of action remain unchanged.

While DLBCL Cohort 017001 pertained to patients with relapsed or refractory LBCL after two or more lines of systemic therapy (3L+), MCL Cohort 017001 pertains to patients with relapsed or refractory MCL after at least two prior lines of systemic therapy. Therefore, since these patient populations may differ in the characteristics of their starting materials ( e.g., memory T cell phenotypes) and their clinical response to the DP, the following studies are included in this section in support of MCL Cohort 017001:

- Phenotypic and functional characterization of DP components manufactured in support of MCL Cohort 017001
- Exploratory correlative analysis of quality attributes associations with clinical efficacy, safety, and pharmacokinetics in MCL Cohort 017001

## Manufacturing Process Development

The Leukapheresis Product was reassessed for R/R MCL to confirm that process characterization results using healthy donor leukapheresis product are still relevant to R/R MCL. This assessment was presented.

The DP v4 manufacturing process produces similar DP when using leukapheresis from patients or healthy donors as all attributes passed the analyses. The methodology described in the original Application is unchanged, and is applied to the MCL clinical study (MCL Cohort 017001) herein.

The residual patient risk assessment based on each unique product quality attribute considered the

<div style=\"page-break-after: always\"></div>

integrated control strategy (ICS). Based on this comprehensive assessment, the overall risk of the DP to patient safety and product efficacy is considered low.

## Assessor's comments:

The Healthy Donor (HD) Leukapheresis product was reassessed for R/R MCL to confirm that process characterization results using HD leukapheresis product are still relevant to R/R MCL. Overall, as all attributes passed the analyses, it can be therefore concluded that the use of HD leukapheresis product for process characterization purposes is still relevant to the R/R MCL patients' setting.

Indeed, the currently EU-approved specifications, including the specification limit (CD8+ cell component) that is updated and accepted (see sections below) within this procedure, are still valid (see sections below). Overall, the MAH's approach is considered informative and therefore endorsed.

## Specifications

The specification for lisocabtagene maraleucel DP components (liso-cel) cover relevant CQAs. The quality parameters taken into account for each cell component include appearance, identity, purity, strength, potency and safety.

The evolution of the specification was presented.

## Assessor's comments:

To support the proposed indication, Relapsed/Refractory mantle cell lymphoma (R/R MCL) label expansion, the Applicant is proposing to update the acceptance criteria for one attribute for the CD8 +  component. The proposed update to the acceptance criteria is based on the data analysis of the approved (3L+ Large LBCL, 2L LBCL and FOL) and proposed indication (MCL). No changes are proposed for the specification of CD4 +  DP component. A detailed assessment of the specification acceptance criteria was provided.

## Justification of Specifications

The acceptance criteria in the specification have been established to confirm the appearance, identity, purity, strength, potency, and safety and to ensure that the quality of released DP component lots remain within experience demonstrated to be safe and effective in Study 017001, JCAR017-BCM-001 (BCM-001), JCAR017-BCM-003 (BCM-003), JCAR017-FOL-001 (FOL-001), Relapsed/Refractory mantle cell lymphoma Cohort 017001 (MCL Cohort 017001). The analytical procedures and acceptance criteria in the specification are applicable to release and stability of drug product components in accordance with ICH Q6B. Conformance to the specification is required prior to release of liso-cel. The justification for the analytical procedures and acceptance criteria in the specification for release and stability testing of drug product components is described.

## Analytical Procedures

The appearance, identity, purity, strength, potency, and safety attributes that are included in the DP specification were selected based on risk assessments that considered product understanding and process capability. The analytical procedures in the commercial specification were selected based on their performance characteristics and suitability for routine and reliable evaluation of these attributes in a quality control environment.

<div style=\"page-break-after: always\"></div>

## Acceptance Criteria in the Specification for Drug Product

In accordance with ICH Q6B, Q8, Q9, and Q10, the following assessment of liso-cel DP lots acceptance criteria were established based on:

1. Clinical manufacturing batches used for evaluating clinical safety and efficacy
2. T cell biology and the quality attribute-clinical outcome relationship established by correlative analyses
3. Data obtained from manufacturing process development and characterization studies
4. Capabilities of the analytical procedures
5. Pharmacopeia specifications

## Assessor's comment:

To support the proposed indication, Relapsed/Refractory mantle cell lymphoma (R/R MCL) label expansion, the Applicant has assessed the approved commercial acceptance criteria using the same methodology as previously presented in the initial filing (initial marketing application).

The MAH proposes to use the same release specification limits for all quality attributes except for one attribute of the CD8+ component that is proposed to be updated. No changes are proposed for the specification of CD4+ DP component and the approved acceptance criteria is maintained.

The specification-setting approach is intended to be holistic, with proposed specification limits based on the totality of clinical, manufacturing, and analytical experience. This is considered well justified and therefore acceptable.

## 2.3. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CAT/CHMP.

## 2.3.1. Ecotoxicity/environmental risk assessment

The MAH provided a justification for not submitting a new Environmental Risk Assessment (ERA), which extends the treatment of liso-cel to include adult patients with relapsed or refractory MCL after at least two lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibition.

No release of Liso-cel into the environment is foreseen. No relevant changes in the manufacturing process of liso-cel were implemented. Testing for absence of replication-competent lentivirus (RCL) in vector lot is in place. Generation of RCL in patients treated with liso-cel is still unlikely. As the enlargement of the treated population, now including adult patients with relapsed or refractory MCL as per the approved indication does not affect the environmental risk of liso-cel, no monitoring in the environment is considered necessary to protect human health and the environment.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

<div style=\"page-break-after: always\"></div>

The clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 1. Description of Study 017001 - MCL Cohort

| Study                                     | Design                                                                                                                                                                         | Study Population                                                                                                                                                                                                          | Number of Liso-cel Treated Subjects   | Dosing                                                                         | PK Sampling Timepoints by qPCR                                                           |
|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Study 017001 Completed LPLV: 16- May-2024 | Phase 1, multicenter, open-label study of JCAR017, CD19-targeted chimeric antigen receptor (CAR) T cells, for relapsed and refractory (R/R) B-cell non- Hodgkin lymphoma (NHL) | Subjects with R/R disease having received ≥ 2 prior lines of systemic MCL therapy and having been treated with an alkylating agent, a Bruton's tyrosine kinase inhibitor, and rituximab (or other CD20- targeted agent) a | Dose Level 1: 6 Dose Level 2: 82      | Dose Level 1: 50 × 10 6 CAR+ T cells b Dose Level 2: 100 × 10 6 CAR+ T cells c | Pre- treatment Evaluation, Days 1, 4, 8, 11, 15, 22, 29; 60, 90, 180, 270, 365, 545, 730 |

## 2.4.2. Pharmacokinetics

The clinical pharmacology information for lisocabtagene maraleucel is based on data from MCL Cohort of Phase 1 Study 017001 (Table 1)

The cut-off date and Data base Lock (DBL) date are 19-Jan-2023 and 31-Mar-2023, respectively. Transgene persistence, B-cell aplasia, and immunogenicity results were updated with longer follow-up (16-May-2024 data cut).

Study 017001 includes the characterization of PK profile of liso-cel as secondary objective. Among the exploratory objectives there are: evaluation of the pharmacodynamic effects of liso-cel, including presence of B-cells and serum immunoglobulins, the immune response to liso-cel, the relationship of PK parameters with BOR, DOR, and PFS and the relationship between PK and pharmacodynamic parameters with CRS and iiNT.

Bioanalytical methods

<div style=\"page-break-after: always\"></div>

Evaluation of PK, pharmacodynamic, and immunogenicity profile of the drug product for the MCL was performed using previously validated methods.

A partial validation due to minor modifications was conducted for anti-therapeutic antibody (ATA) detection method already submitted within the initial marketing authorization application.

## Pharmacokinetic results

The PK analyses were based on qPCR. Noncompartmental PK parameters such as Cmax, Tmax, and AUC(0-28) were calculated for subjects who had PK measurement 28 days after infusion or later.

For flow cytometry, persistence was defined as CD3+ EGFR+ count greater than or equal to LLOD of 0.1 cells/μL, with at least 25 events captured in the CAR T flow cytometry detection gate. All PK data, including persistence, were summarized descriptively.

Pharmacokinetic assessments by flow cytometry (CD3+ EGFRt+, CD4+ EGFRt+, and CD8+ EGFRt+) were considered supportive data that allow for the evaluation of PK parameters per drug product component.

PK Sampling Timepoints by qPCR were collected as follow: Pre-treatment Evaluation, Days 1, 4, 8, 11, 15, 22, 29; 60, 90, 180, 270, 365, 545, 730.

PK sampling for flow cytometry were collected as follow. Pre-treatment Evaluation, Days 1, 4, 8, 11, 15, 22, 29; 60, 90, 180, 270, 365.

The dataset considered is as follow:

Table 2. Analysis dataset and population

| Dataset                                             | Definition                                                                                                                                     |   DL2S |   DL1S |   Total |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|---------|
| Liso-cel-treated Analysis Set (Safety Analysis Set) | All subjects who have received at least one dose of liso-cel                                                                                   |     82 |      6 |      88 |
| Liso-cel-treated Efficacy Analysis Set              | All subjects in the Liso-cel-treated Analysis Set who have PET-positive disease present before liso-cel administration based on IRC assessment |     77 |      6 |      83 |
| qPCR PK Analysis Set                                | All subjects in the Liso-cel-treated Analysis Set who have both baseline and on study PK measurements in blood assessed by qPCR                |     82 |      6 |      88 |

Following infusion, the liso-cel concentration in the peripheral blood detected by qPCR exhibited a rapid expansion followed by a monophasic decline up to 28 days after infusion in both DL1S and DL2S (Figure 1).

<div style=\"page-break-after: always\"></div>

Figure 1. Median Transgene Concentration by qPCR Over Time by Dose Level - qPCR PK Analysis Set MCL

<!-- image -->

Upper error bar represents the third quartile,lower error barrepresents thefirst quartile liso-cel was given on Study Day 1

For all dose levels (N=79), median Cmax, AUC(028) and Tmax by qPCR were 29335.0 copies/μg, 288556.8 day*copies/μg and 10.0 days, respectively ( Table 3).

Table 3.  PK Parameters by qPCR vs Dose Level - qPCR PK Analysis Set MCL

| Transgene                          | DL2S N=82         | DL1S N=6        | Total N=88       |
|------------------------------------|-------------------|-----------------|------------------|
| Cmax, qPCR (copies/ug)             |                   |                 |                  |
| N                                  | 73                | 6               | 79               |
| Median                             | 31631.0           | 9793.0          | 29335.0          |
| Q1, Q3                             | 15740.0, 139924.0 | 2287.0, 17315.0 | 9255.0, 136684.0 |
| Min, Max                           | 206, 5236190      | 1297, 57257     | 206, 5236190     |
| Geometric Mean (CV%)               | 34433.1 (667.8)   | 7740.5 (250.3)  | 30743.0 (664.9)  |
| Tmax, qPCR (day)                   |                   |                 |                  |
| N                                  | 73                | 6               | 79               |
| Median                             | 10.0              | 17.5            | 10.0             |
| Q1, Q3                             | 9.0, 14.0         | 10.0, 27.0      | 9.0, 14.0        |
| Min, Max                           | 3, 28             | 10, 29          | 3, 29            |
| AUC Day 0-28, qPCR (day*copies/ug) |                   |                 |                  |
| N                                  | 73                | 6               | 79               |

<div style=\"page-break-after: always\"></div>

| Transgene            | DL2S N=82        | DL1S N=6        | Total N=88       |
|----------------------|------------------|-----------------|------------------|
| Median               | 329992.3         | 73158.1         | 288556.8         |
| Q1, Q3               | 117687.8,        | 36820.4,        | 91758.9,         |
|                      | 914881.0         | 167235.2        | 900207.6         |
| Min, Max             | 2200, 17047357   | 13954, 281007   | 2200, 17047357   |
| Geometric Mean (CV%) | 299285.2 (540.5) | 68928.4 (154.3) | 267703.1 (532.0) |

2. Noncompartmental PK parameters such as Cmax, Tmax and AUC(0-28) were calculated for subjects who had PK measurement 28 days after infusion or later.
3. Geometric mean is obtained by computing the arithmetic mean of the logarithm-transformed values of PK parameters and then using the exponentiation to return the computation to the original scale. Geometric CV(%) is calculated as follows: CV (%)=100×sqrt(exp(S^2) - 1), where S^2 denotes the variance of the logtransformed values.

Flow cytometry-based PK assessment demonstrated the ability of CD4+ and CD8+ drug product components to expand following liso-cel infusion. A higher expansion of CD8+ EGFRt+ cells was observed compared with CD4+ EGFRt+ cells in both the DL1S and DL2S (Figure 2 and Figure 3).

Figure 2. Flow cytometry PK analysis set (CD4+)

<!-- image -->

Curvesrelativetoeach administration areshownforpatients on thetwodoseschedule Uppererrorbarrepresents the third quartile,lowererrorbarrepresents thefirst quartile JCAR017wasgivenonstudyday1

<div style=\"page-break-after: always\"></div>

Figure 3. Flow cytometry PK analysis set (CD8+)

<!-- image -->

Curvesrelative toeach administration areshownforpatients on thetwodoseschedule. Upper error barrepresents the third quartile,lower errorbar represents the first quartile

JCAR017wasgivenonstudyday1

Pharmacokinetic parameters of CD3+ EGFR+, CD4+ EGFR+, and CD8+ EGFR+ T-cells in the Flow Cytometry PK Analysis Set are summarized by dose level in Table 4.

Table 4. PK parameters by Flow Cytometry vs dose levels

| PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   | PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   | PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   | PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                       | DL2S                                                                  | DL1S                                                                  | Total                                                                 |
|                                                                       | N=82                                                                  | N=6                                                                   | N=88                                                                  |
| CD3+                                                                  |                                                                       |                                                                       |                                                                       |
| Cmax, flow (cells/uL)                                                 |                                                                       |                                                                       |                                                                       |
| N                                                                     | 74                                                                    | 6                                                                     | 80                                                                    |
| Median                                                                | 103.933                                                               | 31.146                                                                | 87.339                                                                |
| Q1, Q3                                                                | 20.337, 410.987                                                       | 1.826, 65.190                                                         | 20.296, 395.974                                                       |
| Min, Max                                                              | 0.352, 4536.539                                                       | 0.713, 146.275                                                        | 0.352, 4536.539                                                       |
| Geometric Mean (CV%)                                                  | 85.826 (846.478)                                                      | 15.140 (908.503)                                                      | 75.354 (920.745)                                                      |
| Tmax, flow (day)                                                      |                                                                       |                                                                       |                                                                       |
| N                                                                     | 74                                                                    | 6                                                                     | 80                                                                    |
| Median                                                                | 10.0                                                                  | 17.0                                                                  | 10.0                                                                  |
| AUC Day 0-28, flow (day*cells/uL)                                     |                                                                       |                                                                       |                                                                       |
| N                                                                     | 74                                                                    | 6                                                                     | 80                                                                    |

<div style=\"page-break-after: always\"></div>

| PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   | PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   | PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   | PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                       | DL2S                                                                  | DL1S                                                                  | Total                                                                 |
|                                                                       | N=82                                                                  | N=6                                                                   | N=88                                                                  |
| Median                                                                | 679.942                                                               | 215.792                                                               | 645.573                                                               |
| Q1, Q3                                                                | 186.918, 2786.831                                                     | 20.479, 295.484                                                       | 167.894, 2767.425                                                     |
| Min, Max                                                              | 5.985, 31736.356                                                      | 8.261, 661.834                                                        | 5.985, 31736.356                                                      |
| Geometric Mean (CV%)                                                  | 669.758 (564.304)                                                     | 106.812 (421.200)                                                     | 583.607 (611.799)                                                     |
| CD4+                                                                  |                                                                       |                                                                       |                                                                       |
| Cmax, flow (cells/uL)                                                 |                                                                       |                                                                       |                                                                       |
| N                                                                     | 73                                                                    | 6                                                                     | 79                                                                    |
| Median                                                                | 14.321                                                                | 2.959                                                                 | 13.787                                                                |
| Q1, Q3                                                                | 2.953, 50.332                                                         | 0.597, 30.276                                                         | 2.643, 49.711                                                         |
| Min, Max                                                              | 0.182, 986.895                                                        | 0.423, 49.711                                                         | 0.182, 986.895                                                        |
| Geometric Mean (CV%)                                                  | 11.914 (658.882)                                                      | 3.842 (686.844)                                                       | 10.933 (675.115)                                                      |
| Tmax, flow (day)                                                      |                                                                       |                                                                       |                                                                       |
| N                                                                     | 73                                                                    | 6                                                                     | 79                                                                    |
| Median                                                                | 10                                                                    | 17                                                                    | 10                                                                    |
| AUC Day 0-28, flow (day*cells/uL)                                     |                                                                       |                                                                       |                                                                       |
| N                                                                     | 73                                                                    | 6                                                                     | 79                                                                    |
| Median                                                                | 122.780                                                               | 24.124                                                                | 120.394                                                               |
| Q1, Q3                                                                | 29.988, 317.241                                                       | 6.791, 187.359                                                        | 24.708, 304.551                                                       |
| Min, Max                                                              | 2.064, 11982.070                                                      | 5.334, 223.995                                                        | 2.064, 11982.070                                                      |
| Geometric Mean (CV%)                                                  | 101.063 (492.518)                                                     | 30.981 (340.907)                                                      | 92.383 (495.992)                                                      |
| CD8+                                                                  |                                                                       |                                                                       |                                                                       |
| Cmax, flow (cells/uL)                                                 |                                                                       |                                                                       |                                                                       |
| N                                                                     | 74                                                                    | 5                                                                     | 79                                                                    |
| Median                                                                | 82.338                                                                | 27.164                                                                | 68.040                                                                |
| Q1, Q3                                                                | 19.725, 294.017                                                       | 14.912, 29.277                                                        | 17.315, 287.745                                                       |
| Min, Max                                                              | 0.241, 4417.860                                                       | 1.386, 114.297                                                        | 0.241, 4417.860                                                       |
| Geometric Mean (CV%)                                                  | 68.198 (1014.377)                                                     | 17.980 (354.527)                                                      | 62.680 (985.494)                                                      |
| Tmax, flow (day)                                                      |                                                                       |                                                                       |                                                                       |

<div style=\"page-break-after: always\"></div>

| PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   | PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   | PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   | PK Parameters by Flow cytometry vs Dose Level - PK Analysis Set MCL   |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                       | DL2S                                                                  | DL1S                                                                  | Total                                                                 |
|                                                                       | N=82                                                                  | N=6                                                                   | N=88                                                                  |
| N                                                                     | 74                                                                    | 5                                                                     | 79                                                                    |
| Median                                                                | 10                                                                    | 13                                                                    | 10                                                                    |
| AUC Day 0-28, flow (day*cells/uL)                                     |                                                                       |                                                                       |                                                                       |
| N                                                                     | 74                                                                    | 5                                                                     | 79                                                                    |
| Median                                                                | 573.685                                                               | 151.736                                                               | 526.022                                                               |
| Q1, Q3                                                                | 137.268, 2084.734                                                     | 69.088, 232.618                                                       | 124.504, 2032.638                                                     |
| Min, Max                                                              | 3.302, 21013.712                                                      | 15.277, 458.882                                                       | 3.302, 21013.712                                                      |
| Geometric Mean (CV%)                                                  | 522.304 (645.185)                                                     | 111.321 (212.072)                                                     | 473.624 (642.002)                                                     |

A high correlation between qPCR (transgene) and flow cytometry (CD3+ EGFRt+ T-cells) PK parameters was observed for Cmax, AUC(0-28), and Tmax, with correlation coefficients of 0.8585, 0.8848, and 0.5745, respectively.

Comparison with data from 3L+ LBCL in Study 017001

No apparent differences in transgene PK parameters were observed between R/R MCL and 3L+ LBCL in Study 017001 (Table 5). PK for subjects in 2L LBCL were also similar to those for subjects in 3L+ LBCL.

Table 5. Summary of liso-cel PK parameters in R/R MCL and 3L+LBCL

|                     | Study 017001                | Study 017001                        |
|---------------------|-----------------------------|-------------------------------------|
| Parameter Statistic | R/R MCL DL1S + DL2S N = 88  | 3L+ LBCL DL1S + DL2S + DL3S N = 261 |
| Cmax (copies/µg)    | Cmax (copies/µg)            | Cmax (copies/µg)                    |
| n Median Q1, Q3     | 79 29335.0 9255.0, 136684.0 | 245 23928.2 8159.3, 78365.7         |
| Tmax (days)         |                             |                                     |
| n Median Q1, Q3     | 79 10.0 9.0, 14.0           | 245 12.0 10.0, 14.0                 |

<div style=\"page-break-after: always\"></div>

|                           | Study 017001               | Study 017001                        |
|---------------------------|----------------------------|-------------------------------------|
| Parameter Statistic       | R/R MCL DL1S + DL2S N = 88 | 3L+ LBCL DL1S + DL2S + DL3S N = 261 |
| AUC(0-28) (day*copies/µg) | AUC(0-28) (day*copies/µg)  | AUC(0-28) (day*copies/µg)           |
| n                         | 79                         | 245                                 |
| Median                    | 288556.8                   | 213730.1                            |
| Q1, Q3                    | 91758.9, 900207.6          | 74964.1, 662966.5                   |

Note: n is the number of subjects who had PK parameters.

## Persistence

For  qPCR,  persistence  was  defined  as  a  transgene  count  greater  than  or  equal  to  the  LLOD  (5 copies/reaction). Persistence of liso-cel transgene was observed up to Day 730.

Table 6. Summary of Persistence by qPCR Over Time vs Dose Level - qPCR PK Analysis Set MCL

| Transgene, x/n (%)   | DL2S N=82    | DL1S N=6   | Total N=88   |
|----------------------|--------------|------------|--------------|
| Day 29               | 71/73 (97.3) | 5/5 (100)  | 76/78 (97.4) |
| Day 60               | 53/57 (93.0) | 3/3 (100)  | 56/60 (93.3) |
| Day 90               | 48/58 (82.8) | 3/3 (100)  | 51/61 (83.6) |
| Day 180              | 28/42 (66.7) | 2/2 (100)  | 30/44 (68.2) |
| Day 270              | 22/36 (61.1) | 2/2 (100)  | 24/38 (63.2) |
| Day 365              | 22/34 (64.7) | 2/2 (100)  | 24/36 (66.7) |
| Day 545              | 17/29 (58.6) | 1/2 (50.0) | 18/31 (58.1) |
| Day 730              | 9/25 (36.0)  | 1/1 (100)  | 10/26 (38.5) |

## Pharmacokinetic Parameters by Subgroup Analysis

No apparent differences in qPCR PK parameters by subgroups of age ( ≥ 65 vs. &lt; 65 years old), sex, race (White vs. others), pre-LDC SPD status ( ≥ 50 vs. &lt; 50 cm2), pre-LDC LDH status ( ≥ 500 vs. &lt; 500 U/L), Ki67 ( ≥ 30 vs. &lt; 30%), and TP53 mutation were observed (data not shown).

A potential association was observed between detection of blastoid morphology and lower Cmax and AUC(0-28). Median Cmax in subjects with blastoid morphology (n = 24) and subjects without blastoid morphology (n = 45) were 16372.0 and 54042.0 copies/μg, resp ectively (p = 0.0053). Median AUC(028) in subjects with blastoid morphology and subjects without blastoid morphology were 134762.3 and 394631.2 day*copies/μg, respectively (p = 0.0066).

<div style=\"page-break-after: always\"></div>

## Patients receiving a nonconforming product

At first infusion, 88 subjects (82 treated at DL2S and 6 treated at DL1S) who underwent leukapheresis received conforming product, and the remaining 4 (3 treated at DL2S and 1 treated at DL1S) received nonconforming product. Expansion was observed from all subjects. Cmax and AUC(0-28) by qPCR ranged from  327.0  to  53106.0  copies/μg  and  1631.6  to  328785.7  day*copies/μg,  respectively,  which  were generally lower than the median values of the all dose levels but within its ranges.

## PK/efficacy and PK/safety Relationship

The relationship between PK parameters (Cmax, Tmax and AUC[0-28]) and dichotomous parameters such as BOR, CRS and iiNT were assessed by Wilcoxon tests. The relationship between PK parameters and multi-categorical parameters were assessed by Kruskal-Wallis tests. The relationship between PK parameters and time-to-event parameters were assessed by Cox proportional hazards models.

PK-efficacy  relationships  were  evaluated  in  subjects  who  were  in  both  the  Liso-cel-treated  Efficacy Analysis Set and PK Analysis Set, while PK safety relationships were evaluated in subjects who were in the PK Analysis Set (Table 7).

Table 7. Relationship Between Pharmacokinetic Parameters of Liso-cel and Clinical Efficacy and Safety, MCL Cohort, DL1S + DL2S

|                                                            | Transgene                                                  | Transgene                                                  | Transgene                                                  | CD4+ EGFRt+                                                | CD4+ EGFRt+                                                | CD4+ EGFRt+                                                | CD8+ EGFRt+                                                | CD8+ EGFRt+                                                | CD8+ EGFRt+                                                |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Variable/ Statistic                                        | Yes                                                        | No                                                         | p- value                                                   | Yes                                                        | No                                                         | p- value                                                   | Yes                                                        | No                                                         | p- value                                                   |
| Efficacy (assessed per IRC)                                | Efficacy (assessed per IRC)                                | Efficacy (assessed per IRC)                                | Efficacy (assessed per IRC)                                | Efficacy (assessed per IRC)                                | Efficacy (assessed per IRC)                                | Efficacy (assessed per IRC)                                | Efficacy (assessed per IRC)                                | Efficacy (assessed per IRC)                                | Efficacy (assessed per IRC)                                |
| Response (BOR of either CR or PR, versus non-response)     | Response (BOR of either CR or PR, versus non-response)     | Response (BOR of either CR or PR, versus non-response)     | Response (BOR of either CR or PR, versus non-response)     | Response (BOR of either CR or PR, versus non-response)     | Response (BOR of either CR or PR, versus non-response)     | Response (BOR of either CR or PR, versus non-response)     | Response (BOR of either CR or PR, versus non-response)     | Response (BOR of either CR or PR, versus non-response)     | Response (BOR of either CR or PR, versus non-response)     |
| Cmax N Median                                              | 67 31631.0                                                 | 8 12444.0                                                  | 0.055 7                                                    | 67 14.3                                                    | 8 6.6                                                      | 0.3154                                                     | 68 82.3                                                    | 7 29.3                                                     | 0.377 1                                                    |
| Q1, Q3                                                     | 16603.0, 139924.0                                          | 3654.5, 34099.5                                            | 0.055 7                                                    | 2.7, 50.3                                                  | 1.5, 27.2                                                  | 0.3154                                                     | 18.9, 281.7                                                | 12.1, 179.3                                                | 0.377 1                                                    |
| Tmax N Median                                              | 67 10.0                                                    | 8 14.0                                                     | 0.125 3                                                    | 67 10.0                                                    | 8 13.5                                                     | 0.2513                                                     | 68 10.0                                                    | 7 10.0                                                     | 0.610 2                                                    |
| Q1, Q3                                                     | 9.0, 14.0                                                  | 10.0, 17.5                                                 | 0.125 3                                                    | 9.0, 14.0                                                  | 10.0, 17.5                                                 | 0.2513                                                     | 9.0, 14.0                                                  | 10.0, 14.0                                                 | 0.610 2                                                    |
| AUC(0-28) N Median                                         | 67 309578.0                                                | 8 142461.5                                                 | 0.116 3                                                    | 67 122.8                                                   | 8 65.5                                                     | 0.2467                                                     | 68 540.5                                                   | 7 232.6                                                    | 0.348 3                                                    |
| Q1, Q3                                                     | 103329.7, 1089840.3                                        | 39903.5, 399860.0                                          | 0.116 3                                                    | 26.9, 317.2                                                | 15.2, 183.4                                                | 0.2467                                                     | 151.9, 1946.3                                              | 124.5, 1407.2                                              | 0.348 3                                                    |
| Complete Response (BOR of CR versus non-complete response) | Complete Response (BOR of CR versus non-complete response) | Complete Response (BOR of CR versus non-complete response) | Complete Response (BOR of CR versus non-complete response) | Complete Response (BOR of CR versus non-complete response) | Complete Response (BOR of CR versus non-complete response) | Complete Response (BOR of CR versus non-complete response) | Complete Response (BOR of CR versus non-complete response) | Complete Response (BOR of CR versus non-complete response) | Complete Response (BOR of CR versus non-complete response) |
| Cmax N                                                     | 59 45068.0                                                 | 16 12444.0                                                 | 0.009 9                                                    | 59 16.8                                                    | 16 3.5                                                     | 0.0616                                                     | 59 94.4                                                    | 16 28.2                                                    | 0.028 4                                                    |
| Median                                                     |                                                            | 2383.5,                                                    | 0.009 9                                                    |                                                            | 1.1, 27.2                                                  | 0.0616                                                     | 24.7, 354.5                                                | 3.5, 138.1                                                 | 0.028 4                                                    |
| Q1, Q3 Tmax                                                | 17111.0, 149423.0 59                                       | 41257.5 16 13.0                                            | 0.009 9                                                    | 3.3, 50.3 59                                               | 16                                                         | 0.0616                                                     | 59                                                         | 16 11.0                                                    | 0.028 4                                                    |
| N Median                                                   | 10.0                                                       |                                                            | 0.222 2                                                    | 10.0                                                       | 14.0                                                       | 0.0178                                                     | 10.0 9.0, 14.0                                             |                                                            | 0.190 3                                                    |
| Q1, Q3                                                     | 9.0, 14.0                                                  |                                                            | 0.009 9                                                    | 9.0, 14.0                                                  |                                                            | 0.0616                                                     |                                                            | 10.0, 14.0                                                 | 0.028 4                                                    |
|                                                            |                                                            | 10.0, 17.0                                                 | 0.009 9                                                    |                                                            | 10.0, 21.0                                                 | 0.0616                                                     |                                                            |                                                            | 0.028 4                                                    |
| AUC(0-28) N                                                | 59                                                         | 16                                                         | 0.012                                                      | 59                                                         | 16                                                         | 0.0635                                                     | 59                                                         | 16                                                         | 0.024                                                      |
| Median                                                     | 394631.2                                                   | 142461.5                                                   | 0.012                                                      | 141.6                                                      | 34.4                                                       | 0.0635                                                     | 601.9                                                      | 197.2                                                      | 0.024                                                      |

<div style=\"page-break-after: always\"></div>

|                                  | Transgene                                         | Transgene                                    | Transgene   | CD4+ EGFRt+               | CD4+ EGFRt+              | CD4+ EGFRt+   | CD8+ EGFRt+                 | CD8+ EGFRt+                     | CD8+ EGFRt+   |
|----------------------------------|---------------------------------------------------|----------------------------------------------|-------------|---------------------------|--------------------------|---------------|-----------------------------|---------------------------------|---------------|
| Variable/ Statistic              | Yes                                               | No                                           | p- value    | Yes                       | No                       | p- value      | Yes                         | No                              | p- value      |
| Q1, Q3                           | 127193.0, 1357441.6                               | 31967.0, 297004.2                            | 8           | 30.1, 317.2               | 14.9, 183.4              |               | 220.7, 2084.7               | 51.8, 856.6                     | 0             |
| PFS                              |                                                   |                                              |             |                           |                          |               |                             |                                 |               |
| Cmax Hazard ratio                | 0.60 (0.40, 0.91)                                 | 0.60 (0.40, 0.91)                            | 0.015 7     | 0.40 (0.26,               | 0.62)                    | <.0001        | 0.53 (0.37, 0.76)           | 0.53 (0.37, 0.76)               | 0.000 5       |
| (95% CI) AUC(0-28) Hazard ratio  | 0.56 (0.37, 0.86)                                 | 0.56 (0.37, 0.86)                            | 0.007 6     | 0.37 (0.23, 0.60)         | 0.37 (0.23, 0.60)        | 0.0001        | 0.50 (0.33, 0.74)           | 0.50 (0.33, 0.74)               | 0.000 6       |
| DOR                              |                                                   |                                              |             |                           |                          |               |                             |                                 |               |
| Cmax Hazard ratio                | 0.63 (0.41, 0.98)                                 | 0.63 (0.41, 0.98)                            | 0.041 4     | 0.42 (0.27, 0.65)         | 0.42 (0.27, 0.65)        | 0.0001        | 0.51 (0.35, 0.75)           | 0.51 (0.35, 0.75)               | 0.000 5       |
| (95% CI) AUC(0-28) Hazard ratio  | 0.60 (0.38, 0.93)                                 | 0.60 (0.38, 0.93)                            | 0.024 1     | 0.39 (0.24, 0.65)         | 0.39 (0.24, 0.65)        | 0.0003        | 0.49 (0.32, 0.74)           | 0.49 (0.32, 0.74)               | 0.000 7       |
| Safety                           |                                                   |                                              |             |                           |                          |               |                             |                                 |               |
| CRS                              |                                                   |                                              |             |                           |                          |               |                             |                                 |               |
| Cmax n Median                    | 50 42872.5                                        | 29 17106.0                                   | 0.002 4     | 50 16.3 3.5, 60.3         | 29 9.7 1.4, 39.8         | 0.1047        | 50 105.6 33.9,              | 29 29.3 3.8, 196.2              | 0.013 3       |
| Q1, Q3 Tmax n Median             | 19685.0, 183107.0 50 10.0                         | 2287.0, 61058.0 29 14.0                      | 0.012 4     | 50 10.0                   | 29 14.0                  | 0.0049        | 323.7 50 10.0               | 29 13.0                         | 0.134 1       |
| Q1, Q3 AUC(0-28) n Median Q1, Q3 | 9.0, 12.0 50 375005.5                             | 10.0, 15.0 29 167235.2                       | 0.003 8     | 9.0, 14.0 50 142.8 32.0,  | 10.0, 16.0 29 85.6 15.2, | 0.0649        | 9.0, 14.0 50 785.8 227.7,   | 9.0, 16.0 29 313.7              | 0.017 6       |
| iiNT Cmax n Median Q1, Q3        | 142331.5, 1534211.5 25 113596.0 31631.0, 235480.0 | 33369.2, 498878.9 54 19683.5 5466.0, 61058.0 | 0.000 6     | 333.4 26 52.7 15.8, 114.3 | 195.2 53 4.8 1.5, 22.8   | <.0001        | 2157.0 26 236.0 96.9, 641.5 | 32.2, 1318.6 53 34.0 7.9, 131.6 | <.000 1       |
| Tmax n Median                    | 25 10.0                                           | 54 10.0                                      | 0.178 9     | 26 10.0 9.0, 14.0         | 53 11.0 9.0, 14.0        | 0.1967        | 26 10.0 9.0, 12.0           | 53 10.0 10.0, 14.0 53           | 0.063 5       |
| Q1, Q3 AUC(0-28) n Median        | 9.0, 12.0                                         | 9.0, 14.0 54 217964.6                        |             | 26 315.9                  | 53 39.5                  |               | 26 1899.8                   | 292.0                           | <.000 1       |
|                                  | 25 900207.6                                       |                                              | 0.000 9     |                           |                          | <.0001        |                             |                                 |               |

<div style=\"page-break-after: always\"></div>

|                     | Transgene           | Transgene         | Transgene   | CD4+ EGFRt+   | CD4+ EGFRt+   | CD4+ EGFRt+   | CD8+ EGFRt+    | CD8+ EGFRt+   | CD8+ EGFRt+   |
|---------------------|---------------------|-------------------|-------------|---------------|---------------|---------------|----------------|---------------|---------------|
| Variable/ Statistic | Yes                 | No                | p- value    | Yes           | No            | p- value      | Yes            | No            | p- value      |
| Q1, Q3              | 284430.4, 2170312.0 | 50383.9, 619493.4 |             | 122.8, 738.5  | 18.3, 173.0   |               | 774.4, 4176.9  | 83.1, 833.0   |               |
| iiNT Grade ≥ 3      |                     |                   |             |               |               |               |                |               |               |
| Cmax                |                     |                   |             |               |               |               |                |               |               |
| n                   | 8                   | 71                |             | 8             | 71            |               | 8              | 71            |               |
| Median              | 126760.0            | 25639.0           | 0.022       | 84.6          | 11.0          | 0.0020        | 290.9          | 60.2          | 0.054 1       |
| Q1, Q3              | 49445.5, 2055100.0  | 8132.0, 115263.0  | 4           | 55.3, 117.5   | 2.4, 39.8     |               | 118.8, 543.0   | 15.3, 196.2   |               |
| Tmax                |                     |                   |             |               |               |               |                |               |               |
| n                   | 8                   | 71                |             | 8             | 71            |               | 8              | 71            |               |
| Median              | 12.0                | 10.0              | 0.722       | 14.0          | 10.0          | 0.1315        | 10.0           | 10.0          | 0.861         |
| Q1, Q3              | 8.5, 17.5           | 9.0, 14.0         |             | 11.5, 14.0    | 9.0, 14.0     |               | 10.0, 13.5     | 9.0, 14.0     | 9             |
| AUC(0-28)           |                     |                   |             |               |               |               |                |               |               |
| n                   | 8                   | 71                |             | 8             | 71            |               | 8              | 71            |               |
| Median              | 1439165.1           | 269192.2          | 0.006 2     | 717.2         | 82.5          | 0.0004        | 2425.4         | 473.8         | 0.018 1       |
| Q1, Q3              | 691457.7, 8406557.3 | 70874.4, 702938.1 |             | 445.7, 1474.8 | 23.5, 234.0   |               | 1430.2, 4229.8 | 106.2, 1714.9 |               |

## Immunogenicity

Immune responses to liso-cel were evaluated with an ATA assay to the ECD of liso-cel CAR, which binds to CD19, using a multi-tiered approach including a screening assay, a confirmatory assay, and a titer assay.  Clinical  plasma  samples  were  analyzed  for  the  presence  of  anti-liso-cel  antibodies  using  a validated ECL immunoassay.

Sampling Timepoints for ATA evaluation were collected as follow: Pre-treatment Evaluation, Days 15, 29, 60, 90, 180, 270, 365, 545, 730.

Table 8. Anti-Therapeutic Antibodies vs Dose Level - Liso-cel-treated Analysis Set MCL

|                                             | DL2S N = 82   | DL1S N = 6   | Total N = 88   |
|---------------------------------------------|---------------|--------------|----------------|
| Prevalence of anti-therapeutic antibodies a |               |              |                |
| Total subjects for evaluation               | 82            | 6            | 88             |
| Yes, n (%)                                  | 11 (13.4)     | 0            | 11 (12.5)      |
| No, n (%)                                   | 71 (86.6)     | 6 (100)      | 77 (87.5)      |
| Incidence of anti-therapeutic antibodies b  |               |              |                |
| Total subjects for evaluation               | 80            | 6            | 86             |
| Yes, n (%)                                  | 17 (21.3)     | 0            | 17 (19.8)      |
| No, n (%)                                   | 63 (78.8)     | 6 (100)      | 69 (80.2)      |

Treatment-induced antibodies

<div style=\"page-break-after: always\"></div>

|                               | DL2S N = 82   | DL1S N = 6   | Total N = 88   |
|-------------------------------|---------------|--------------|----------------|
| Total subjects for evaluation | 70            | 6            | 76             |
| Yes, n (%)                    | 14 (20.0)     | 0            | 14 (18.4)      |
| No, n (%)                     | 56 (80.0)     | 6 (100)      | 62 (81.6)      |
| Treatment-boosted antibodies  |               |              |                |
| Total subjects for evaluation | 10            | 0            | 10             |
| Yes, n (%)                    | 3 (30.0)      | 0            | 3 (30.0)       |
| No, n (%)                     | 7 (70.0)      | 0            | 7 (70.0)       |

a Prevalence of anti-therapeutic antibodies is defined as the percentage of subjects with pre-existing antibodies that bind to liso-cel.

b Incidence of anti-therapeutic antibodies is defined as the percentage of subjects with treatment-induced or treatmentboosted antibodies that bind to liso-cel. In a subject without pre-existing antibodies, development of antibodies after first infusion of liso-cel is considered treatment-induced. In a subject with pre-existing antibodies, an increased level of antibodies after first infusion of liso-cel is considered treatment-boosted.

Table 9. Summary of Clinical Outcomes and PK Parameters by ATA

| Variable/Statistic                 | Prevalence of ATA a   | Prevalence of ATA a   | Incidence of ATA b   | Incidence of ATA b   |
|------------------------------------|-----------------------|-----------------------|----------------------|----------------------|
|                                    | Yes                   | No                    | Yes                  | No                   |
| Cmax (copies/μg)                   |                       |                       |                      |                      |
| N                                  | 10                    | 69                    | 16                   | 63                   |
| Median                             | 54357.5               | 29335.0               | 76117.0              | 25639.0              |
| Q1, Q3                             | 9255.0, 172071.0      | 14564.0, 115263.0     | 20811.0, 143053.5    | 8132.0, 115263.0     |
| AUC(0-28) (day*copies/ug)          |                       |                       |                      |                      |
| N                                  | 10                    | 69                    | 16                   | 63                   |
| Median                             | 449932.7              | 288556.8              | 479454.1             | 269192.2             |
| Q1, Q3                             | 117687.8, 842036.3    | 91758.9, 900207.6     | 217964.6, 765618.8   | 70874.4, 914881.0    |
| Response (per IRC), n (%)          | 8/11 (72.7)           | 61/72 (84.7)          | 14/14 (100.0)        | 55/67 (82.1)         |
| Complete response (per IRC), n (%) | 8/11 (72.7)           | 52/72 (72.2)          | 14/14 (100.0)        | 46/67 (68.7)         |
| CRS any Grade, n (%)               | 5/11 (45.5)           | 49/77 (63.6)          | 9/17 (52.9)          | 43/69 (62.3)         |
| CRS Grade ≥ 3, n (%)               | 0/11                  | 1/77 (1.3)            | 0                    | 0                    |
| iiNT any Grade, n (%)              | 4/11 (36.4)           | 23/77 (29.9)          | 4/17 (23.5)          | 22/69 (31.9)         |
| iiNT Grade ≥ 3, n (%)              | 1/11 (9.1)            | 7/77 (9.1)            | 1/17 (5.9)           | 7/69 (10.1)          |

<div style=\"page-break-after: always\"></div>

Table 9. Summary of Clinical Outcomes and PK Parameters by ATA

|                                   | Prevalence of ATA a   | Prevalence of ATA a   | Incidence of ATA b   | Incidence of ATA b   |
|-----------------------------------|-----------------------|-----------------------|----------------------|----------------------|
| Variable/Statistic                | Yes                   | No                    | Yes                  | No                   |
| Hypersensitivity c , n (%)        | 1/11 (9.1)            | 19/77 (24.7)          | 4/17 (23.5)          | 15/69 (21.7)         |
| Hypersensitivity Grade ≥ 3, n (%) | 0/11                  | 2/77 (2.6)            | 0/17                 | 1/69 (1.4)           |

Among the four subjects receiving nonconforming product, one had pre-existing ATA.

## 2.4.3. Pharmacodynamics

## Mechanism of action

Breyanzi is a CD19 directed genetically modified autologous cellular immunotherapy administered as a defined composition to reduce variability in CD8+ and CD4+ T cell dose. The CAR is comprised of a murine FMC63 monoclonal antibody-derived single chain variable fragment (scFv), IgG4 hinge region, CD28 transmembrane domain, 4 1BB (CD137) costimulatory domain, and CD3 zeta activation domain. CD3 zeta signalling is critical for initiating T cell activation and antitumour activity, while 4 1BB (CD137) signalling enhances the expansion and persistence of Breyanzi. CAR binding to CD19 expressed on the cell surface of tumour and normal B cells induces activation and proliferation of CAR T-cells, release of pro-inflammatory cytokines, and cytotoxic killing of target cells.

## Primary and secondary pharmacology

The clinical pharmacology of liso-cel has been evaluated in Study 017001 in subjects with R/R MCL. Pharmacodynamic objectives were exploratory objectives.

## B-cell Aplasia

B-cell aplasia, defined as CD19 B-cells comprising less than 3% of peripheral blood lymphocytes, is an on-target effect of liso-cel.  In  the  total  Liso-cel-treated  Analysis  Set,  (DL1S  and  DL2S,  n  =  88),  an increase in the proportion of subjects with B-cell aplasia was observed from 58% of subjects at baseline to 98% of subjects by Month 2, with 69% of subjects maintaining B-cell aplasia through Month 12 (Table 10).

<div style=\"page-break-after: always\"></div>

Table 10. B-cell Aplasia Incidence Over Time vs Dose Level - Liso-cel-Treated Analysis Set MCL

| Visit Category                   | DL2S N=82   | DL1S N=6   | Total N=88   |
|----------------------------------|-------------|------------|--------------|
| <3% CD19+ B-cells of lymphocytes | n/N (%)     | n/N (%)    | n/N (%)      |
| Baseline                         | 46/82 (56)  | 5/6 (83)   | 51/88 (58)   |
| Day 4                            | 46/66 (70)  | 5/5 (100)  | 51/71 (72)   |
| Day 8                            | 66/79 (84)  | 6/6 (100)  | 72/85 (85)   |
| Day 11                           | 62/68 (91)  | 6/6 (100)  | 68/74 (92)   |
| Day 15                           | 72/77 (94)  | 6/6 (100)  | 78/83 (94)   |
| Day 22                           | 70/75 (93)  | 6/6 (100)  | 76/81 (94)   |
| Day 29                           | 71/73 (97)  | 5/5 (100)  | 76/78 (97)   |
| Month 2                          | 57/58 (98)  | 3/3 (100)  | 60/61 (98)   |
| Month 3                          | 55/57 (96)  | 3/3 (100)  | 58/60 (97)   |
| Month 6                          | 35/42 (83)  | 2/2 (100)  | 37/44 (84)   |
| Month 9                          | 26/36 (72)  | 2/2 (100)  | 28/38 (74)   |
| Month 12                         | 22/33 (67)  | 2/2 (100)  | 24/35 (69)   |
| Month 18                         | 1/2 (50)    | 0          | 1/2 (50)     |

Concentration values  after  the  initiation  of  retreatment  or  additional  cycles  of  liso-cel  or  after  another  anticancer treatment (including lymphodepletion) are excluded from the summaries.

Baseline is defined as the last measurement prior to liso-cel infusion n/N = (number of subjects with B-cell aplasia)/(number of subjects for evaluation).

## Serum Immunoglobulins

IgG &lt; 500 mg/dL was present in 40% of the subjects at baseline, increased to 68% of subjects by Month 6, and 53% of subjects at Month 24. Similar results were observed between dose levels (DL1S, DL2S), however the number of DL1S subjects was small (n = 6). The median IgG level was reduced from baseline for all post liso-cel infusion collections, consistent with the assessment of hypogammaglobulinemia.  The  analysis  of  serum  IgG  levels  did  not  take  into  account  potential confounding by the administration of IVIG for the treatment of hypogammaglobulinemia.

## Pharmacodynamic-Safety Relationship

Pharmacodynamic-Safety relationships were evaluated in the Liso-cel-treated Analysis Set. Correlative analyses were performed to evaluate the relationships of baseline and peak values (ie, Cmax) of soluble biomarkers and CRP/ferritin with selective safety endpoints including CRS and iiNT.

The number of subjects with Grade ≥ 3 CRS (N&lt;5) analyzed was insufficient to assess a relationship.

## Soluble Biomarkers

A total of 37 soluble biomarkers were analyzed to examine changes in cytokine and chemokine levels following liso-cel infusion. Soluble biomarkers SAA, GM-CSF, IFN-g, IL-2, IL-4, IL-5, and IL-6 were the only analytes which demonstrated a Pharmacodynamic-safety Relationship. For soluble factors such as SAA, GM-CSF, IFN-g, IL-2, IL-5, and IL-6 where an increased trend after infusion was observed, peak elevation was noted at the Day 4 or 8 collections and decreased by Day 29.

No baseline soluble biomarker levels had an association comparing any grade CRS versus no CRS, or

<div style=\"page-break-after: always\"></div>

any grade iiNT versus no iiNT, or Grade 3 or greater iiNT categories. Among the soluble biomarkers, Cmax of SAA, GM-CSF, IFNγ , IL-2, IL-4, IL-5, and IL-6 were associated with any grade CRS versus no CRS, while only IL-2 was associated with any grade iiNT versus no iiNT.

## C-reactive Protein (CRP) and Ferritin

Median  post-infusion  serum  CRP  for  DL2S  increased  by  Day  8  from  Day  1  levels,  although  a  wide interquartile range was observed, and then decreased by Day 29. Median post-infusion CRP in DL1S demonstrated an overall decrease from Day 1 levels, however, the number of DL1S subjects was small with wide interquartile ranges (n = 6).

Median serum ferritin observed for DL1S and DL2S had a slight upward trend from Day 1 levels between Day 11 and Day 22 but was equivalent by Day 29. However, a wide range of ferritin levels were observed at each timepoint within each dose level.

There were no associations in the baseline CRP or ferritin for subjects with any grade CRS versus subjects with no CRS, subjects with any grade iiNT versus subjects with no iiNT, nor in subjects with Grade 3 or higher iiNT versus subjects with no iiNT. There was an association of peak CRP, but not peak ferritin, in subjects with any grade CRS versus subjects with no CRS.

There were no associations of peak CRP or ferritin levels with iiNT status.

## 2.4.4. Discussion on clinical pharmacology

The clinical pharmacology profile of liso-cel in subjects with R/R MCL has been characterized based on the results from clinical study 017001; subjects in the MCL Cohort received either DL1S (50 x 10 6 CAR+ T cells, 6 subjects) or DL2S (100 x 10 6  CAR+ T cells, 82 subjects).

The bioanalytical methods used in this application are the same as submitted in the initial MA.

The MAH submitted the bioanalytical reports for PK and ATA.  The qPCR method shows an acceptable performance for all concentrations. Overall, this application makes use of previously validated methods with  adequate  performance  or  provided  some  partial  validation  where  missing.  This  is  considered acceptable.

The liso-cel concentration in the peripheral blood detected by qPCR exhibited a rapid expansion with a median Tmax of 10 days (range: 3 to 29 days). The median Tmax in DL1S is longer (17 days) compared to DL2S, however the number of subjects is smaller.  The expansion declines up to 28 days after infusion in both DL1S and DL2S. Higher median Cmax and AUC0-28 by qPCR is observed in DL2S respect to DL1S, however the number of patients treated with DL1S was smaller. A large inter-subject variability is observed with both doses.

Flow  cytometry-based  PK  assessment  demonstrated  the  ability  of  CD4+  and  CD8+  drug  product components to expand following liso-cel infusion. A higher expansion of CD8+ EGFRt+ cells was observed compared with CD4+ EGFRt+ cells in both the DL1S and DL2S. The same trend in qPCR is observed in median  Cmac  and  AUC0-28  of  CD3+  EGFR+,  CD4+  EGFR+,  and  CD8+  EGFR+  T-cells,  with  lower expansion in DL1S. This is expected due to the high correlation between qPCR (transgene) and flow cytometry.

In the current variation, the MAH submitted a comparison between R/R MCL DL1S+DL2S versus 3L+LBCL (pooling  all  three  doses  used  in  017001  study  (also  object  of  the  initial  marketing  authorization  for Breyanzi)). Based on this comparison, the Cmax, AUC0-28 as well as Tmax are comparable between R/R MCL and 3L+LBCL.

<div style=\"page-break-after: always\"></div>

A PK comparison at the same dose level in R/R MCL and DLBCL patients enrolled in study 017001 showed that PK parameters for DL2S dose (100 × 10 6  CAR+ T cells) are comparable (R/R MCL median Cmax 31631.0 copies/ug, median AUC0-28 329992.3 day*copies/ug, median Tmax 10.0 days; DLBCL cohort: median Cmax 25098.5 copies/ug, AUC0-28 229062.6 day*copies/ug, median Tmax 11 days).

For  qPCR,  persistence  was  defined  as  a  transgene  count  greater  than  or  equal  to  the  LLOD  (5 copies/reaction). Persistence of liso-cel transgene was observed up to Day 730.

The  majority  of  subjects  demonstrated  long-term  persistence  of  CAR+  T  cells  based  on  transgene detection in peripheral blood with 51 out of 61 patients had transgene persistence (82.8%) on Day 90; data on persistence is available up to Day 730 with 10 out of 26 (38.5%) showing transgene persistence. This is in line with data on persistence in the already approved indications.

The effect on PK of selected baseline demographic and disease characteristics in subjects receiving lisocel was evaluated. A potential association between the presence of blastoid morphology and lower Cmax and AUC0-28 was observed. However, as reported in the efficacy section, ORR rates are between 8090% but still clinically relevant in patients with blastoid morphology, in absence of a clear trend of lack of efficacy. The potential association between the presence of blastoid morphology and lower expansion could be affected by the small number of enrolled patients in that subgroup (N=16). No conclusion can be drawn on the effect of lower Cmax and AUC0-28 in patients with blastoid morphology.

Four subjects (3 treated at DL2S and 1 treated at DL1S) received a nonconforming product; their median Cmax  and  AUC0-28  are  lower,  however  the  ranges  are  included  in  that  of  subjects  receiving  the conforming product.

The  relationship  between  PK  and  clinical  efficacy  and  safety  has  been  investigated.  A  potential relationship was observed between higher transgene PK parameters (Cmax and AUC[0-28]) and higher CR rate and longer PFS and DOR per IRC. No apparent relationship was observed between transgene PK parameters and response (BOR of either CR or PR, versus non-response).

A potential relationship was observed between higher transgene PK parameters (Cmax and AUC[0-28]) and higher incidence of any grade CRS, any grade iiNT and Grade ≥ 3 iiNT. The relationship between PK parameters and Grade ≥ 3 CRS was not assessed because the number of subjects with Grade ≥ 3 CRS (n = 1) was less than 5.

PK-efficacy/safety relationships were generally similar between R/R MCL and 3L+ LBCL. Some difference in PK-efficacy relationship between R/R MCL and 3L+ LBCL (ie, relationship between PK and response) could be due to a smaller number of subjects in the MCL Cohort relative to the DLBCL Cohort of Study 017001 and the high ORR observed in the MCL Cohort, resulting in a smaller number of subjects in certain subgroups (ie, non-responders).

The assessment of immune response to liso-cel was also performed and the prevalence and incidence of ATA in R/R MCL patients are in line with that observed in the already approved indications. In patients who  received  Breyanzi  for  MCL,  pre-existing  ATAs  were  detected  in  13%  (11/88)  of  patients,  and treatment-induced or treatment-boosted ATAs were detected in 20% (17/86) of patients.

It  was  observed  that  median  Cmax  and  AUC0-28  are  higher  in  subject  with  pre-existing  ATA  or treatment-induced  or  treatment-boosted  ATA.  A  similar  trend  has  been  already  observed  in  LBCL patients. The effect of ATA on efficacy seems to suggest a better outcome in subjects who had treatmentinduced or treatment-boosted ATA. It is suggest in the submitted dossier that it could be due to a longer follow-up of responders respect to non-responders since the median time to first positive ATA in subjects with treatment-induced ATA was 9.8 months. No clear conclusion can be done on this aspect.

## Pharmacodynamic

<div style=\"page-break-after: always\"></div>

The clinical pharmacology of liso-cel has been evaluated in Study 017001 in subjects with R/R MCL and pharmacodynamic objectives were exploratory objectives.

B-cell aplasia was observed in 58% of subjects at baseline increasing to 98% of subjects by Month 2, with 69% of subjects maintaining B-cell aplasia through Month 12. At baseline, 40% of subjects had IgG &lt; 500 mg/dL which increased to 68% of subjects by Month 6 and remained above baseline through Month 24. However, there is a difference in baseline B-cell aplasia in the group of subjects administered with DL1S vs subjects administered with DL2S (baseline % of subjects with B-cell aplasia: DL1S = 83%; DL2S = 56%). Considering the small number of patients in DL1S group, no conclusion can be drawn on the significance of this difference and its impact on efficacy.

For soluble factors such as SAA, GM-CSF, IFNγ, IL -2 and IL-5 where an increased trend after infusion was observed, peak elevation was observed at the day 4 or day 8 collection and decreased by Day 29. Peak levels of soluble biomarkers SAA, GM-CSF, IFNγ, IL-2, IL-4, IL-5, and IL-6 were associated with any grade CRS, while only IL-2 was found to be associated with any grade iiNT. Peak CRP levels had an association with any grade CRS. The frequency of Grade ≥ 3 CRS was too low to assess any potential relationship with these events. No baseline soluble factor, CRP, or ferritin levels were associated with any grade CRS, any grade iiNT or Grade ≥ 3 iiNT.

## 2.4.5. Conclusions on clinical pharmacology

Overall, the clinical pharmacology of Breyanzi in R/R MCL has been well characterised, and can be considered adequate for the new indication.

## 2.5. Clinical efficacy

## 2.5.1. Dose response study(ies)

Dosing recommendations were mainly based on results from Phase I Study 017001. The study comprises a Dose Finding (DF), Dose Expansion (DE) and Dose Confirmation (DC).

## Dose-finding Group

Initially for dose-finding in the mantle cell lymphoma (MCL) cohort, eligible subjects were assigned to receive a liso-cel dose of 50×10 6  CAR+ T cells (DL1). Dose escalation/de-escalation in this study was guided by a modified continuous reassessment method (mCRM) that implemented Bayesian methodology to estimate the probabilities of DLT (P[DLT]) and CR (P[CR]). With each subject's information, the dose-toxicity and dose-response model was updated, and new P[DLT] and P[CR] was estimated. The P[DLT] and P[CR] based on investigator assessment, in conjunction with rules for enrolment and stopping, were used to determine the dose allocation for each subject. This trial was designed with an open enrolment feature, meaning that subjects were enrolled as they became available for the trial. The accrual rate into the trial was governed by allowing only a certain number of subjects enrolled with unknown DLT information per regimen.

Enrolment could have been stopped for early futility if no doses or schedules were determined to be either safe or effective. Prior to opening a new regimen for enrolment, the SRC reviewed the safety and efficacy data to provide recommendations to follow or override the mCRM algorithm's allocation of a subject or subjects.

## Dose-expansion Groups

A dose regimen was allowed to continue from the dose-finding phase of the study to the doseexpansion phase for further safety and efficacy evaluation if it met early success criteria for enrolment suspension. The criteria were that it was likely to be safe (P[DLT &lt; 0.33] &gt; 0.7) and efficacious (P[CR

<div style=\"page-break-after: always\"></div>

&gt; 0.25] &gt; 0.9). If multiple regimens continued to the DE phase, enrolment within DE groups was prioritized to the highest dose, unless the order of prioritization was changed or enrolment to an expansion group stopped in consultation with the steering committee (SC).

## DLT assessment

In the DF and DE groups, DLTs were assessed from the time of liso-cel administration until day 28. In all groups, AEs and SAEs were collected.

## Dose-confirmation Group for the MCL Cohort

Dose-Response for Efficacy and Safety Analysis for the DLBCL Cohort in Study 017001 and PK Comparison Across Indications have been conducted for extrapolation to the new indication.

The dose-response analysis for efficacy and safety performed for DLBCL Cohort were provided to the Agency during the initial marketing authorization application (MAA), EMEA/H/C/004731/0000.

Ad hoc analyses were conducted to explore the possible relationship of clinical outcomes for three of the dose regimens explored in the DLBCL Cohort of Study 017001:

DL1S: 50 × 10 6  CAR+ T cells (25 × 10 6  CD8+ CAR+ T cells and 25 × 10 6  CD4+ CAR+ T cells), singledose regimen

DL2S: 100 × 10 6  CAR+ T cells (50 × 10 6  CD8+ CAR+ T cells and 50 × 10 6  CD4+ CAR+ T cells), singledose regimen

DL3S: 150 × 10 6  CAR+ T cells (75 × 10 6  CD8+ CAR+ T cells and 75 × 10 6  CD4+ CAR+ T cells), singledose regimen

Based on univariate analysis (EMEA/H/C/004731/0000), the administered dose of CAR+ viable T cells had no relationship with BOR over the dose range studied. There were no clear relationships between administered dose and other key clinical outcomes such as DOR, PFS, cytokine release syndrome (CRS), investigator-identified neurologic toxicity (iiNT), or incidence of Grade ≥ 3 infection.

Further analysis also showed no clear relationship between Cmax or AUC(0-28) and administered dose (44 to 156 ×10 6  CAR+ T cells) (EMEA/H/C/004731/0000).

In addition, more recent PK comparisons across indications show that there is no apparent difference in transgene PK parameters across R/R MCL, 3L+ LBCL, 2L LBCL, and 3L+ FL.

In agreement with the recommendation of the SC, based on the preliminary evidence for an efficacy dose-response, extrapolation from previous dose analysis in DLBCL, as well as acceptable safety in both DL1S and DL2S to date, a recommended regimen of a single dose of 100 × 10 6  CAR+ T cells (DL2S) was selected for the MCL Cohort DC group . The study enrolled subjects at this regimen for further testing in the DC group.

## 2.5.2. Main study

## Title of Study

Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

## Methods

## Study 017001 design

<div style=\"page-break-after: always\"></div>

<!-- image -->

flu/cy

Two disease-specific cohorts were enrolled in this study; the DLBCL cohort, object of the initial marketing authorisation (Breyanzi EPAR), and the Mantle Cell Lymphoma (MCL) cohort which included subjects with MCL having received ≥ 2 prior lines of systemic MCL therapy and having been treated with an alkylating agent, a BTKi, and rituximab (or other CD20-targeted agent).

The study consisted of 3 periods:

Pre-treatment period : After successful screening, eligible subjects were enrolled and underwent leukapheresis to enable liso-cel product generation. If necessary, anticancer therapy for disease control (ie, bridging therapy) was allowed while liso-cel was being manufactured (ie, during the period between screening and lymphodepletive chemotherapy (LDC); in this case, subjects were required to have PET-positive disease prior to treatment with LDC and liso-cel. All subjects were required to meet relevant eligibility criteria before liso-cel administration.

Treatment period : The treatment period included a lymphodepletive chemotherapy (LDC) with fludarabine and cyclophosphamide followed by 1 (single-dose schedule) or 2 (2 dose schedule) doses of liso-cel administered IV. Day 1 was defined as the day of first liso-cel administration. In the singledose schedule, liso-cel was administered 2 to 7 days after completion of LDC. In the 2 dose schedule, subjects received the first dose as described above, and a second dose of liso-cel was given 14 days after the first dose of liso-cel (without further LDC between the 2 doses). The following dose levels were planned to be evaluated:

- -Dose Level 1 (DL1) : 50 × 10 6  CAR+ T cells (25 × 10 6  CD8+ CAR+ T cells and 25 × 10 6 CD4+ CAR+ T cells); single and 2-dose regimens tested: DL1S and DL1D , respectively
- -Dose Level 2 (DL2) : 100 × 10 6  CAR+ T cells (50 × 10 6  CD8+ CAR+ T cells and 50 × 10 6 CD4+ CAR+ T cells); single-dose regimen only: DL2S
- -Dose Level 3 (DL3) : 150 × 10 6  CAR+ T cells (75 × 10 6  CD8+ CAR+ T cells and 75 × 10 6 CD4+ CAR+ T cells); single-dose regimen only: DL3S

In the MCL cohort, only DL1S and DL2S were eventually evaluated. As highlighted above, a recommended regimen of a single dose of 100 × 10 6  CAR+ T cells (DL2S) was selected for the MCL Cohort DC group. This target dose of liso-cel for MCL is the same as approved for the other indications, i.e., 100 × 10 6  CAR+ viable T cells (consisting of a target 1:1 ratio of CD4+ and CD8+ T cell components) within a range of 44 to 120 × 10 6  CAR+ viable T cells, administered by IV infusion.

The first response evaluation was performed at approximately 28 days after liso-cel infusion.

Post-treatment follow-up period : After Day 29, subjects entered the post-treatment follow-up period, and were followed on this study for safety, disease progression, and survival for 2 years at approximately 3, 6, 9, 12, 18 and 24 months after their last dose of liso-cel, including after disease progression and/or the initiation of additional anticancer therapies.

<div style=\"page-break-after: always\"></div>

Long-term Follow-up : Upon discontinuation from the study, subjects who received liso-cel were asked to participate in a separate long-term follow-up study (Study GC-LTFU-001) for survival, longterm toxicity, and viral vector safety for up to 15 years post-last dose of liso-cel per health authority guidance on viral vector-based gene therapy products.

## Study participants

## Inclusion and exclusion criteria

## Main inclusion criteria

Subjects must meet all of the following criteria to be enrolled into this study:

- -Age ≥ 18 years at the time of consent
- -MCL diagnosis, confirmed with cyclin D1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization [FISH], or PCR) with relapsed or refractory disease after at least 2 prior lines of systemic MCL therapy). Subjects must have been treated with an alkylating agent, Bruton's tyrosine kinase inhibitor (BTKi), and rituximab (or other CD20targeted agent).
- -Archived tumor biopsy tissue available from the last relapse and corresponding pathology report available or, if at least one tumor-involved site is deemed accessible at time of screening, willing to undergo pre-treatment biopsy (excisional when possible) for disease confirmation. If the subject has never had a CR, a sample from the most recent biopsy is acceptable.
- -Positron emission tomography (PET)-positive disease according to the 'Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification' (Cheson, 2014)
- -Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- -Adequate organ functions including:
- o adequate bone marrow function to receive lymphodepleting as assessed by the investigator
- o Serum creatinine ≤ 1.5 x age-adjusted upper limit of normal (ULN) OR calculated creatinine clearance (Cockcroft and Gault) &gt; 30 mL/min/1.73 m 2  and
- o Alanine aminotransferase (ALT) ≤ 5 x ULN and total bilirubin &lt; 2.0 mg/dL (or&lt; 3.0 mg/dL for subjects with Gilbert's syndrome or lymphomatous infiltration of the liver)
- o adequate cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA) scan performed within 1 month of determination of eligibility
- -The study included patients with prior autologous and/or allogeneic HSCT in the absence of acute or chronic graft versus-host disease (GVHD)
- -Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on biopsy since completing the prior CD19-targeted therapy.

## Main exclusion criteria

- -Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)

<div style=\"page-break-after: always\"></div>

- -History of another primary malignancy not in remission for at least 2 years.
- -Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis
- -Subjects with uncontrolled and or active infections
- -Presence of Graft Versus Host Disease (GVHD)

## Treatments

## Pre-treatment period

## Leukapheresis

A leukapheresis collection was performed on each subject to obtain a sufficient quantity of peripheral blood mononuclear cells (PBMCs) for the production of the JCAR017 investigational product. In case of technical issues during the procedure or in the processing of the product such that it cannot be used for JCAR017 administration, a subsequent collection procedures were performed.

## Anticancer Treatments between Leukapheresis and Lymphodepleting (Bridging therapy)

If necessary, anticancer treatment was allowed for disease control while JCAR017 is being produced (i.e., after leukapheresis and prior to lymphodepleting chemotherapy); low dose chemotherapy (e.g., vincristine, rituximab, cyclophosphamide ≤ 300 mg/m2) is allowed if completed at least 7 days prior to the start of lymphodepleting chemotherapy.  Local radiation was allowed to a single lesion or subset of lesions if other un-irradiated PET-positive lymphoma lesions are present. If anticancer treatment is necessary during this time, the pre-treatment PET and CT assessments and other pre-treatment study procedures must have been performed after the completion of the anticancer treatment.

## Treatment period

## Lymphodepleting Therapy

Subjects received fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide (300 mg/m2/day for 3 days) prior to treatment with JCAR017. Lymphodepleting chemotherapy must be completed between 2 and 7 days before JCAR017 administration.

## Liso-cel Treatment

Liso-cel is comprised of autologous CD4+ and CD8+ T cells that express a CD19-specific CAR, provided as frozen cell suspensions for IV administration and in 2 individually formulated CD4+ and CD8+ T-cell suspensions in media containing DMSO for direct IV administration in equal CAR+ T cell quantities into the subject. The dose of JCAR017 was in between 50 and 150 x 10 6 ; only patients treated with a target dose of 50 or 100 x 10 6  were included in the analysis set.

## Post treatment period

Prophylactic or treatment measures for the management of CRS, neurotoxicity and other Adverse Events were allowed if considered necessary by treating clinicians.

## Objectives

## Study assessment

Efficacy assessments of response and progression were performed both by investigators and by an IRC. Disease evaluation at baseline and at response was determined according to the Lugano 2014 criteria.

<div style=\"page-break-after: always\"></div>

| Response Category   | PET-CT-Based Criteriab                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CR                  | Score 1, 2, or 3? with or without residual mass No evidence of FDG-avid disease in marrowd                                                                                                                                                                                                                                                                                                                                        |
| PR                  | Score 4 or 5? with reduced uptake compared with baseline and residual masses of any size Bone marrow with residual uptake higher than in normal marrow but reduced compared with baseline (Diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in marrow in the context of a nodal response, should consider further evaluation with MRI, biopsy, or interval scan. |
| SD                  | Score 4 or 5? with no significant change in FDG uptake from baseline Bone marrow unchanged from baseline                                                                                                                                                                                                                                                                                                                          |
| PD                  | Score 4 or 5? with an increase in intensity of uptake from nadir New FDG-avid foci consistent with lymphoma (may need biopsy or repeat scan if uncertain about etiology of foci)                                                                                                                                                                                                                                                  |

- Based on the Deauville 5-point Scale: 1: no uptake; 2: uptake ≤ mediastinum; 3: uptake &gt; mediastinum ≤ liver; ？ 4: moderately increased uptake &gt; liver; 5: markedly increased uptake &gt; liver and/or new lesions related to lymphoma; X: new areas of uptake unlikely to be related to lymphoma
- b. CT scans alone that are done per protocol, can be used to follow subjects for ongoing response in the absence of PET.
- C. If BMA/BMB performed, assessment should be by morphology. If indeterminate then IHC should be used (Cheson, 2014).
- d. For subjects in the MCL cohort who have evidence of bone marrow lymphoma involvement prior to LDC infusion based on the BMA/BMB or on PET scan performed closest to and prior to LDC, if the post-infusion BMA/BMB documenting no lymphoma involvement is done &gt;28 days post the PET scan documenting first CR, then that response assessment should be downgraded to PR and the result of the BMA/BMB negative for lymphoma involvement should be applied to the subsequent response assessment (including PET scan). For BMA/BMB results, the assessment window will be extended to + 42 days if there are no subsequent response assessment time points. This + 42-day window will only apply to overall assessments associated with the subject's last response assessment time point

Assessment of bone marrow involvement by lymphoma in the MCL cohort required a post-infusion bone marrow aspirate/bone marrow biopsy (BMA/BMB), performed within the visit window and up to a maximum of 28 days after the PET confirming CR.

Table 11. BMA/BMB Requirements in MCL Cohort

| Baseline              | Baseline                  | Post-Baseline                                                                                                                                                                                               |
|-----------------------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BM involvement by PET | BM involvement by BMA/BMB | To confirm CR assessed by PET scan                                                                                                                                                                          |
| Yes                   | Yes                       | Require BMA/BMB                                                                                                                                                                                             |
| Yes                   | No or Missing             | Require BMA/BMB                                                                                                                                                                                             |
| No                    | Yes                       | Require BMA/BMB                                                                                                                                                                                             |
| No                    | No                        | No BMA/BMB required                                                                                                                                                                                         |
| No                    | Missing                   | Require BMA/BMB if subject has prolonged cytopenia (laboratory-based Grade ≥ 3 anemia, neutropenia or thrombocytopenia at the Day 29 visit) that has not resolved to Grade ≤2 on or before the Day 90 visit |

BMA/BMB = Bone marrow aspirate/bone marrow biopsy; CR = Complete remission; MCL = Mantle Cell Lymphoma; PET = Positron emission tomography.

The evaluation of response was in charge of an Independent Review Committee (IRC).

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

Primary Endpoint

Table 12. Primary efficacy endpoint for Study 017001 MCL Cohort

| Objective                                        |                                                                                                                                   | Endpoint Description                                                                                                                                                                                                                                                                       |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                          |                                                                                                                                   |                                                                                                                                                                                                                                                                                            |
| To assess the antitumor activity of liso-cel ORR | To assess the antitumor activity of liso-cel ORR                                                                                  | The ORR was defined as the proportion of subjects with a Best Overall Response (BOR) of either CR or PR. The BOR was the best disease response recorded from the time of liso-cel infusion until disease progression, the start of another anticancer therapy, HSCT or end of study (EOS). |
| Estimands for the primary objective              | Estimands for the primary objective                                                                                               |                                                                                                                                                                                                                                                                                            |
| Population                                       | Adult patients with relapsed or refractory mantle cell lymphoma after at least 2 lines of systemic therapy.                       | Adult patients with relapsed or refractory mantle cell lymphoma after at least 2 lines of systemic therapy.                                                                                                                                                                                |
| Treatment condition<s>                           | Assignment to liso-cel, single administration, in a single arm trial                                                              | Assignment to liso-cel, single administration, in a single arm trial                                                                                                                                                                                                                       |
| Endpoint (variable)                              | ORR: proportion of subjects with a BOR of either CR or PR which is assessed by PET-CT by IRC using the 2014 Lugano Classification | ORR: proportion of subjects with a BOR of either CR or PR which is assessed by PET-CT by IRC using the 2014 Lugano Classification                                                                                                                                                          |
| Population-level summary                         | Overall response rate is defined as proportion of subjects with an IRC assessed BOR of either CR or PR.                           | Overall response rate is defined as proportion of subjects with an IRC assessed BOR of either CR or PR.                                                                                                                                                                                    |
| Intercurrent events and strategy to handle them  | Intercurrent events and strategy to handle them                                                                                   | Intercurrent events and strategy to handle them                                                                                                                                                                                                                                            |
| Subsequent Anti - cancer Therapy                 | Strategy While-on-treatment Rationale Assessments before the intercurrent event will be included                                  | Strategy While-on-treatment Rationale Assessments before the intercurrent event will be included                                                                                                                                                                                           |
| HSCT                                             | Strategy While-on-treatment Rationale Assessments before the intercurrent event will be included                                  | Strategy While-on-treatment Rationale Assessments before the intercurrent event will be included                                                                                                                                                                                           |
| Progression Assessed by IRC                      | Strategy While on treatment Rationale Assessment after the intercurrent event will be included                                    | Strategy While on treatment Rationale Assessment after the intercurrent event will be included                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Death   | Strategy                                                                      |
|---------|-------------------------------------------------------------------------------|
|         | While on treatment Rationale Assessment before the intercurrent event will be |

## Table 13 Secondary efficacy endpoints/PRO Objectives and Endpoints for Study 017001

Secondary Endpoints MCL Cohort

| Objective                                                                 | Endpoint    | Endpoint Description                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------------------------------------------------------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To assess the rate of CR and durability of antitumor activity of liso-cel | CR rate DOR | CR rate was defined as the proportion of subjects with a BOR of CR from the time of the liso-cel infusion until disease progression, or the start of another anticancer therapy or HSCT or EOS. DOR was defined as the interval from the first documentation of CR or PR to the earlier date of disease progression or death due to any cause. The first documentation of CR or PR was defined as the latest of all dates of required measurements to establish the response. |
| To estimate the PFS and OS of subjects treated with liso- cel             | PFS         | PFS was defined as the time from the date of the liso-cel infusion to the earlier date of disease progression or death due to any cause. The progression date was defined as the earliest date of all assessments that lead to a progression.                                                                                                                                                                                                                                 |
|                                                                           | PFS ratio   | PFS ratio was defined as the ratio of PFS to the most recent line of therapy (including systemic treatments, radiotherapy, and HSCT prior to liso- cel) to the PFS on liso-cel based on investigator assessment. The PFS to the most recent line of therapy prior to liso-cel was the time from the start date of the most recent line of therapy prior to liso-cel to the date of progression or informed consent if date of progression is entirely missing.                |
|                                                                           | OS          | OS was defined as the interval from the date of the liso-cel infusion to the date of death due to any cause. The OS analysis included all available survival information with long-term follow-up data.                                                                                                                                                                                                                                                                       |
| To assess HRQoL and health economics and outcome research                 | HRQoL       | Measurement of HRQoL changes as assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 and the EuroQol instrument EQ-5D-5L.                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

Table 13 Secondary efficacy endpoints/PRO Objectives and Endpoints for Study 017001 MCL Cohort

| Objective   | Endpoint                      | Endpoint Description                                                                      |
|-------------|-------------------------------|-------------------------------------------------------------------------------------------|
|             | Hospital resource utilization | Numbers of ICU inpatient days and non-ICU inpatient days and reasons for hospitalization. |

## First key secondary endpoint: complete response (CR) rate

| Population                                      | Adult patients with relapsed or refractory mantle cell lymphoma after at least 2 lines of systemic therapy.                                  |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment condition<s>                          | Assignment to liso-cel, single administration, in a single arm trial                                                                         |
| Endpoint (variable)                             | CRR: proportion of subjects with a BOR of CR after liso-cel infusion which is assessed by PET-CT by IRC using the 2014 Lugano Classification |
| Population-level summary                        | Complete response rate is defined as proportion of subjects with an IRC assessed BOR of CR.                                                  |
| Intercurrent events and strategy to handle them | Intercurrent events and strategy to handle them                                                                                              |
| Subsequent anticancer therapy                   | Strategy While on treatment Rationale Assessments before the intercurrent event will be included                                             |
| HSCT                                            | Strategy While on treatment Rationale Assessments before the intercurrent event will be included                                             |
| Progression assessed by IRC                     | Strategy While on treatment Rationale Assessments after the intercurrent event will be included                                              |
| Death                                           | Strategy While on treatment Rationale Assessments before the intercurrent events will be included.                                           |

<div style=\"page-break-after: always\"></div>

## Second key secondary endpoint: Duration of response (DOR)

| Population                                                             | Adult patients with relapsed or refractory mantle cell lymphoma after at least 2 lines of systemic therapy.                                                                                                                  |
|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment condition<s>                                                 | Assignment to liso-cel, single administration, in a single arm trial                                                                                                                                                         |
| Endpoint (variable)                                                    | DOR: time from first response (CR or PR) to disease progression or death from any cause, whichever occurs first up to 60 months after liso-cel infusion (EOS), which is assessed by IRC using the Lugano 2014 Classification |
| Population-level summary                                               | Median DOR with 95% CI                                                                                                                                                                                                       |
| Intercurrent events and strategy to handle them                        | Intercurrent events and strategy to handle them                                                                                                                                                                              |
| Received a subsequent anti-cancer therapy (including systemic therapy, | FDA censoring Strategy While on treatment Rationale Censor at last adequate response assessment before the intercurrent event. Sensitivity analysis (EMA censoring rules)                                                    |
| Received retreatment before PD or death                                | FDA censoring Strategy While-on-treatment Rationale Censor at last adequate response assessment before the intercurrent event .                                                                                              |

<div style=\"page-break-after: always\"></div>

| Strategy While on treatment Rationale Censor at last adequate response assessment before the intercurrent event.   |
|--------------------------------------------------------------------------------------------------------------------|

DOR was assessed based on the IRC evaluations for subjects who achieved a CR or PR using the Lugano 2014 criteria. A description of the censoring rules used for this application is found in Table 14. Sensitivity analyses were performed without censoring HSCT and without censoring new anticancer therapy, HSCT and missing at least two consecutive scheduled disease assessments

Table 14. Censoring rules for DOR and PFS

|                                                                                         | EMA Guidelines   | EMA Guidelines                                                            | FDA Guidelines   | FDA Guidelines                                                                     |
|-----------------------------------------------------------------------------------------|------------------|---------------------------------------------------------------------------|------------------|------------------------------------------------------------------------------------|
| Scenario                                                                                | Censor/ Event    | Date                                                                      | Censor/ Event    | Date                                                                               |
| Death or PD                                                                             | Event            | Earlier of PD or death                                                    | Event            | Earlier of PD or death                                                             |
| Start new subsequent anti-lymphoma therapy before PD or death                           | Event            | Earlier of PD or death                                                    | Censor           | Last adequate assessment date before starting new subsequent anti-lymphoma therapy |
| Experienced an event after missing at least 2 consecutive scheduled disease assessments | Event            | Earlier of PD or death                                                    | Censor           | Last adequate assessment date before 2consecutive missing assessment timepoints    |
| No documented PD and No Death                                                           | Censor           | Last adequate assessment date on or prior to the earliest censoring event | Censor           | Last adequate assessment date on or prior to the earliest censoring event          |

Censoring rules based on EMA guidance (2013) for cancer trial endpoints and FDA Guidance (2007)

## Sensitivity analyses

Sensitivity analyses of primary and secondary efficacy endpoints, including ORR, CR rate, DOR, PFS, and OS, was performed based on:

- -the Leukapheresed (ITT) Set
- -the response determined by investigator
- -Liso-cel-treated Efficacy Analysis Set

All the subjects in the ITT Set were used for the purpose of the ITT analyses. In the ITT analysis of ORR and CR rate, a subject in the ITT Set who achieved a BOR of CR or PR was considered a responder. A subject in the ITT Set who did not receive CAR-T cell product was considered not evaluable (ie, a non-responder). In the ITT analyses of PFS and OS, the date of the first leukapheresis

<div style=\"page-break-after: always\"></div>

served as the reference date instead of the date of the first liso-cel infusion. The ITT analyses of the primary and secondary efficacy endpoints were presented by assigned dose level and overall.

The analysis methods for all sensitivity analyses were the same as described for the primary analysis for the corresponding endpoints.

Post-hoc sensitivity analyses for DOR, PFS and OS were conducted to evaluate the impact of COVID-19 related deaths on the above-mentioned time to event endpoints, censoring the subjects who died in ongoing CR as discontinued from the study for DOR and PFS and alive for OS, and censoring the subject who died after experiencing PD as alive for OS.

## Subgroup analyses

Efficacy subgroup analyses were performed based on the following variables:

- Age: &lt; 65 versus ≥ 65 years and &lt; 75 versus ≥ 75 years at the time of the first liso-cel infusion
- Sex: male versus female
- Ethnicity: Hispanic or Latino versus not Hispanic or Latino
- Race: white versus other races
- Prior HSCT status: yes versus no
- Prior response status: refractory vs relapsed to last prior therapy. The status is refractory if a subject achieved less than a CR to last prior therapy; otherwise the status is relapsed
- Response to prior chemotherapy, defined as: chemorefractory vs chemosensitive to last prior chemotherapy-containing therapy. The status is chemorefractory if a subject achieved SD or PD to last chemotherapy-containing regimen or relapsed &lt;12 months after ASCT; otherwise the status is chemosensitive
- CNS disease status: known CNS disease vs no known CNS disease at the time of the first lisocel infusion
- Ki67 proliferation index: ≥ 30% versus &lt; 30%
- TP53 mutations: yes versus no
- Blastoid morphology: yes versus no

Subgroup analyses were performed for the primary and secondary efficacy endpoints. Forest plots were only generated for ORR and CRR. Some groupings of classes were considered if there were too few subjects in some subgroups.

Data from subjects treated with nonconforming product were analyzed separately from those treated with liso-cel and were excluded from the primary efficacy analysis.

## Sample size

The ORR and CR rates in patients with MCL who have received 1 or more prior therapies are low, 18% to 64% and 7% to 35%, respectively (Chiappella 2009, Chiappella 2015, Witzig 2017, Martin 2016, Morschhauser 2013, Andorsky 2016, Wang 2015). Based on a meta-analysis using random-effects model, the estimated ORR is 40% (95% CI: 28, 55) and CR is 18% (95% CI: 10, 30).

For MCL cohort, based on the null hypothesis of primary efficacy endpoint ORR ≤ 40% and an alternative hypothesis of ORR &gt; 40%, being powered for ORR = 65%, a sample size of 50 subjects in the MCL primary analysis set (PAS) from the Dose Finding, Dose Expansion and Dose Confirmation

<div style=\"page-break-after: always\"></div>

groups will provide 93% power to demonstrate statistical significance based on an exact test at a 1sided significance level of 0.025. For the key secondary efficacy endpoint of CR rate, based on the null hypothesis of CR rate ≤ 18% and an alternative hypothesis of CR rate &gt; 18%, being powered for CR rate = 40%, 50 subjects will provide 97% power to demonstrate statistical significance based on an exact test at a 1-sided significance level of 0.025. The key secondary hypothesis (regarding CR rate) will only be tested at the same significance level as for the ORR if the primary hypothesis for ORR is rejected.

## Randomisation

Not applicable as the study is a single arm trial

## Blinding (masking)

Not applicable as the study is an open label study

## Statistical methods

The MCL cohort consisted of subjects with R/R disease having received ≥ 2 prior lines of systemic MCL therapy including an alkylating agent, BTKi, and rituximab (or other CD20-targeted agent). Prior to Protocol Amendment 7, subjects were required to have received at least 1 prior therapy.

The statistical analysis plan (SAP) is based on Amendment 07 of the study protocol, dated 19 December 2019.

The primary efficacy endpoint was ORR, the key secondary endpoint was CR rate, and the secondary efficacy endpoints included DOR and PFS based on the Lugano 2014 criteria. The findings of the IRC were considered primary for these efficacy endpoints.

The hypothesis testing was planned to be done at the time of the primary analysis and to be conducted on the MCL PAS based on the IRC assessments at a one-sided significance level of 0.025.

The primary analysis for the MCL Cohort was to occur after at least 50 subjects in the MCL PAS from DE, DF, and DC group of MCL treated at the recommended regimen; these subjects had been followed for at least 6 months from first response or until death, disease progression, or withdrawal from study.

Based on health authority feedback received in April 2021 to provide data for registration from at least 60 subjects treated with liso-cel who had at least 6 months follow-up for DOR, it was decided to perform the primary analysis once a minimum of 70 subjects were treated and had at least 6 months follow-up from the first objective response.

## Hypothesis Testing

The primary analysis conducted on the MCL PAS based on the IRC assessments was planned for this study at one-sided significance level of 0.025.

Two hypothesis tests were performed in the following sequential order for primary endpoint (ORR) and key secondary endpoint (CR):

H0 : ORR ≤ 40% versus H 1: ORR &gt; 40%; 2) H0 : CR rate ≤ 18% versus H 1: CR rate &gt; 18%

The null hypothesis was rejected if the p-value was less than 0.025. Only after rejecting the null hypothesis in the first hypothesis test, the second hypothesis testing could be performed. A p-value and the 2-sided 95% exact CI based on the Clopper-Pearson method for the ORR and CR rate were provided.

<div style=\"page-break-after: always\"></div>

Results of these hypothesis testing analyses were reported in the 017001 Addendum 02 CSR (data cut off 19-Jan-2023) and showed that both endpoints were met. Hypothesis testing was not repeated at the final analysis (data cut off 16-May-2024).

The updated efficacy analysis was based on the MCL PAS and MCL Liso-cel-treated Efficacy Analysis set from the 16-May-2024 data cut.

For binary endpoints (ORR and CR rate), the frequency distribution (n, %) was provided along with the 2-sided 95% exact CI based on Clopper-Pearson method. For time-to-event endpoints (DOR, PFS, and OS), the KM product limit method was used to estimate the survival function. Event rates at specific time points were estimated from KM curves. Medians together with two-sided 95% CIs were calculated. 95% CIs for all endpoints were two sided.

## Results

## Participant flow

<!-- image -->

- c  1 subject underwent leukapheresis and was retrospectively determined to have met exclusion criteria 2 regarding prior malignancies (this subject was discontinued prior to receiving LDC and liso-cel infusion).
- d  Defined as any product wherein one of the CD8 or CD4 cell components did not meet one of the requirements to be considered liso-cel but was considered appropriate for infusion.

## Recruitment

A total of 105 subjects were screened for the MCL cohort at 14 sites in the US; as of the 16-May-2024 data cut-off, 40 (45.5%) subjects in the Liso cel-treated Analysis Set had completed the study and 0 were ongoing.

## Conduct of the study

The original protocol for this study was dated 21-May-2015. As of the data cutoff date of 19 January 2023 for the addendum 2 CSR and the 16-May-2024 for this closeout CSR, 8 protocol amendments and 2 administrative letters were filed during the conduct of the study.

<div style=\"page-break-after: always\"></div>

Table 15. summary key changes to protocol 017001

| Document (Amendment)/Date   | Summary of Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 1/ 24-Sep-2015    | Correctedandcompletedeligibilitycriteriaforadequaterenalfunction Provided additional information for continued liso-cel treatment (additional cycles) in subjects who achieve a response following liso-celtherapy.(Note,the optionfor additional cycles was removed inAmendment 6.) Madelocal analysis of cytokinesanoptionalevaluation Provided additional dosing recommendations for administration of LDC Added instructions to administer the neuropsychological test at the EOSvisit forsubjects who withdrawmore than 2 months after the Day 90visit and before Day 180 Specified conditions under which assessment of immunoglobulins is not required Specified that neuropsychological tests will only be administered to English-speaking subjects Added details regarding number of subjects enrolled in the regimen-finding portion of the study, the number of subjects within eachdiseasecohort, and thenumberofsubjects thatmaybe addedtoagivendoseregimenforfurtherevaluation characteristicsbyborrowingefficacydataacross disease cohorts. |
| Amendment 2/ 14-Mar-2016    | A second group of subjects may be enrolled and treated at a higher dose of liso-cel (100 x 10° CAR+ T cells) on the single- and 2 dose schedules if acceptable safety is observed among at least 6 subjects treated with 50 x 10° CAR+ T cells (Group A) on a single- dose schedule. Theplannedmaximumsamplesizewasincreasedfrom70to90subjects. Language regarding possible exploration of altemative doses or schedules of LDC was removed. Updated clinical data from patients with ALL and NHL who were treated with JCAR014 in the Fred Hutchinson 2639 study (NCT #01865617). A separate Bayesian adaptive design simulation report for Dose Level 2(Group B) was added.                                                                                                                                                                                                                                                                                                                                                                               |
| Amendment 3/ 29-Jun-2016    | Allowed for a third, higher liso-cel dose level (150 x 10° CAR+ T cells) Allowed for expansion groups to be opened at a dose level once that level has been shown likely to be safe and efficacious during the dose-finding portion of the study Made efficacy a primary endpoint rather than secondary Updated the sample size of the study and otherstatistical methods as aresult of the above changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

| Document (Amendment)/Date   | Summary of Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                             | Added an SC to be responsible for overseeing the conduct and scientific validity and integrity of the trial, and clarified the role of the SRC Specified that efficacy evaluations will be performed both by the investigator and by a central IRC Lengthened the follow-uptime onthis studyto 2years before subjects enrollinthe long termfollowup study, and added appropriate evaluations for this time period Clarified that subjects with PMBCL are allowed Changed inclusion criteria tonolongerallowsubjects withrelapse within1year of frontlinechemo-immunotherapy andnoteligible for auto-HSCT (ie, disallowed second-line transplant ineligible subjects) Specified that subjectsmust have archived tumorbiopsy tissue available or,if at least one tumor-involved siteis deemed accessible at time of screening,willing to undergobiopsyfor disease confirmation at baseline Added an exclusion for prior CAR T-cell or other genetically-modified T cell therapy Clarified that steroids can be used after lack of response, subsequent therapy for lymphoma, or 1 year following liso-cel treatment Included additional informationregarding MAS Clarified the timing of pre-treatment PET and CT scans Removedoptionalblooddrawsforcytokines Expanded definitions ofrelationship to study drug.The previous definitions ofrelationship to study drug focused on the time course of the event with regards to liso-cel treatment. The updated definitions allow a causal relationship for any reason. With the longer duration of this study, this change allows for long-term sequelae to be assessed more accurately. |
| Amendment 4/ 05-Jan-2017    | Defined a more homogeneous PAS for efficacy analyses. Added provision for a DC group to further test the safety and efficacy at arecommended dose regimen already estimated tobe safe and effective. Added a prespecified interim analysis after approximately50 subjects in the PAS have been followed for at least 3months oruntil death, disease progression, or withdrawal from study, and the primary analysis after at least 75 subjects in the PAS have been treated and the last subject has been followed for at least 6 months or until death, disease progression, or withdrawal from study. A final analysis will be carried out after all subjects have completed or discontinued the study due to any reason. No formal hypothesis testing will be performed at the final analysis. Added chemorefractory subgroup and an efficacy hypothesis for this subgroup. Changed CR and DOR from primary to secondary endpoints, changed assessment of CR using Bayesian methods to exploratory, and added PFS ratio as a secondary endpoint.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Document (Amendment)/Date   | Summaryof Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                             | Added subgroup analyses for safety and efficacy analyses. Clarified that all subjects in the DLBCL Cohort must have relapsed orrefractory disease after atleast 2 lines of therapy or after autologous HSCT and clarified definition of DLBCL subjects with regard to current WHO guidelines. Allowed subjects with CNS involvement of their lymphoma, and excluded subjects with CNS-only disease. Added HRQoL and HEOR as secondary objectives. Added guidance for administration of liso-cel in an outpatient setting when appropriate. updating the CRS management algorithm Updated the safety reporting rules (including increasing the reporting period for all AEs from 30 to 90 days following liso-cel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Amendment 5/ 14-Aug-2017    | Allowed for more than 1 dose confirmation group, and added reference to stopping rules for a dose confirmation group were implemented to help detect safety and futility signals that may have occurred during the course of a DC group. Amended the timing of the prespecified interim analysis to occur when the following conditions were met: 1) at least 75 subjects in the PAS have been treated at 1 recommended regimen across the DF, DE, and DC groups; 2) approximately the first 50 subjects treated in the DC group of the PAS have been followed for at least 3 months, or until death, disease progression, or withdrawal from the study; 3) at least the first 20 subjects treated in the DC group of the PAS have been followed for at least 6 months or until death, disease progression, or withdrawal from the study. Added safety and futility monitoring boundaries for DC group Excluded further enrollment of subjects with ECOG performance status of 2 at screening Updated CRS management algorithm and guidance regarding NT based on most recent data. More specific language was added regarding actions to be taken in cases of potential CRS, especially for Grade 1 and 2 events. Changed DL 1 to 25 x 10° CAR+ T cells (previously was 10 x 10° CAR+ T cells). Updated PAS to exclude FL3B and DLBCL transformed from indolent histologies, as well as those with ECOG performance status of 2 or prior allo-HSCT Specified evaluations needed in subjects who receive leukapheresis but no treatment |
| Amendment 6/13- Apr-2018    | scans and allow collection of follow-up response data 6 months from first response.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

| Document (Amendment)/Date   | Summary of Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                             | Added sentence to emphasize that fludarabine doses should be adjusted in subjects withrenal insufficiency, in accordance with the fludarabine label Changed the PK objective from primary to secondary Refined CRS and NT management algorithms to be consistent with letter previously sent to sites Added guidance regarding subject clinical stability prior to liso-cel administration Removed the possibility of additional cycles for subjects who responded to liso-cel but did not achieve CR Added flexibility to enrollment numbers to ensure adequate enrollment for the PAS |
| Amendment 7/ 19-Dec-2019    | Updated inclusion criterion to specify that subjects must have failed 2lines of prior systemic therapy and have been treated with Defined and allowed inclusion of a dose-confirmation group for the MCL cohort Updated the definition of the MCL primary analysis set, study duration, timing of analysis, statistical methods, sample size, and power calculations.                                                                                                                                                                                                                   |
| Amendment 8/ 30-Aug-2021    | Included the requirement of having a post-baseline assessment to confirm CR in MCL subjects with a baseline bone marrow bone marrow biopsy.                                                                                                                                                                                                                                                                                                                                                                                                                                             |

## Impact of COVID-19 Pandemic

Two Dear Investigator Letters (dated 13-Mar-2020 and 19-Mar-2020) were sent to the sites detailing the required adjustments to the conduct of the study due to the pandemic and outlined the temporary suspension of screening, enrolment, and apheresis in all cellular therapy trials conducted by the Sponsor. A follow-up Dear Investigator Letter dated 27-Apr-2020 described the conditions to resume screening and consent for new subjects at the clinical sites, outlining study conduct considerations and approaches to protect the safety of study subjects and personnel, and to ensure scientific integrity, in light of the potential impact of COVID-19 disruptions to the study. The dear Investigator Letters were also submitted to regulatory health authorities and/or the ethics committees. As a result of these guidance, study enrolment was on hold for approximately 2 months and resumed in May 2020. As of

<div style=\"page-break-after: always\"></div>

the data cutoff date of 19-Jan-2023 for the addendum 2 CSR, the study and the COVID-19 pandemic were still ongoing. At the time of the final analysis (data cutoff date of 16-May2024) WHO had already declared an end to the global Public Health Emergency for COVID-19 (05-May-2023).

## Protocol deviations

## · GCP deviation and serious breach

The contract research organisation, which provided eCOA services for the study, experienced a cybersecurity event on 20-Sep- 2020 that resulted in taking their clinical servers offline while the event was investigated and effectively controlled. While the CRO servers were offline, CRO provided a series of communications including mitigations for continuity to Sponsor and site staff. Upon restoring CRO's servers on 01-Oct-2020, all data were uploaded to the clinical database. Based on the scope of the cybersecurity event, and because the data transmissions were simply delayed and there was no safety reporting impacted, Sponsor has determined that the cybersecurity event had no impact on patient safety or data integrity.

No GCP deviations impacting the study were reported.

Table 16. Summary of major protocol deviations - Liso-cel-treated Analysis Set

|                                                | DL2S N = 82   | DL1S N=6   | Total N =88   |
|------------------------------------------------|---------------|------------|---------------|
| Subjects with Major Protocol Deviations, n (%) | 6 (7.3)       | 0          | 6 (6.8)       |
| Study Treatment Deviation, n (%)               | 4 (4.9)       | 0          | 4 (4.5)       |
| Prohibited Medications Deviation, n (%)        | 1 (1.2)       | 0          | 1 (1.1)       |
| Study Procedure Deviation, n (%)               | 1 (1.2)       | 0          | 1 (1.1)       |
| Number of subjects with, n (%)                 |               |            |               |
| One major protocol deviation                   | 6 (7.3)       |            | 6 (6.8)       |

## Baseline data

Table 17. Demographic and Baseline Characteristics - PAS, Liso-cel-treated Analysis Set and the Leukapheresed Set (ITT) MCL

|                  | PAS DL2S N = 75   | Liso-cel-treated Analysis Set (DL2S+DL1S) N = 88   | Leukapheresed Set (ITT) (DL2S+DL1S) N = 104   |
|------------------|-------------------|----------------------------------------------------|-----------------------------------------------|
| Age (years) a    |                   |                                                    |                                               |
| N                | 75                | 88                                                 | 104                                           |
| Median           | 69.0              | 68.5                                               | 68.0                                          |
| Min, Max         | 36, 86            | 36, 86                                             | 36, 86                                        |
| Age Group, n (%) |                   |                                                    |                                               |
| < 65 years       | 20 (26.7)         | 24 (27.3)                                          | 33 (31.7)                                     |
| ≥ 65 years       | 55 (73.3)         | 64 (72.7)                                          | 71 (68.3)                                     |
| < 75 years       | 60 (80.0)         | 70 (79.5)                                          | 82 (78.8)                                     |

<div style=\"page-break-after: always\"></div>

Table 17. Demographic and Baseline Characteristics - PAS, Liso-cel-treated Analysis Set and the Leukapheresed Set (ITT) MCL

|                                           | PAS DL2S N = 75   | Liso-cel-treated Analysis Set (DL2S+DL1S) N = 88   | Leukapheresed Set (ITT) (DL2S+DL1S) N = 104   |
|-------------------------------------------|-------------------|----------------------------------------------------|-----------------------------------------------|
| ≥ 75 years                                | 15 (20.0)         | 18 (20.5)                                          | 22 (21.2)                                     |
| Sex, n (%)                                |                   |                                                    |                                               |
| Male                                      | 56 (74.7)         | 67 (76.1)                                          | 81 (77.9)                                     |
| Female                                    | 19 (25.3)         | 21 (23.9)                                          | 23 (22.1)                                     |
| Race Group, n (%)                         |                   |                                                    |                                               |
| White                                     | 65 (86.7)         | 77 (87.5)                                          | 90 (86.5)                                     |
| Others: Include Other                     |                   |                                                    |                                               |
| Races                                     | 7 (9.3)           | 8 (9.1)                                            | 11 (10.6)                                     |
| Unknown or Missing                        | 3 (4.0)           | 3 (3.4)                                            | 3 (2.9)                                       |
| Race, n (%)                               |                   |                                                    |                                               |
| American Indian or Alaska Native          | 0                 | 0                                                  | 1 (1.0)                                       |
| Asian                                     | 4 (5.3)           | 5 (5.7)                                            | 6 (5.8)                                       |
| Black or African American                 | 2 (2.7)           | 2 (2.3)                                            | 3 (2.9)                                       |
| Native Hawaiian or Other Pacific Islander | 1 (1.3)           | 1 (1.1)                                            | 1 (1.0)                                       |
| White                                     | 65 (86.7)         | 77 (87.5)                                          | 90 (86.5)                                     |
| Not Reported                              | 3 (4.0)           | 3 (3.4)                                            | 3 (2.9)                                       |
| Ethnicity, n (%)                          |                   |                                                    |                                               |
| Hispanic or Latino                        | 4 (5.3)           | 4 (4.5)                                            | 5 (4.8)                                       |
| Not Hispanic or Latino                    | 68 (90.7)         | 81 (92.0)                                          | 96 (92.3)                                     |
| Unknown                                   | 3 (4.0)           | 3 (3.4)                                            | 3 (2.9)                                       |
| Screening ECOG, n (%)                     |                   |                                                    |                                               |
| 0                                         | 41 (54.7)         | 48 (54.5)                                          | 56 (53.8)                                     |
| 1                                         | 34 (45.3)         | 40 (45.5)                                          | 47 (45.2)                                     |
| 2                                         | 0                 | 0                                                  | 1 (1.0)                                       |

Pre-LDC ECOG score, n (%) b

<div style=\"page-break-after: always\"></div>

Table 17. Demographic and Baseline Characteristics - PAS, Liso-cel-treated Analysis Set and the Leukapheresed Set (ITT) MCL

|                                | PAS DL2S N = 75   | Liso-cel-treated Analysis Set (DL2S+DL1S) N = 88   | Leukapheresed Set (ITT) (DL2S+DL1S) N = 104   |
|--------------------------------|-------------------|----------------------------------------------------|-----------------------------------------------|
| 0                              | 37 (49.3)         | 41 (46.6)                                          | 42 (40.4)                                     |
| 1                              | 37 (49.3)         | 45 (51.1)                                          | 49 (47.1)                                     |
| 2                              | 0                 | 1 (1.1)                                            | 1 (1.0)                                       |
| 3 c                            | 1 (1.3)           | 1 (1.1)                                            | 1 (1.0)                                       |
| LDH prior to LDC, U/L          |                   |                                                    |                                               |
| N                              | 75                | 88                                                 | 93                                            |
| Median                         | 235.0             | 233.5                                              | 236.0                                         |
| Min, Max                       | 78, 4651          | 78, 4651                                           | 78, 4651                                      |
| ≥ 500 U/L, n (%) d             | 7 (9.3)           | 10 (11.4)                                          | 11 (11.8)                                     |
| < 500 U/L, n (%) d             | 68 (90.7)         | 78 (88.6)                                          | 82 (88.2)                                     |
| SPD per IRC prior to LDC, cm 2 |                   |                                                    |                                               |
| N                              | 71                | 80                                                 | 84                                            |
| Median                         | 11.760            | 13.855                                             | 14.590                                        |
| Min, Max                       | 0.66, 77.20       | 0.66, 99.51                                        | 0.66, 99.51                                   |
| ≥ 50 cm 2 , n (%) d            | 4 (5.6)           | 7 (8.8)                                            | 8 (9.5)                                       |
| < 50 cm 2 , n (%) d            | 67 (94.4)         | 73 (91.3)                                          | 76 (90.5)                                     |
| Baseline CRP, mg/L             |                   |                                                    |                                               |
| N                              | 75                | 87                                                 | 91                                            |
| Median                         | 14.300            | 15.000                                             | 15.500                                        |
| Min, Max                       | 0.25, 1444.00     | 0.25, 1444.00                                      | 0.25, 1444.00                                 |
| < 20 mg/L, n (%) d             | 50 (66.7)         | 53 (60.9)                                          | 54 (59.3)                                     |
| ≥ 20 mg/L, n (%) d             | 25 (33.3)         | 34 (39.1)                                          | 37 (40.7)                                     |
| Screening LVEF, n (%)          |                   |                                                    |                                               |
| N                              | 75                | 88                                                 | 104                                           |
| Median                         | 60.0              | 60.0                                               | 60.0                                          |
| Min, Max                       | 45, 88            | 45, 88                                             | 45, 88                                        |

<div style=\"page-break-after: always\"></div>

Table 17. Demographic and Baseline Characteristics - PAS, Liso-cel-treated Analysis Set and the Leukapheresed Set (ITT) MCL

|                        | PAS DL2S N = 75   | Liso-cel-treated Analysis Set (DL2S+DL1S) N = 88   | Leukapheresed Set (ITT) (DL2S+DL1S) N = 104   |
|------------------------|-------------------|----------------------------------------------------|-----------------------------------------------|
| ≥ 40 to < 50%, n (%) d | 4 (5.3)           | 5 (5.7)                                            | 5 (4.8)                                       |
| ≥ 50%, n (%) d         | 71 (94.7)         | 83 (94.3)                                          | 99 (95.2)                                     |
| Pre-LDC CrCl, n (%)    |                   |                                                    |                                               |
| N                      | 74                | 87                                                 | 92                                            |
| Median                 | 80.679            | 79.688                                             | 80.679                                        |
| Min, Max               | 39.93, 195.66     | 39.93, 195.66                                      | 39.93, 195.66                                 |
| < 60 mL/min, n (%) d   | 17 (23.0)         | 19 (21.8)                                          | 19 (20.7)                                     |
| ≥ 60 mL/min, n (%) d   | 57 (77.0)         | 68 (78.2)                                          | 73 (79.3)                                     |

Baseline is the last observation collected on or prior to the date of the first product infusion

a Age (years)=(date of first liso-cel infusion - date of birth + 1) / 365.25 (rounded down to an integer).

b Pre-LDC ECOG score is the most recent ECOG score prior to the start of lymphodepleting chemotherapy.

c Note: this subject [redacted]

d Percentages are based on number of subjects with non-missing results.

Table 18. Baseline Disease Characteristics - PAS, Liso-cel-treated Analysis Set and the Leukapheresed Set (ITT) MCL

|                                 | PAS DL2S N = 75   | Liso-cel-treated Analysis Set (DL2S+DL1S) N = 88   | Leukapheresed Set (ITT) (DL2S+DL1S) N = 104   |
|---------------------------------|-------------------|----------------------------------------------------|-----------------------------------------------|
| Ki67 proliferation fraction (%) |                   |                                                    |                                               |
| N                               | 68                | 81                                                 | 97                                            |
| Median                          | 60.00             | 60.00                                              | 65.00                                         |
| Min, Max                        | 5.0, 95.0         | 5.0, 95.0                                          | 5.0, 100.0                                    |
| ≥ 30%                           | 56 (74.7)         | 66 (75.0)                                          | 82 (78.8)                                     |
| < 30%                           | 12 (16.0)         | 15 (17.0)                                          | 15 (14.4)                                     |
| TP53 mutation                   |                   |                                                    |                                               |
| Yes                             | 18 (24.0)         | 20 (22.7)                                          | 25 (24.0)                                     |
| No                              | 30 (40.0)         | 34 (38.6)                                          | 37 (35.6)                                     |

<div style=\"page-break-after: always\"></div>

Table 18. Baseline Disease Characteristics - PAS, Liso-cel-treated Analysis Set and the Leukapheresed Set (ITT) MCL

|                                             | PAS DL2S N = 75   | Liso-cel-treated Analysis Set (DL2S+DL1S) N = 88   | Leukapheresed Set (ITT) (DL2S+DL1S) N = 104   |
|---------------------------------------------|-------------------|----------------------------------------------------|-----------------------------------------------|
| Indeterminate                               | 2 (2.7)           | 4 (4.5)                                            | 6 (5.8)                                       |
| Not Done                                    | 25 (33.3)         | 30 (34.1)                                          | 36 (34.6)                                     |
| Blastoid morphology                         |                   |                                                    |                                               |
| Yes                                         | 21 (28.0)         | 27 (30.7)                                          | 30 (28.8)                                     |
| No                                          | 43 (57.3)         | 48 (54.5)                                          | 55 (52.9)                                     |
| Not Done                                    | 11 (14.7)         | 13 (14.8)                                          | 19 (18.3)                                     |
| Complex karyotype                           |                   |                                                    |                                               |
| Yes                                         | 23 (30.7)         | 26 (29.5)                                          | 30 (28.8)                                     |
| No                                          | 29 (38.7)         | 35 (39.8)                                          | 40 (38.5)                                     |
| Indeterminate                               | 4 (5.3)           | 4 (4.5)                                            | 4 (3.8)                                       |
| Not Done                                    | 19 (25.3)         | 23 (26.1)                                          | 30 (28.8)                                     |
| Refractory or Relapsed a , n (%)            |                   |                                                    |                                               |
| Refractory                                  | 49 (65.3)         | 58 (65.9)                                          | 70 (67.3)                                     |
| Relapsed                                    | 26 (34.7)         | 30 (34.1)                                          | 34 (32.7)                                     |
| Prior BTKi                                  | 75 (100)          | 84 (95.5)                                          | 98 (94.2)                                     |
| Refractory to BTKi a                        | 41 (54.7)         | 47 (53.4)                                          | 55 (52.9)                                     |
| Prior ibrutinib                             | 58 (77.3)         | 66 (75.0)                                          | 74 (71.2)                                     |
| Refractory to ibrutinib a                   | 30 (40.0)         | 35 (39.8)                                          | 41 (39.4)                                     |
| Prior venetoclax                            | 24 (32.0)         | 24 (27.3)                                          | 31 (29.8)                                     |
| Refractory to venetoclax a                  | 17 (22.7)         | 17 (19.3)                                          | 22 (21.2)                                     |
| Prior alkylator                             | 75 (100)          | 88 (100)                                           | 104 (100)                                     |
| Prior bendamustine                          | 49 (65.3)         | 55 (62.5)                                          | 65 (62.5)                                     |
| Prior anthracycline                         | 54 (72.0)         | 65 (73.9)                                          | 75 (72.1)                                     |
| Chemorefractory or chemosensitive b , n (%) |                   |                                                    |                                               |
| Chemorefractory                             | 22 (29.3)         | 28 (31.8)                                          | 34 (32.7)                                     |

<div style=\"page-break-after: always\"></div>

Table 18. Baseline Disease Characteristics - PAS, Liso-cel-treated Analysis Set and the Leukapheresed Set (ITT) MCL

|                                                              | PAS DL2S N = 75   | Liso-cel-treated Analysis Set (DL2S+DL1S) N = 88   | Leukapheresed Set (ITT) (DL2S+DL1S) N = 104   |
|--------------------------------------------------------------|-------------------|----------------------------------------------------|-----------------------------------------------|
| Relapse <12 m after ASCT                                     | 3 (4.0)           | 3 (3.4)                                            | 5 (4.8)                                       |
| Last Chemo                                                   | 19 (25.3)         | 25 (28.4)                                          | 29 (27.9)                                     |
| Chemosensitive                                               | 53 (70.7)         | 60 (68.2)                                          | 70 (67.3)                                     |
| Active CNS disease at first liso-cel infusion                |                   |                                                    |                                               |
| Yes                                                          | 7 (9.3)           | 7 (8.0)                                            | 7 (6.7)                                       |
| No                                                           | 68 (90.7)         | 81 (92.0)                                          | 87 (83.7)                                     |
| Not available                                                | 0                 | 0                                                  | 10 (9.6)                                      |
| Best prior response c                                        |                   |                                                    |                                               |
| Complete response                                            | 63 (84.0)         | 71 (80.7)                                          | 83 (79.8)                                     |
| Partial response                                             | 9 (12.0)          | 12 (13.6)                                          | 13 (12.5)                                     |
| Stable disease                                               | 1 (1.3)           | 2 (2.3)                                            | 3 (2.9)                                       |
| Progressive disease                                          | 2 (2.7)           | 3 (3.4)                                            | 5 (4.8)                                       |
| Months from eligible diagnosis to first liso- cel infusion d |                   |                                                    |                                               |
| N                                                            | 75                | 88                                                 | 92                                            |
| Median                                                       | 67.90             | 63.75                                              | 67.35                                         |
| Min, Max                                                     | 3.9, 299.5        | 3.9, 299.5                                         | 3.9, 299.5                                    |

a  Relapsed vs Refractory is defined as best response of CR vs best response of PR, SD, or PD to last systemic or transplant treatment with curative intent. Determined by the response to the CRF question 'Was disease relapsed or refractory to last therapy?'. Refractory to prior BTKi, ibrutinib, or venetoclax is defined as any response to prior BTKi, ibrutinib, or venetoclax is less than PR.

b  Chemorefractory is defined as experiencing SD or PD to last chemo-containing regimen or relapsed &lt;12 months after ASCT; otherwise, it is chemosensitve.

c  Best prior response is the best response to any prior therapy.

d  Eligible diagnosis is defined as a subject's mantle cell lymphoma diagnosis which met eligibility for the clinical trial. The date of this diagnosis captured in the database is used for calculating the time from diagnosis. When diagnosis dates are partial, imputed diagnosis dates have been used to calculate duration to liso-cel infusion.

<div style=\"page-break-after: always\"></div>

Table 19. Prior Treatments - PAS, Liso-cel-treated Analysis Set and the Leukapheresed Set (ITT) MCL

|                                               | PAS (DL2S) N=75   | Liso-cel-treated Analysis Set (DL2S+DL1S) N=88   | Leukapheresed Set (ITT) (DL2S+DL1S) N=104   |
|-----------------------------------------------|-------------------|--------------------------------------------------|---------------------------------------------|
| Prior treatment a , n (%)                     |                   |                                                  |                                             |
| Hematopoietic stem cell transplant            | 24 (32.0)         | 29 (33.0)                                        | 36 (34.6)                                   |
| Allogeneic                                    | 4 (5.3)           | 6 (6.8)                                          | 8 (7.7)                                     |
| Autologous                                    | 22 (29.3)         | 26 (29.5)                                        | 33 (31.7)                                   |
| Radiotherapy                                  | 22 (29.3)         | 24 (27.3)                                        | 28 (26.9)                                   |
| Systemic Treatment                            | 75 (100)          | 88 (100)                                         | 104 (100)                                   |
| Number of prior systemic treatments b         |                   |                                                  |                                             |
| N                                             | 75                | 88                                               | 104                                         |
| Mean (StD)                                    | 3.8 (1.99)        | 3.7 (1.94)                                       | 3.7 (1.91)                                  |
| Median                                        | 3.0               | 3.0                                              | 3.0                                         |
| Min, Max                                      | 2, 11             | 1, 11                                            | 1, 11                                       |
| Number of prior systemic treatments b , n (%) |                   |                                                  |                                             |
| 1 prior regimen                               | 0                 | 2 (2.3)                                          | 2 (1.9)                                     |
| 2 prior regimens                              | 25 (33.3)         | 29 (33.0)                                        | 32 (30.8)                                   |
| 3 prior regimens                              | 17 (22.7)         | 19 (21.6)                                        | 27 (26.0)                                   |
| 4 prior regimens                              | 9 (12.0)          | 12 (13.6)                                        | 13 (12.5)                                   |
| ≥ 5 prior regimens                            | 24 (32.0)         | 26 (29.5)                                        | 30 (28.8)                                   |

Intrathecal (IT) chemotherapy is not calculated in the systemic lines of prior treatment, if given  a  Only regimens post diagnosis of MCL are included. Bridging anticancer therapy for disease control was not counted as a prior systemic regimen unless the outcome was complete response.

HSCT was not included as systemic therapy

<div style=\"page-break-after: always\"></div>

Table 20. Summary of Anticancer Treatment for Disease Control (Bridging Therapy) - PAS, Liso-cel-treated Analysis Set and the Leukapheresed Set (ITT) MCL

|                                | PAS (DL2S) N=75   | Liso-cel-treated Analysis Set (DL2S+DL1S) N=88   | Leukapheresed Set (ITT) (DL2S+DL1S) N=104   |
|--------------------------------|-------------------|--------------------------------------------------|---------------------------------------------|
| Anticancer Treatment a , n (%) |                   |                                                  |                                             |
| Yes                            | 49 (65.3)         | 58 (65.9)                                        | 69 (66.3)                                   |
| No                             | 26 (34.7)         | 30 (34.1)                                        | 35 (33.7)                                   |
| Type of Treatment b , n (%)    |                   |                                                  |                                             |
| Systemic Treatment only        | 35 (71.4)         | 42 (72.4)                                        | 51 (73.9)                                   |
| Radiotherapy only              | 3 (6.1)           | 3 (5.2)                                          | 3 (4.3)                                     |
| Both                           | 11 (22.4)         | 13 (22.4)                                        | 15 (21.7)                                   |

Bridging therapies are included in this table unless the outcome is complete response

a  CRF captured new anticancer treatment for disease control that was started after consent and prior to lymphodepleting chemotherapy. The percentage is calculated based on the number of subjects in each treatment arm.

b  The denominator is the number of subjects who received anticancer treatment.

Among the 88 subjects in the Liso cel-treated Analysis Set, 86 subjects were retrospectively confirmed by the central pathology laboratory as MCL diagnosis. Only 1/86 subject had received prior CD19targeted therapy.

## Numbers analysed

Table 21. Study 017001 MCL Cohort - Protocol-defined Analysis Sets and Populations

| Analysis set                      | Definition                                                                                                       | DL2S n (%)   | DL1S n (%)   | Total N (%)   |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|
| Leukapheresed Set (ITT) (n)       | All subjects who signed informed consent, who met all inclusion/exclusion criteria, and underwent leukapheresis. | 94           | 10           | 104           |
| Liso-cel-treated Analysis Set (n) | All subjects who received at least one dose of conforming liso-cel cell product.                                 | 82 (87.2)    | 6 (60.0)     | 88 (84.6)     |

<div style=\"page-break-after: always\"></div>

Table 21. Study 017001 MCL Cohort - Protocol-defined Analysis Sets and Populations

| Analysis set                                       | Definition                                                                                                                                                                                                                                                                                                                     | DL2S n (%)   | DL1S n (%)   | Total N (%)   |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|
| Liso-cel-treated Efficacy Analysis Set (EAS) (n)   | All subjects in the MCL Cohort and Liso-cel- treated Analysis Set who had PET-positive disease present per IRC before liso-cel administration. Those subjects without baseline PET/CT disease assessment repeated after anticancer therapy for disease control and                                                             | 77 (81.9)    | 6 (60.0)     | 83 (79.8)     |
| Liso-cel- treated Primary Analysis Set (PAS) a (n) | All subjects in the MCL Cohort and Liso-cel- treated Analysis who met all of the following: PET-positive disease at baseline per IRC assessment Failed at least 2 prior lines of systemic therapy including an alkylating agent, a BTKi, and rituximab (or other CD20- targeted agent) Received DL2S (ie, recommended regimen) |              | 0            | 75 (72.1)     |
| Pharmacokinetic Analysis Set (n)                   | All subjects in Liso-cel-treated Analysis Set who had the necessary baseline and on-study PK measurements to provide interpretable results for the specific parameters of interest.                                                                                                                                            | 82 (87.2)    | 6 (60.0)     | 88 (84.6)     |
| PRO/QoL QLQ- C30 Evaluable Set                     | Subjects in the Liso-cel-treated Analysis Set who had a baseline and at least one post baseline assessment that was analyzable.                                                                                                                                                                                                | 68 (72.3)    | 1 (10.0)     | 69 (66.3)     |

## Extent of exposure

## Lymphodepleting Chemotherapy

In all subjects (total, DL1S+DL2S) in the Liso-cel-treated Analysis Set, most subjects (71.6%) received the full specified dose of fludarabine or cyclophosphamide at the planned time. In the Liso-cel-treated Analysis Set, the median time from last LDC to liso-cel treatment was 4.0 days (range: 3 to 13 days), which was consistent with the protocol, with only 1 subject that received liso-cel infusion beyond the protocol specified window of 7 days, following the completion of LDC.

## Manufacturing

<div style=\"page-break-after: always\"></div>

Table 22. Manufacturing Summary - Leukapheresed set MCL

|                                                                  | DL2S t6=N    | DLIS N=10    | Total N=104   |
|------------------------------------------------------------------|--------------|--------------|---------------|
| Time from Leukapheresis to liso-cel Product Availability (Day) a |              |              |               |
| N                                                                |              |              | 88            |
| Mean (StD)                                                       |              |              | 27.8 (12.20)  |
| Median                                                           |              |              | 24.5          |
| Q1, Q3                                                           |              |              | 21.0, 28.5    |
| Min, Max                                                         |              |              | 17,80         |
| Time from Leukapheresis to liso-cel Infusion (Day)“              |              |              |               |
| N                                                                | 82           | 6            | 88            |
| Mean (StD)                                                       | 53.5 (65.85) | 53.2 (10.50) | 53.5 (63.59)  |
| Median                                                           | 38.0         | 53.5         | 39.0          |
| Q1, Q3                                                           | 32.0, 46.0   | 43.0, 57.0   | 33.0, 48.0    |
| Min, Max                                                         | 28, 489      | 42, 70       | 28, 489       |

a Data from non-conforming product will not be included in the calculation.

<div style=\"page-break-after: always\"></div>

## Liso-cel Treatment in the PAS

## Table 23. Liso-cel exposure - PAS MCL

- At cut-off date 19 January 2023:
- At cut-off date 16 May 2024:

|                           | DL1S N=74    |
|---------------------------|--------------|
| CD8 dose (10cells)        |              |
| N                         | 2            |
| Mean (StD)                | 49.8 (0.07)  |
| Median                    | 49.8         |
| Q1, Q3                    | 49.8,49.9    |
| Min, Max                  | 50, 50       |
| CD4 volume infused (mL)   |              |
| N                         | 2            |
| Mean (StD)                | 2.15 (0.354) |
| Median                    | 2.15         |
| Q1, Q3                    | 1.90, 2.40   |
| Min, Max                  | 1.9,2.4      |
| CD4 dose (10°cells)       |              |
| N                         | 2            |
| Mean (StD)                | 49.6 (0.62)  |
| Median                    | 49.6         |
| Q1,Q3                     | 49.2, 50.1   |
| Min, Max                  | 49, 50       |
| Total volume infused (mL) |              |
| N                         | 2            |
| Mean (StD)                | 5.15 (2.333) |
| Median                    | 5.15         |
| Q1,Q3                     | 3.50, 6.80   |
| Min, Max                  | 3.5, 6.8     |
| Total dose (10* cells)    |              |
| N                         | 2            |
| Mean (StD)                | 99.4 (0.69)  |
| Median                    | 99.4         |
| Q1,Q3                     | 98.9,99.9    |
| Min, Max                  | 99,100       |

<div style=\"page-break-after: always\"></div>

DL2S

|                                                                                 | N=75         |
|---------------------------------------------------------------------------------|--------------|
| Cycle 1, Dose 1                                                                 |              |
| CD8 volume infused (mL)                                                         |              |
| N                                                                               | 75           |
| Mean (StD)                                                                      | 2.98 (1.940) |
| Median                                                                          | 2.40         |
| Q1, Q3                                                                          | 1.70, 3.60   |
| Min, Max                                                                        | 1.0, 13.5    |
| CD8 dose (106 cells)                                                            |              |
| N                                                                               | 75           |
| Mean (StD)                                                                      | 48.5 (5.21)  |
| Median                                                                          | 49.8         |
| Q1, Q3                                                                          | 49.4, 50.3   |
| Min, Max                                                                        | 22,56        |
| CD4 volume infused (mL)                                                         |              |
| N                                                                               | 75           |
| Mean (StD)                                                                      | 1.97 (0.644) |
| Median                                                                          | 1.80         |
| Q1,Q3                                                                           | 1.50, 2.40   |
| Min, Max                                                                        | 0.9, 3.9     |
|                                                                                 | DL2S N=75    |
| CD4 dose (10° cells)                                                            |              |
| N                                                                               | 75           |
| Mean (StD)                                                                      | 49.0 (2.75)  |
| Median                                                                          | 49.4         |
| Q1, Q3                                                                          | 49.0, 50.4   |
| Min, Max                                                                        | 35, 52       |
| Total volume infused (mL)                                                       |              |
| N                                                                               | 75           |
| Mean (StD)                                                                      | 4.95 (2.191) |
| Median                                                                          | 4.50         |
| Q1, Q3                                                                          | 3.40, 6.20   |
| Min, Max                                                                        | 2.1, 16.1    |
| Total dose (106 cells)                                                          |              |
| N                                                                               | 75           |
| Mean (StD)                                                                      | 97.5 (7.62)  |
| Median                                                                          | 99.6         |
| Q1, Q3                                                                          | 98.6,100.3   |
| Min, Max                                                                        | 62,103       |
| Ratioof CD4:CD8Dose Administered                                                |              |
| N                                                                               | 75           |
| Mean (StD)                                                                      | 1.02 (0.123) |
| Median                                                                          | 1.00         |
| Q1, Q3                                                                          | 0.98, 1.02   |
| Min, Max                                                                        | 0.8, 1.8     |
| Subjects received additional cycles, n (%) Subjects received retreatment, n (%) | 0 2 (2.7)    |
| Retreatment                                                                     |              |
| CD8 volume infused (mL)                                                         |              |
| N                                                                               | 2            |
| Mean (StD)                                                                      | 3.00 (1.980) |
| Median                                                                          | 3.00         |
| Q1, Q3                                                                          | 1.60, 4.40   |
| Min, Max                                                                        | 1.6, 4.4     |

<div style=\"page-break-after: always\"></div>

|                           | DL2S N=75    |
|---------------------------|--------------|
| CD8 dose (10° cells)      |              |
| N                         | 2            |
| Mean (StD)                | 49.8 (0.07)  |
| Median                    | 49.8         |
| Q1,Q3                     | 49.8, 49.9   |
| Min, Max                  | 50, 50       |
| CD4 volume infused (mL)   |              |
| N                         | 2            |
| Mean (StD)                | 2.15 (0.354) |
| Median                    | 2.15         |
| Q1, Q3                    | 1.90, 2.40   |
| Min, Max                  | 1.9, 2.4     |
| CD4 dose (10% cells)      |              |
| N                         | 2            |
| Mean (StD)                | 49.6 (0.62)  |
| Median                    | 49.6         |
| Q1, Q3                    | 49.2, 50.1   |
| Min, Max                  | 49, 50       |
| Total volume infused (mL) |              |
| N                         | 2            |
| Mean (StD)                | 5.15 (2.333) |
| Median                    | 5.15         |
| Q1, Q3                    | 3.50, 6.80   |
| Min, Max                  | 3.5,6.8      |
| Total dose (106 cells)    |              |
| N                         | 2            |
| Mean (StD)                | 99.4 (0.69)  |
| Median                    | 99.4         |
| Q1, Q3                    | 98.9, 99.9   |
| Min, Max                  | 99,100       |

## Outcomes and estimation

## Primary Efficacy Endpoint - Overall Response Rate per IRC Assessment in the PAS

Table 24 . Overall Response Rate - IRC Assessment - PAS MCL

|               | DL2S N=75   |
|---------------|-------------|
| BOR a , n (%) |             |
| CR            | 56 (74.7)   |
| PR            | 9 (12.0)    |
| SD            | 5 (6.7)     |
| Non-PD        | 0           |
| PD            | 1 (1.3)     |
| NE            | 4 (5.3)     |
| ORR, n (%)    |             |
| CR+PR         | 65 (86.7)   |

<div style=\"page-break-after: always\"></div>

Table 24 . Overall Response Rate - IRC Assessment - PAS MCL

|                              | DL2S N=75   |
|------------------------------|-------------|
| 95% CI b                     | 76.8, 93.4  |
| CR Rate, n (%)               |             |
| CR                           | 56 (74.7)   |
| 95% CI b                     | 63.3, 84.0  |
| Partial Response Rate, n (%) |             |
| PR                           | 9 (12.0)    |
| 95% CI b                     | 5.6, 21.6   |

Data cutoff: of 16-May-2024 (median follow-up 19.53 months)

a  BOR is the best disease response recorded from the time of the final liso-cel infusion of the initial cycle until disease progression, end of study, the start of another anticancer therapy or HSCT.

b  2-sided 95% exact Clopper-Pearson CIs.

<div style=\"page-break-after: always\"></div>

## Subgroup analysis for the primary endpoint of ORR

## Figure 4. Forest Plot of Overall Response Rate (ORR) - IRC Assessment - PAS MCL

## · At cut-off date 19 January 2023:

<!-- image -->

ORR and 2-sided 95% exact Clopper-Pearson confidence intervals are displayed.

<div style=\"page-break-after: always\"></div>

## · At cut-off date 16 May 2024:

ORR and 2-sided 95% exact Clopper-Pearson confidence intervals are displayed.

<!-- image -->

Sensitivity Analyses of ORR

<div style=\"page-break-after: always\"></div>

## Table 25. Sensitivity Analyses of ORR - Liso-cel-treated Efficacy Analysis Set and Leukapheresed Set MCL

- At cut-off date 16 May 2024:

|                                                                      | DL2S                                                                 | DL1S       | Total      |
|----------------------------------------------------------------------|----------------------------------------------------------------------|------------|------------|
| Investigator Assessment - Liso-cel-treated Efficacy Analysis Set MCL | Investigator Assessment - Liso-cel-treated Efficacy Analysis Set MCL |            |            |
| All Subjects, N                                                      | 77                                                                   | 6          | 83         |
| ORR, n (%)                                                           | 66 (85.7)                                                            | 3 (50.0)   | 69 (83.1)  |
| 95% CI a                                                             | 75.9,92.6                                                            | 11.8, 88.2 | 73.3,90.5  |
| IRCAssessment-LeukapheresedSetMCL                                    | IRCAssessment-LeukapheresedSetMCL                                    |            |            |
| All Subjects, N                                                      | 94                                                                   | 10         | 104        |
| ORR, n (%)                                                           | 70 (74.5)                                                            | 3 (30.0)   | 73 (70.2)  |
| 95% CI a                                                             | 64.4, 82.9                                                           | 6.7, 65.2  | 60.4, 78.8 |

## Secondary efficacy endpoint: Complete Response Rate (CRR)

Because the null hypothesis for the first hypothesis test of H0: ORR ≤ 40% versus H1: ORR &gt; 40% was rejected, the second hypothesis H0: CR rate ≤ 18% versus H1: CR rate &gt; 18% was tested. The study met its key secondary efficacy endpoint and rejected the nu ll hypothesis of CR rate ≤ 18% (p &lt;0.0001) in the MCL Cohort PAS. The IRC-assessed CR rate was 74.7% (95% CI: 63.3, 84.0) (see table of ORR above).

## Subgroup Analysis of CR rate

## Figure 5. Forest Plot of Complete Response Rate - IRC Assessment - PAS MCL

- At cut-off date 19 January 2023:

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## · At cut-off date 16 May 2024:

CRR and 2-sided 95% exact Clopper-Pearson confidence intervals are displayed.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Sensitivity analyses of CRR

Table 26. Sensitivity Analyses of CR Rate - Liso-cel-treated Efficacy Analysis Set and Leukapheresed Set MCL

## · At cut-off date 16 May 2024:

|                                                                      | DL2S                                                                 | DL1S      | Total      |
|----------------------------------------------------------------------|----------------------------------------------------------------------|-----------|------------|
| Investigator Assessment - Liso-cel-treated Efficacy Analysis Set MCL | Investigator Assessment - Liso-cel-treated Efficacy Analysis Set MCL |           |            |
| All Subjects, N                                                      | 77                                                                   | 6         | 83         |
| CR rate, n (%)                                                       | 58 (75.3)                                                            | 2 (33.3)  | 60 (72.3)  |
| 95% CI a                                                             | 64.2, 84.4                                                           | 4.3,77.7  | 61.4, 81.6 |
| IRC Assessment - Leukapheresed Set MCL                               | IRC Assessment - Leukapheresed Set MCL                               |           |            |
| All Subjects, N                                                      | 94                                                                   | 10        | 104        |
| CR rate, n (%)                                                       | 61 (64.9)                                                            | 3 (30.0)  | 64 (61.5)  |
| eI %S6                                                               | 54.4,74.5                                                            | 6.7, 65.2 | 51.5, 70.9 |

In the Liso-cel-treated Efficacy Analysis Set, IRC assessed CR rate was 75.3% (95% CI: 64.2, 84.4) for DL2S, 33.3% (95% CI: 4.3, 77.7) for DL1S, and 72.3% (95% CI: 61.4, 81.6) for the total population (DL1S+DL2S).

## Secondary Efficacy Endpoint: Duration of Response

Table 27. Duration of Response (DOR) - IRC Assessment - EMA Censoring - PAS MCL

## · At cut-off date 16 May 2024:

|                               | DL2S N = 75    |
|-------------------------------|----------------|
| Subjects Achieved CR or PR, n | 65             |
| Progression or Death, n (%) c | 39 (60.0)      |
| Progression                   | 28 (43.1)      |
| Death                         | 11 (16.9)      |
| Censored, n (%) c             | 26 (40.0)      |
| Ongoing                       | 0              |
| Completed the study           | 24 (36.9)      |
| Discontinued the study        | 2 (3.1)        |
| Received liso-cel retreatment | 0              |
| Duration of Response (Months) |                |
| Median (95% CI) a             | 11.3, 5.7-24.0 |
| Q1, Q3                        | 2.6, 24.0      |
| Min, Max                      | 0.0+, 24.0     |

<div style=\"page-break-after: always\"></div>

Table 27. Duration of Response (DOR) - IRC Assessment - EMA Censoring - PAS MCL

## · At cut-off date 16 May 2024:

|                                                            | DL2S N = 75     |
|------------------------------------------------------------|-----------------|
| Probability of Continued Response Post-initial Response, % |                 |
| ≥ 6 months                                                 | 62.0            |
| 95% CI a                                                   | 48.9-72.7       |
| ≥ 12 months                                                | 47.7            |
| 95% CI a                                                   | 35.0-59.3       |
| ≥ 18 months                                                | 39.4            |
| 95% CI a                                                   | 27.4-51.2       |
| ≥ 24 months                                                | 39.4            |
| 95% CI a                                                   | 27.4-51.2       |
| Follow-up (Months)                                         |                 |
| Median (95% CI) b                                          | 23.0, 22.8-23.1 |
| Min, Max                                                   | 0.0+, 24.0      |

Figure 6. Duration of Response - IRC Assessment - EMA Censoring - PAS MCL

## · At cut-off date 16 May 2024:

<!-- image -->

<div style=\"page-break-after: always\"></div>

## DOR in the Liso-cel-treated Efficacy Analysis Set

Table 28. Duration of Response (DOR) - IRC Assessment - EMA Censoring - Liso-cel-treated Efficacy Analysis Set MCL

## · At cut-off date 16 May 2024:

|                                                            | DL2S N = 77                                                | DL1S N = 6      | Total N = 83    |
|------------------------------------------------------------|------------------------------------------------------------|-----------------|-----------------|
| Subjects Achieved CR or PR, n                              | 67                                                         | 2               | 69              |
| Progression or Death, n (%) c                              | 40 (59.7)                                                  | 0               | 40 (58.0)       |
| Progression                                                | 29 (43.3)                                                  | 0               | 29 (42.0)       |
| Death                                                      | 11 (16.4)                                                  | 0               | 11 (15.9)       |
| Censored, n (%) c                                          | 27 (40.3)                                                  | 2 (100)         | 29 (42.0)       |
| Ongoing                                                    | 0                                                          | 0               | 0               |
| Completed the study                                        | 25 (37.3)                                                  | 2 (100)         | 27 (39.1)       |
| Discontinued the study                                     | 2 (3.0)                                                    | 0               | 2 (2.9)         |
| Received liso-cel retreatment                              | 0                                                          | 0               | 0               |
| Duration of Response (Months)                              |                                                            |                 |                 |
| Median, 95% CI a                                           | 11.5, 6.2-24.0                                             | NR, NR-NR       | 13.3, 6.7-24.0  |
| Q1, Q3                                                     | 3.3, 24.0                                                  | NR, NR          | 3.3, 24.0       |
| Min, Max                                                   | 0.0+, 24.0                                                 | 17.3+, 22.9+    | 0.0+, 24.0      |
| Probability of Continued Response Post-initial Response, % | Probability of Continued Response Post-initial Response, % |                 |                 |
| ≥ 6 months                                                 | 63.2                                                       | 100.0           | 64.3            |
| 95% CI a                                                   | 50.3-73.6                                                  | NR-NR           | 51.6-74.4       |
| ≥ 12 months                                                | 49.3                                                       | 100.0           | 50.8            |
| 95% CI a                                                   | 36.7-60.7                                                  | NR-NR           | 38.4-62.0       |
| ≥ 18 months                                                | 39.7                                                       | 100.0           | 41.4            |
| 95% CI a                                                   | 27.7-51.3                                                  | NR-NR           | 29.5-52.9       |
| ≥ 24 months                                                | 39.7                                                       | NR              | 41.4            |
| 95% CI a                                                   | 27.7-51.3                                                  | NR-NR           | 29.5-52.9       |
| Follow-up (Months)                                         |                                                            |                 |                 |
| Median, 95% CI b                                           | 23.0, 22.8-23.1                                            | 20.1, 17.3-22.9 | 22.9, 22.8-23.1 |
| Min, Max                                                   | 0.0+, 24.0                                                 | 17.3+, 22.9+    | 0.0+, 24.0      |

a  KM method is used to obtain 2-sided 95% CIs.  b  Reverse KM method is used to obtain the median follow-up and its 95% CIs.  c  Denominator is number of subjects achieved CR or PR.  +  Censored.

<div style=\"page-break-after: always\"></div>

Figure 7. Duration of Response - IRC Assessment - EMA Censoring - Liso-cel-treated Efficacy Analysis Set MCL

## · At cut-off date 16 May 2024:

<!-- image -->

## Sensitivity Analysis of DOR

The results for sensitivity analyses of DOR using EMA censoring rules were:

- -Investigator-assessed median DOR in the PAS was 11.3 months (95% CI: 5.7, 23.3).
- -IRC-assessed median DOR in the Leukapheresed Set was 15.2 months (95% CI: 7.0, 24.0).

Other Secondary Efficacy Endpoint: Progression Free Survival (PFS)

Table 29. Progression-Free Survival (PFS) - IRC Assessment - EMA Censoring - PAS MCL

## · At cut-off date 16 May 2024:

|                   | DL2S N = 75   |
|-------------------|---------------|
| PFS Events, n (%) | 48 (64.0)     |
| Progression       | 30 (40.0)     |
| Death             | 18 (24.0)     |
| Censored, n (%)   | 27 (36.0)     |
| Ongoing           | 0             |

<div style=\"page-break-after: always\"></div>

Table 29. Progression-Free Survival (PFS) - IRC Assessment - EMA Censoring - PAS MCL

## · At cut-off date 16 May 2024:

|                               | DL2S N = 75     |
|-------------------------------|-----------------|
| Completed the study           | 25 (33.3)       |
| Discontinued the study        | 2 (2.7)         |
| Received liso-cel retreatment | 0               |
| PFS (Months)                  |                 |
| Median (95% CI) a             | 8.6, 6.1-16.6   |
| Q1, Q3                        | 3.2, 24.9       |
| Min, Max                      | 0.1, 24.9       |
| Probability of PFS, %         |                 |
| ≥ 6 months                    | 65.8            |
| 95% CI a                      | 53.8-75.5       |
| ≥ 12 months                   | 46.2            |
| 95% CI a                      | 34.5-57.2       |
| ≥ 18 months                   | 37.6            |
| 95% CI a                      | 26.5-48.7       |
| ≥ 24 months                   | 33.9            |
| 95% CI a                      | 22.9-45.2       |
| Follow-up (Months)            |                 |
| Median (95% CI) b             | 24.0, 23.7-24.0 |
| Min, Max                      | 0.1, 24.9       |

<div style=\"page-break-after: always\"></div>

Figure 8. Progression-Free Survival - IRC Assessment - EMA Censoring - PAS MCL

## · At cut-off date 16 May 2024:

<!-- image -->

In the Liso-cel-treated Efficacy Analysis Set using EMA censoring rules , the median IRCassessed PFS was 10.7 months (95% CI: 6.1, 17.8) for DL2S and 10.7 months (95% CI: 6.1, 16.6) for total.

## Sensitivity Analysis of PFS

The results for sensitivity analyses of PFS using EMA censoring rules were:

- Investigator-assessed median PFS in the PAS was 7.8 months (95% CI: 5.3, 15.9)
- IRC-assessed median PFS in the Leukapheresed Set was 9.6 months (95% CI: 7.2, 17.7)

## Other secondary endpoints: Overall Survival

Table 30. Overall Survival (OS) - PAS MCL

|                      | DL2S N = 75     |
|----------------------|-----------------|
| Death, n (%)         | 41 (54.7)       |
| Alive, n (%)         | 34 (45.3)       |
| OS (Months)          |                 |
| Median, 95% CI a     | 18.4 (13.5, NR) |
| Q1, Q3               | 6.7, NR         |
| Min, Max             | 0.4, 62.1 +     |
| Probability of OS, % |                 |

<div style=\"page-break-after: always\"></div>

Table 30. Overall Survival (OS) - PAS MCL

|                    | DL2S N = 75       |
|--------------------|-------------------|
| ≥ 6 months         | 79.9              |
| 95% CI a           | 68.9, 87.4        |
| ≥ 12 months        | 63.6              |
| 95% CI a           | 51.5, 73.4        |
| ≥ 18 months        | 52.5              |
| 95% CI a           | 40.5, 63.2        |
| ≥ 24 months        | 47.0              |
| 95% CI a           | 35.3, 57.9        |
| ≥ 30 months        | 45.0              |
| 95% CI a           | 33.2, 56.1        |
| ≥ 36 months        | 45.0              |
| 95% CI a           | 33.2, 56.1        |
| ≥ 42 months        | 41.8              |
| 95% CI a           | 29.4, 53.7        |
| ≥ 48 months        | 41.8              |
| 95% CI a           | 29.4, 53.7        |
| Follow-up (Months) |                   |
| Median, 95% CI b   | 35.5 (26.5, 36.4) |
| Min, Max           | 0.4, 62.1 +       |

The OS analysis includes all available survival information with long-term follow-up data. Data cutoff date: 16-May2024 for 017001 and 31-Jan-2024 for LTFU.  a  KM method is used to obtain 2-sided 95% CIs.  b  Reverse KM method is used to obtain the median follow-up and its 95% CIs.  +  Alive.

<div style=\"page-break-after: always\"></div>

Figure 9. Overall Survival - PAS MCL

## · At cut-off date 16 May 2024:

<!-- image -->

In the Liso-cel-treated Efficacy Analysis Set , the median OS was 20.7 months (95% CI: 13.5, NR) for DL2S and 18.4 months (95% CI: 12.9, NR) for total.

## Sensitivity analysis for OS

Results of a sensitivity analysis of OS in the Leukapheresed Set showed a median OS of 19.6 months (95% CI: 12.5, NR) in the total (DL2S+DL1S) Leukapheresed Set. The median OS follow-up time was 31.5 months (95% CI: 26.7, 37.5) in the total Leukapheresed Set.

## Impact of COVID-19 on Efficacy (Sensitivity Analysis)

Among the 7 subjects who died due to COVID 19 in the PAS and the Liso-cel-treated Efficacy Analysis Set, 6 subjects with a CR died in ongoing response within the first year post-liso-cel treatment (Day 72 to 325); these events were censored as discontinued the study and had an impact in the time to event endpoints as follows: for DOR and PFS and alive for OS. The last subject, who died of COVID-19 after experiencing PD, was censored as alive for OS.

DOR, using EMA censoring rules: the median DOR per IRC assessment in the PAS was 15.2 months (95% CI: 6.7, 24.0)

PFS using EMA censoring rules: the median PFS per IRC assessment was 12.3 months (95% CI: 6.1, 24.9)

OS: the median OS was 36.3 months (95% CI: 16.5, NR)

Similar results for the COVID-19 sensitivity analysis were observed in the Liso-cel-treated Efficacy Analysis Set.

## Clinical Outcomes Assessments (EORTC QLQ-C30, EQ-5D-5L, EQ-5D-5L VAS)

The PRO/QoL QLQ-C30 and EQ-5D-5L Evaluable Set includes subjects in the MCL Cohort Liso-celtreated Set who had a baseline and at least one post baseline assessment that was analyzable.

<div style=\"page-break-after: always\"></div>

Table 31. Summary of Compliance Rates for HRQoL Questionnaires - PRO/QoL (QLQ-C30) Evaluable Set MCL

## · At cut-off date 19 January 2023:

| Visit              | DL2S N=65 n (%)   | DLIS N=1 n (%)   | Total N=66 n (%)   |
|--------------------|-------------------|------------------|--------------------|
| EORIC QLQ-C30      |                   |                  |                    |
| Baseline           | 65/65 (100)       | 1/1 (100)        | 66/66 (100)        |
| Post Dose Day 29   | 49/65 (75.4)      | 1/1 (100)        | 50/66 (75.8)       |
| Post Dose Month 2  | 45/64 (70.3)      | 1/1 (100)        | 46/65 (70.8)       |
| Post Dose Month 3  | 41/62 (66.1)      | 1/1 (100)        | 42/63 (66.7)       |
| Post Dose Month 6  | 36/57 (63.2)      | 1/1 (100)        | 37/58 (63.8)       |
| Post Dose Month 9  | 29/52 (55.8)      | 1/1 (100)        | 30/53 (56.6)       |
| Post Dose Month 12 | 27/45 (60.0)      | 1/1 (100)        | 28/46 (60.9)       |
| Post Dose Month 18 | 16/34 (47.1)      | 1/1 (100)        | 17/35 (48.6)       |
| Post Dose Month 24 | 12/25 (48.0)      | 1/1 (100)        | 13/26 (50.0)       |
| EQ-5DEvaluableSet  |                   |                  |                    |
| Baseline           | 65/65 (100)       | 1/1 (100)        | 66/66 (100)        |
| Post Dose Day 29   | 48/65 (73.8)      | 1/1 (100)        | 49/66 (74.2)       |
| Post Dose Month 2  | 45/64 (70.3)      | 1/1 (100)        | 46/65 (70.8)       |
| Post Dose Month 3  | 40/62 (64.5)      | 1/1 (100)        | 41/63 (65.1)       |
| Post Dose Month 6  | 36/57 (63.2)      | 1/1 (100)        | 37/58 (63.8)       |
| Post Dose Month 9  | 29/52 (55.8)      | 1/1 (100)        | 30/53 (56.6)       |
| Post Dose Month 12 | 25/45 (55.6)      | 1/1 (100)        | 26/46 (56.5)       |
| Post Dose Month 18 | 16/34 (47.1)      | 1/1 (100)        | 17/35 (48.6)       |
| Post Dose Month 24 | 12/25 (48.0)      | 1/1 (100)        | 13/26 (50.0)       |

A subject is considered as compliant at a visit if at least 15 out of the 30 items in the QLQ-C30 were answered.

A subject is considered as compliant at a visit if at least 1 out of the 5 items in the EQ-5D-5L or VAS were answered.

The denominator for each assessment is the number of subjects in the EQ-5D evaluable population who were still staying in the study at the specified assessment visits.

The denominator for each assessment is the number of subjects in the QLQ-C30 evaluable set who were still staying in the study at the specified assessment visits.

<div style=\"page-break-after: always\"></div>

## · At cut-off date 16 May 2024:

| Visit                    | DL2S N=68 n (%)          | DL1S N=1 n (%)   | Total N=69 n (%)   |
|--------------------------|--------------------------|------------------|--------------------|
| EORTCQLQ-C30EvaluableSet | EORTCQLQ-C30EvaluableSet |                  |                    |
| Baseline                 | 68/68 (100)              | 1/1 (100)        | 69/69 (100)        |
| Post Dose Day 29         | 51/68 (75.0)             | 1/1 (100)        | 52/69 (75.4)       |
| Post Dose Month 2        | 47/67 (70.1)             | 1/1 (100)        | 48/68 (70.6)       |
| Post Dose Month 3        | 43/65 (66.2)             | 1/1 (100)        | 44/66 (66.7)       |
| Post Dose Month 6        | 39/60 (65.0)             | 1/1 (100)        | 40/61 (65.6)       |
| Post Dose Month 9        | 32/55 (58.2)             | 1/1 (100)        | 33/56 (58.9)       |
| Post DoseMonth 12        | 31/47 (66.0)             | 1/1 (100)        | 32/48 (66.7)       |
| Post Dose Month18        | 21/39 (53.8)             | 1/1 (100)        | 22/40 (55.0)       |
| Post DoseMonth 24        | 17/34 (50.0)             | 1/1 (100)        | 18/35 (51.4)       |
| EQ-5DEvaluableSet        | EQ-5DEvaluableSet        |                  |                    |
| Baseline                 | 68/68 (100)              | 1/1 (100)        | 69/69 (100)        |
| Post Dose Day 29         | 50/68 (73.5)             | 1/1 (100)        | 51/69 (73.9)       |
| Post Dose Month 2        | 47/67 (70.1)             | 1/1 (100)        | 48/68 (70.6)       |
| Post Dose Month 3        | 42/65 (64.6)             | 1/1 (100)        | 43/66 (65.2)       |
| Post Dose Month 6        | 39/60 (65.0)             | 1/1 (100)        | 40/61 (65.6)       |
| Post Dose Month 9        | 32/55 (58.2)             | 1/1 (100)        | 33/56 (58.9)       |
| Post Dose Month 12       | 29/47 (61.7)             | 1/1 (100)        | 30/48 (62.5)       |
| Post Dose Month18        | 21/39 (53.8)             | 1/1 (100)        | 22/40 (55.0)       |
| PostDoseMonth 24         | 17/34 (50.0)             | 1/1 (100)        | 18/35 (51.4)       |

Asubjectis consideredascompliant atavisit if atleast15outofthe30itemsintheQLQ-C30were answered.

Asubjectis considered ascompliant at avisit if at least1out of the5items intheEQ-5D-5LorVASwere answered.

The denominator for each assessment is the number of subjects in the EQ-5D evaluable population who were still staying in the study at the specified assessment visits.

The denominator for each assessment is the number of subjects in the QLQ-C30 evaluable set who were still staying inthestudy at thespecified assessment visits.

## EORTC QLQ-C30

On the EORTC QLQ-C30 , liso-cel consistently demonstrated improvements over time in evaluations of group-level mean change in the primary domains of fatigue (mean change [SD]= -11.9 [27.03] from baseline to Month 6, then stable), GHS/QoL (mean change [SD] = 18.1 [22.32] from baseline to Month 6, then stable) and physical functioning (mean [SD] change in domain score = 8.0 [23.98] from baseline to month 6). Pain was stable until 1 year (mean change [SD] = 1.6 [24.08]) and then showed some worsening at 1.5 and 2 years. The analysis of additional functioning domains showed an improvement also in emotional functioning (mean change [SD] = 3.8 [14.49], stable after 6 months), role functioning (mean change [SD] in domain score = 20.0 [34.43], stable after 6 months) and social functioning (mean change [SD] in domain score = 20.4 [33.01], stable after 6 months). Of the remaining domains, cognitive functioning, insomnia, financial difficulties, diarrhoea, and constipation did not reach a clinically meaningful change over time.

<div style=\"page-break-after: always\"></div>

## EQ-5D-5L

## Table 32. Summary of Baseline and Change from Baseline for US based EQ-5D-5L Index Score PRO/QoL (EQ-5D) Evaluable Set in MCL Cohort JCAR017-Treated Set

## · At cut-off date 19 January 2023:

| EQ-5D-5LU.S. BasedIndexValue   | DL2S N=65        | DLIS N=1      | Total N=66       |
|--------------------------------|------------------|---------------|------------------|
| Baseline                       |                  |               |                  |
| n1                             | 65               | 1             | 66               |
| Mean (StD)                     | 0.8443 (0.12784) | 0.7560 (-)    | 0.8430 (0.12732) |
| Median                         | 0.8530           | 0.7560        | 0.8530           |
| Q1,Q3                          | 0.7910,1.0000    | 0.7560,0.7560 | 0.7900,1.0000    |
| Min, Max                       | 0.540,1.000      | 0.756,0.756   | 0.540,1.000      |

## · At cut-off date 16 May 2024:

| EQ-5D-5LU.S. BasedIndexValue   | DL2S N=68        | DL1S N=1      | Total N=69       |
|--------------------------------|------------------|---------------|------------------|
| Baseline                       |                  |               |                  |
| n                              | 68               |               | 69               |
| Mean (StD)                     | 0.8468 (0.12647) | 0.7560 (-)    | 0.8454 (0.12601) |
| Median                         | 0.8530           | 0.7560        | 0.8530           |
| Q1, Q3                         | 0.7935,1.0000    | 0.7560,0.7560 | 0.7910,1.0000    |
| Min, Max                       | 0.540,1.000      | 0.756,0.756   | 0.540,1.000      |

## Table 33. Clinically Meaningful Change from Baseline for US based EQ-5D-5L Index Score PRO/QoL (EQ-5D) Evaluable Set in MCL Cohort JCAR017-Treated Set

## · At cut-off date 19 January 2023:

|                  | DL2S N=65 n (%)   | DLIS N=1 n (%)   | Total N=66 n (%)   |
|------------------|-------------------|------------------|--------------------|
| Post Dose Day 29 |                   |                  |                    |
| n                | 48                | 1                | 49                 |
| Improvement      | 12 (25.0)         | 1 (100)          | 13 (26.5)          |
| No Change        | 24 (50.0)         | 0                | 24 (49.0)          |
| Deterioration*   | 12 (25.0)         | 0                | 12 (24.5)          |
| PostDoseMonth 2  |                   |                  |                    |
| 11               | 45                | 1                | 46                 |
| Improvement      | 16 (35.6)         | 1(100)           | 17 (37.0)          |
| No Change*       | 24 (53.3)         | 0                | 24 (52.2)          |
| Deterioration*   | 5 (11.1)          | 0                | 5 (10.9)           |

<div style=\"page-break-after: always\"></div>

## · At cut-off date 16 May 2024:

|                  | DL2S N=68 n (%)   | DL1S N=1 n (%)   | Total N=69 n (%)   |
|------------------|-------------------|------------------|--------------------|
| Post Dose Day 29 |                   |                  |                    |
| n                | 50                | 1                | 51                 |
| Improvement      | 12 (24.0)         | 1 (100)          | 13 (25.5)          |
| No Change        | 26 (52.0)         | 0                | 26 (51.0)          |
| Deteriorationa   | 12 (24.0)         | 0                | 12 (23.5)          |
| Post DoseMonth 2 |                   |                  |                    |
| n                | 47                | 1                | 48                 |
| Improvement      | 16 (34.0)         | 1 (100)          | 17 (35.4)          |
| No Change'       | 25 (53.2)         | 0                | 25 (52.1)          |
| Deterioration a  | 6 (12.8)          | 0                | 6 (12.5)           |

## EQ-5D-5L VAS

## Table 34. Summary of Baseline and Change from Baseline for EQ-5D-VAS PRO/QoL (EQ-5D) Evaluable Set in MCL Cohort JCAR017-Treated Set

## · At cut-off date 19 January 2023:

| EQ-5D-5L5 items&EQ-VAS   | DL2S N=65    | DLIS N=1   | Total N=66   |
|--------------------------|--------------|------------|--------------|
| Baseline                 |              |            |              |
|                          | 65           |            | 66           |
| Mean (StD)               | 66.7 (22.26) | 75.0 (-)   | 66.8 (22.11) |
| Median                   | 65.0         | 75.0       | 67.0         |
| Q1,Q3                    | 52.0, 85.0   | 75.0, 75.0 | 52.0, 85.0   |
| Min, Max                 | 16,100       | 75,75      | 16,100       |

## · At cut-off date 16 May 2024:

| EQ-5D-5L5 items&EQ-VAS   | DL2S N=68    | DL1S N=1   | Total N=69   |
|--------------------------|--------------|------------|--------------|
| Baseline                 |              |            |              |
| n                        | 68           |            | 69           |
| Mean (StD)               | 67.4 (22.22) | 75.0 (-)   | 67.5 (22.07) |
| Median                   | 67.0         | 75.0       | 69.0         |
| Q1, Q3                   | 52.0,88.5    | 75.0,75.0  | 52.0,88.0    |
| Min, Max                 | 16,100       | 75,75      | 16,100       |

<div style=\"page-break-after: always\"></div>

Table 35. Clinically Meaningful Change from Baseline for EQ-5D VAS PRO/QoL (EQ-5D) Evaluable Set in MCL Cohort JCAR017-Treated Set

## · At cut-off date 19 January 2023:

|                 | DL2S N=65 n (%)   | DLIS N=l (%) uI   | Total N=66 n (%)   |
|-----------------|-------------------|-------------------|--------------------|
| Post DoseDay29  |                   |                   |                    |
| 11              | 48                | 1                 | 49                 |
| Improvement     | 20 (41.7)         | 1 (100)           | 21 (42.9)          |
| No Change       | 15 (31.3)         | 0                 | 15 (30.6)          |
| Deterioration*  | 13 (27.1)         | 0                 | 13 (26.5)          |
| PostDoseMonth 2 |                   |                   |                    |
| 11              | 45                | 1                 | 46                 |
| Improvement     | 24 (53.3)         | 1 (100)           | 25 (54.3)          |
| No Change       | 13 (28.9)         | 0                 | 13 (28.3)          |
| Deterioration\"  | 8 (17.8)          | 0                 | 8 (17.4)           |

## · At cut-off date 16 May 2024:

|                  | DL2S N=68 n (%)   | DL1S N=1 n (%)   | Total N=69 n (%)   |
|------------------|-------------------|------------------|--------------------|
| Post Dose Day 29 |                   |                  |                    |
| n                | 50                |                  | 51                 |
| Improvement      | 21 (42.0)         | 1 (100)          | 22 (43.1)          |
| No Change'       | 16 (32.0)         | 0                | 16 (31.4)          |
| Deterioration a  | 13 (26.0)         | 0                | 13 (25.5)          |
| Post DoseMonth 2 |                   |                  |                    |
| n                | 47                |                  | 48                 |
| Improvement      | 24 (51.1)         | 1 (100)          | 25 (52.1)          |
| No Change\"       | 15 (31.9)         | 0                | 15 (31.3)          |
| Deterioration a  | 8 (17.0)          | 0                | 8 (16.7)           |

## · Efficacy data in section 5.1:

## Efficacy Set for the Proposed Indication (Modified Efficacy Analysis Set or 'Efficacy Set')

The efficacy set was defined as all patients treated within the approved dose of Liso-cel (DL1S and DL2S), treated at least 2 prior lines of systemic therapy including a BTKi and analyzed according to EMA censoring rules.

Table 36. Overall Efficacy Summary per IRC Assessment in the Efficacy Set to Support Section 5 of the SmPC

## · At cut-off date 16 May 2024:

|            | DL2S+DL1S (N = 81)   |
|------------|----------------------|
| ORR, n (%) |                      |
| CR+PR      | 67 (82.7)            |
| 95% CI a   | 72.7, 90.2           |

CR Rate, n (%)

<div style=\"page-break-after: always\"></div>

Table 36. Overall Efficacy Summary per IRC Assessment in the Efficacy Set to Support Section 5 of the SmPC

## · At cut-off date 16 May 2024:

| (N =                                                               | DL2S+DL1S 81)     |
|--------------------------------------------------------------------|-------------------|
| CR                                                                 | 58 (71.6)         |
| 95% CI a                                                           | 60.5, 81.1        |
| PR Rate, n (%)                                                     |                   |
| PR                                                                 | 9 (11.1)          |
| 95% CI a                                                           | 5.2, 20.0         |
| DOR, months b                                                      |                   |
| Subjects with CR or PR                                             |                   |
| Median (95% CI) c                                                  | 11.5 (6.2, 24.0)  |
| Min, Max                                                           | 0.0+, 24.0        |
| Median follow-up (95% CI) d                                        | 22.9 (22.8, 23.0) |
| Probability of continued response post-initial response, %(95% CI) |                   |
| ≥ 6 months                                                         | 63.2 (50.3, 73.6) |
| ≥ 12 months                                                        | 49.3 (36.7, 60.7) |
| ≥ 18 months                                                        | 41.2 (29.2, 52.9) |
| ≥ 24 months                                                        | 41.2 (29.2, 52.9) |
| Subjects with CR                                                   |                   |
| Median (95% CI) c                                                  | 15.2 (7.5, 24.0)  |
| Min, Max                                                           | 0.6, 24.0         |

Efficacy Set = subjects in the PAS (N=75) and DL1S subjects (N=6) in the EAS.

a  2-sided 95% exact Clopper-Pearson CIs.

b  EMA censoring rules used for DOR.  c  KM method was used to obtain 2-sided 95% CIs.  d  Reverse KM method is used to obtain the median follow-up and its 95% CI. + censored value

## All Leukapheresed Set

## Table 37.    All Leukapheresed: Response rate, duration of response (IRC assessment)

## · At cut-off date 16 May 2024:

|                              | All Leukapheresed (N=104)   |
|------------------------------|-----------------------------|
| Overall response rate, n (%) | 73 (70.2)                   |
| [95% CI] a                   | [60.4, 78.8]                |
| Complete response, n (%)     | 64 (61.5)                   |
| [95% CI] a                   | [51.5, 70.9]                |

<div style=\"page-break-after: always\"></div>

|                                                                                            | All Leukapheresed (N=104)      |
|--------------------------------------------------------------------------------------------|--------------------------------|
| Partial response, n (%) [95% CI] a                                                         | 9 (8.7) [4.0, 15.8]            |
| Number of responders Duration of response (DOR)(months) Median [95% CI] c Range            | 73 15.2 [7.0, 24.0] 0.0+, 24.0 |
| Rate of continued remission d ,% [95% CI] At 24 months Median follow-up for DOR (months) d | 44.8 (32.9; 55.9)              |
| Median, [95% CI] Range                                                                     | 23.0 [22,8, 23.1] 0.0+, 24.0   |

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 38.  Summary of Efficacy for trial 017001

| Title: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL).   | Title: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL).                                                                                                                                                    | Title: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL).                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                          | 017001                                                                                                                                                                                                                                                                                                                                     | 017001                                                                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                    | This is an open-label, multicenter, multicohort, seamless design, Phase 1 study to determine the safety, antitumor activity, and PK of liso-cel in adult subjects with MCL having received ≥ 2 prior lines of systemic MCL therapy and having been treated with an alkylating agent, a BTKi, and rituximab (or other CD20-targeted agent). | This is an open-label, multicenter, multicohort, seamless design, Phase 1 study to determine the safety, antitumor activity, and PK of liso-cel in adult subjects with MCL having received ≥ 2 prior lines of systemic MCL therapy and having been treated with an alkylating agent, a BTKi, and rituximab (or other CD20-targeted agent). |
|                                                                                                                                                                                           | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                                                                          | - Lymphodepleting chemotherapy (LDC), day 0-day 29 - Single-dose schedule (DL1S or DL2S): liso-cel administration from 2 to 7 day after completion of LDC not applicable                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                           | Duration of Extension phase:                                                                                                                                                                                                                                                | Duration of Extension phase:                                                                                                                                                                                                                                                | - Post-treatment follow-up period: after Day 29, subjects entered the post- treatment follow-up period, and were followed for approximately 2 years - Long-term Follow-up: subjects who received liso-cel were asked to participate in a separate long-term follow-up study (Study GC-LTFU-001) for up to 15 years post-last dose   |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis                | Single-arm study                                                                                                                                                                                                                                                            | Single-arm study                                                                                                                                                                                                                                                            | Single-arm study                                                                                                                                                                                                                                                                                                                    |
| Treatments groups         | Liso-cel, a CD19-directed genetically modified autologous cellular immunotherapy composed of autologous CD4+ and CD8+ T cells that express a CD19- specific CAR, provided as 2 individually formulated CD4+ and CD8+ frozen T-cell suspensions administered in a 1:1 ratio. | Liso-cel, a CD19-directed genetically modified autologous cellular immunotherapy composed of autologous CD4+ and CD8+ T cells that express a CD19- specific CAR, provided as 2 individually formulated CD4+ and CD8+ frozen T-cell suspensions administered in a 1:1 ratio. | Subjects entered the treatment period of the study, which commenced with LDC and ended with the Day 29 evaluation. The treatment cycle included LDC with fludarabine and cyclophosphamide followed by 1 single-dose of liso-cel administered IV.                                                                                    |
| Treatments groups         | Single-dose schedule                                                                                                                                                                                                                                                        | Single-dose schedule                                                                                                                                                                                                                                                        | Liso-cel administration from 2 to 7 day after completion of LDC.                                                                                                                                                                                                                                                                    |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                                                                            | ORR (CR or PR)                                                                                                                                                                                                                                                              | The ORR was defined as the proportion of subjects with a BOR of either CR or PR. The BOR was the best disease response recorded from the time of the liso-cel infusion until disease progression, EOS, the start of another anticancer therapy, or HSCT.                                                                            |

<div style=\"page-break-after: always\"></div>

|                      | Secondary endpoints   | CR rate DOR PFS PFS ratio OS HRQoL Hospital resource utilization                                                  | CR rate was defined as the proportion of subjects with a BOR of CR from the time of the liso-cel infusion until disease progression, end of study, or the start of another anticancer therapy or HSCT. DOR was defined as the interval from the first documentation of CR or PR to the earlier date of disease progression or death due to any cause. PFS was defined as the time from the date of the liso-cel infusion to the earlier date of disease progression or death due to any cause. PFS ratio was defined as the ratio of PFS to the most recent line of therapy (including systemic treatments, radiotherapy, and HSCT prior to liso- cel) to the PFS on liso-cel based on investigator assessment. OS was defined as the interval from the date of the liso-cel infusion to the date of death due to any cause.   |
|----------------------|-----------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | Exploratory endpoints | ATAs to liso- cel B-cell numbers Plasma cytokines and chemokines Liso-cel product characteristics CD19 expression | Immune responses to liso-cel were evaluated with a validated ATA assay to detect the presence of plasma antibodies that bind to the extracellular region of liso-cel. Measurement of B-cell numbers, plasma cytokines and chemokines, changes in tumor and tumor microenvironment factors. Liso-cel product characteristics. Evaluation of tumor biopsies for CD19 expression and attributes of tumor and tumor microenvironment.                                                                                                                                                                                                                                                                                                                                                                                              |
| Database lock        | 17-Jul-2024           | 17-Jul-2024                                                                                                       | 17-Jul-2024                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Results and Analysis | Results and Analysis  | Results and Analysis                                                                                              | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Analysis description | Final Analysis        | Final Analysis                                                                                                    | Final Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description   | Leukapheresed Intent to Treat Set: all subjects who signed informed consent, who met all inclusion/exclusion criteria, and underwent leukapheresis. Liso-cel-treated Efficacy Analysis Set: subjects who have PET-positive disease present before liso-cel administration based on IRC assessment. Includes subjects treated with DL1S and DL2S. Primary Analysis Set (PAS): subjects that have PET-positive disease at baseline and have failed at least 2 prior lines of systemic therapy including an alkylating agent, a BTKi, and rituximab (or other CD20-targeted agent), treated at the recommended regimen (DL2S) with conforming product.   | Leukapheresed Intent to Treat Set: all subjects who signed informed consent, who met all inclusion/exclusion criteria, and underwent leukapheresis. Liso-cel-treated Efficacy Analysis Set: subjects who have PET-positive disease present before liso-cel administration based on IRC assessment. Includes subjects treated with DL1S and DL2S. Primary Analysis Set (PAS): subjects that have PET-positive disease at baseline and have failed at least 2 prior lines of systemic therapy including an alkylating agent, a BTKi, and rituximab (or other CD20-targeted agent), treated at the recommended regimen (DL2S) with conforming product.   | Leukapheresed Intent to Treat Set: all subjects who signed informed consent, who met all inclusion/exclusion criteria, and underwent leukapheresis. Liso-cel-treated Efficacy Analysis Set: subjects who have PET-positive disease present before liso-cel administration based on IRC assessment. Includes subjects treated with DL1S and DL2S. Primary Analysis Set (PAS): subjects that have PET-positive disease at baseline and have failed at least 2 prior lines of systemic therapy including an alkylating agent, a BTKi, and rituximab (or other CD20-targeted agent), treated at the recommended regimen (DL2S) with conforming product.   | Leukapheresed Intent to Treat Set: all subjects who signed informed consent, who met all inclusion/exclusion criteria, and underwent leukapheresis. Liso-cel-treated Efficacy Analysis Set: subjects who have PET-positive disease present before liso-cel administration based on IRC assessment. Includes subjects treated with DL1S and DL2S. Primary Analysis Set (PAS): subjects that have PET-positive disease at baseline and have failed at least 2 prior lines of systemic therapy including an alkylating agent, a BTKi, and rituximab (or other CD20-targeted agent), treated at the recommended regimen (DL2S) with conforming product.   | Leukapheresed Intent to Treat Set: all subjects who signed informed consent, who met all inclusion/exclusion criteria, and underwent leukapheresis. Liso-cel-treated Efficacy Analysis Set: subjects who have PET-positive disease present before liso-cel administration based on IRC assessment. Includes subjects treated with DL1S and DL2S. Primary Analysis Set (PAS): subjects that have PET-positive disease at baseline and have failed at least 2 prior lines of systemic therapy including an alkylating agent, a BTKi, and rituximab (or other CD20-targeted agent), treated at the recommended regimen (DL2S) with conforming product.   |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Leukapheresed Set                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Efficacy set                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Liso-cel- treated Efficacy Analysis Set                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Primary Analysis Set (PAS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability  | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | N=104                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | N=81                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | N=83                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | N=75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability  | ORR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 70.2%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 82.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 83.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 86.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability  | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 60.4%, 78.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 72.7%, 90.2%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 73.3%, 90.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 76.8%, 93.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability  | CR rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 61.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 71.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 72.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 74.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability  | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 51.5%, 70.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 60.5%, 81.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 61.4%, 81.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 63.3%, 84.0%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability  | DOR (Months), Median 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 15.2 7.0, 24.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11.5 6.2, 24.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14.5 6.2, 24.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11.5 5.7, 24.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability  | PFS (Months), Median 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 9.6 7.2, 17.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12.3 6.6, 24.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12.3 6.5, 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability  | OS (Months), Median 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 19.6 12.5, NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18.4 12.9, NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 18.4 13.5, NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Analysis performed across trials (pooled analyses and meta-analysis)

Systematic Literature Review of Clinical Efficacy and Safety of Third-Line or Later (3L+) Treatments for Bruton's Tyrosine Kinase Inhibitor (BTKi)-Exposed Adults with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)

<div style=\"page-break-after: always\"></div>

## Aim of the study

The aim of this study was to conduct a systematic literature review (SLR) to identify evidence on the clinical efficacy and safety of 3L+ treatment options for adult R/R MCL patients who have been previously exposed to a BTKi. As a secondary objective, the feasibility of conducting meta-analyses (MAs) of reported key efficacy outcomes (ie, overall response rate [ORR], OS, and progression-free survival [PFS]) was considered using the studies identified in the SLR.

## Methodology

Searches in databases (Ovid MEDLINE®, Embase, and the Cochrane Central Register of Controlled Trials using the Ovid interface) were restricted to randomized controlled trials (RCTs), single-arm studies, and non-randomized studies (including real-world evidence [RWE], registries, retrospective cohort, cross-sectional, and case-control) published from database inception, with the most recent searches conducted on 7-Aug-2024. Study eligibility criteria were assessed according to pre-specified Population, Intervention, Comparator, Outcome, and Study design (PICOS) criteria, which included BTKi-exposed adult R/R MCL patients in the 3L+ setting who received systemic treatments recommended by NCCN/ESMO guidelines and/or treatments deemed relevant to current clinical practice for MCL. All identified articles were screened by 2 independent reviewers; any discrepancies were resolved through discussion or a third (independent) reviewer. Conference abstracts published from 2020 onwards were included only if considered relevant by two reviewers.

Eligible studies (ie, those with full text publications) underwent quality assessment using checklists recommended by the National Institute for Health and Care Excellence (NICE) to assess the potential risk of bias.

## Statistical considerations

Meta-analysis feasibility assessments were conducted for included studies that reported ORR, CR rate, OS, and/or PFS outcomes and was determined based on a qualitative assessment of heterogeneity in study characteristics and clinically significant patient baseline characteristics.

## Results

Nineteen studies were included: 5 (26%) interventional studies and 14 (74%) observational studies.

Ten studies (53%) investigated non-CAR T-cell therapies, including pirtobrutinib and 9 (47%) examined CAR T-cell therapies, including brexu-cel and liso-cel.

<div style=\"page-break-after: always\"></div>

Table 39. Summary of efficacy outcomes across treatments in 3L+ BTKi-exposed MCL patients

<!-- image -->

| Treatment                                              | Response outcome ranges across studies                                                                    | Response outcome ranges across studies                                                                     | Response outcome ranges across studies                                                                             | Response outcome ranges across studies                                                                | Survival outcome ranges acrosstudies                                                                      | Survival outcome ranges acrosstudies                                                          |
|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
|                                                        | ORR                                                                                                       | CR                                                                                                         | PR                                                                                                                 | Median DOR (months)                                                                                   | Median OS (months)                                                                                        | Median PFS (months)                                                                           |
| Non-CAR T-cell therapies(n=10 studies)                 | Non-CAR T-cell therapies(n=10 studies)                                                                    | Non-CAR T-cell therapies(n=10 studies)                                                                     | Non-CAR T-cell therapies(n=10 studies)                                                                             | Non-CAR T-cell therapies(n=10 studies)                                                                | Non-CAR T-cell therapies(n=10 studies)                                                                    | Non-CAR T-cell therapies(n=10 studies)                                                        |
| Rinuximab-bendamustinecombinationregimens(n=3sthudies) | Rinuximab-bendamustinecombinationregimens(n=3sthudies)                                                    | Rinuximab-bendamustinecombinationregimens(n=3sthudies)                                                     | Rinuximab-bendamustinecombinationregimens(n=3sthudies)                                                             | Rinuximab-bendamustinecombinationregimens(n=3sthudies)                                                | Rinuximab-bendamustinecombinationregimens(n=3sthudies)                                                    | Rinuximab-bendamustinecombinationregimens(n=3sthudies)                                        |
| BR (n= 1 study)                                        | 53% (median follow-up: NR)                                                                                | 40% (median follow-up: NR)                                                                                 | 13% (median follow-up: NR)                                                                                         | NR                                                                                                    | NR                                                                                                        | NR                                                                                            |
| R-BAC (n=2 studies)                                    | 83% (median follow-up: 18 months) (m=1 study)                                                             | 60% (median follow-up: 18 months) (m=1 study)                                                              | NR                                                                                                                 | NR                                                                                                    | 12.5 (median follow-up: NR) to 14 (median follow- up: 23 months) (n=2 studies)                            | 10.1 (media fllow-up: NR) (n=1 study)                                                         |
| Lenalidomide-based regimens(n=I sthucy)                | Lenalidomide-based regimens(n=I sthucy)                                                                   | Lenalidomide-based regimens(n=I sthucy)                                                                    | Lenalidomide-based regimens(n=I sthucy)                                                                            | Lenalidomide-based regimens(n=I sthucy)                                                               | Lenalidomide-based regimens(n=I sthucy)                                                                   | Lenalidomide-based regimens(n=I sthucy)                                                       |
| Lenalidomide +rituximab (n=1 study)                    | 27% (median follow-up: NR)                                                                                | 9.1% (median follow-up: NR)                                                                                | 18.2% (median follow-up: NR)                                                                                       | 4.6 (median follow-up: NR)                                                                            | NR                                                                                                        | NR                                                                                            |
| Mixed treatment basket(n=5shdies)                      | Mixed treatment basket(n=5shdies)                                                                         | Mixed treatment basket(n=5shdies)                                                                          | Mixed treatment basket(n=5shdies)                                                                                  | Mixed treatment basket(n=5shdies)                                                                     | Mixed treatment basket(n=5shdies)                                                                         | Mixed treatment basket(n=5shdies)                                                             |
| Various treatments (n= 5 studies)                      | NR                                                                                                        | NR                                                                                                         | NR                                                                                                                 | NR                                                                                                    | 3.6 (median follow-up: NR)to 13.2 (median follow-up: NR) (m= 5 studies)                                   | NR                                                                                            |
| BTKi therapies (n = 2 shudies)                         | BTKi therapies (n = 2 shudies)                                                                            | BTKi therapies (n = 2 shudies)                                                                             | BTKi therapies (n = 2 shudies)                                                                                     | BTKi therapies (n = 2 shudies)                                                                        | BTKi therapies (n = 2 shudies)                                                                            | BTKi therapies (n = 2 shudies)                                                                |
| Pitobrutinib (n= 2 studies)                            | 52% , 49.3%, 62.9% (median follow-up: 6 months, 24.2 months, NR. respectively) (n=2 studies)              | 25%, 15.8%, 11.4% (median follow-up: 6 months, 24.2 months, NR, respectively) (m=2 studies)                | 27% , 33.6%, 51.4% (median follow-up: 6 months, 24.2 months, NR, respectively) (m= 2 studies)                      | 21.6 (median follow-up: 24.2 months) (n= 1 study)b                                                    | 15.5 (median fllow-up: 12.3 months) to 23.5 (median follow-up: 24.2 months) (m= 2 studies)                | 5.6 (median follow-up: 15.9 months) to 9.4 (median follow-up: 7.4 months)c (n=2 studies)      |
| CAR T-cell therapies (n = 9 studies)                   | CAR T-cell therapies (n = 9 studies)                                                                      | CAR T-cell therapies (n = 9 studies)                                                                       | CAR T-cell therapies (n = 9 studies)                                                                               | CAR T-cell therapies (n = 9 studies)                                                                  | CAR T-cell therapies (n = 9 studies)                                                                      | CAR T-cell therapies (n = 9 studies)                                                          |
| Brexu-cel (n= 8 studies)                               | ZUMIA-2:93% and91% (median follow-up: 12.3 and 35.6 months, respectively) (n=1 study)                     | ZUNIA-2:67%,68%, 67.6% (median follow-up: 12.3 months, 35.6 months, 47.5 months, respectively) (m=1 study) | ZUNIA-2: 27%, 24%, 23.5% (median follow-up: 12.3 months, 35.6 months, 47.5 months, respectively) (n= 1 study)      | ZUMIA-2: 28.2(median follow-up: 35.6 months) (n= 1 study)d                                            | ZUMIA-2: 46.6 (median follow-up: 35.6 months) (m=1 study)                                                 | ZUMIA-2: 25.8 (median fllow-up: 35.6 (m= 1 study)f                                            |
| Brexu-cel (n= 8 studies)                               | Observational: 81% (median follow-up: 14.3 months) to 100% (median follow-up: 11.7 months) (m= 7 studies) | Observational: 47% (median follow-up: 14.3 months) to 94%(median follow-up: 11.7 months) (n=7 studies)     | Observational: 6% (median follow-up: 11.7 and 13.3 months) to 17.6% (median follow-up: 24.5 months) (n= 3 studies) | Observational: 5.3 (median follow-up: 3.3 months) to 19(median follow-up: 24.5 months) (m=2 studies)d | Observational: 14.7 (median follow-up: 14.3 months) to 23.3(median follow-up: 12.2 months) (n=3 studies)* | Observational: 6.3 (median follow-up: NR) to 21 (median follow-up: 13.3 months) (n=4 studies) |
| Liso-cel (m=1 study)                                   | 86.5% (median fllow-up: 16.1 months)                                                                      | 74.3% (median follow-up: 16.1 months)                                                                      | 10.8% (median follow-up: 16.1 months)                                                                              | 11.3(median follow-up: 16.1 months)s                                                                  | 18.2 (median follow-up: 23.8 months)                                                                      | 12.3 (median fllow-up: 23.5 months)                                                           |

Matching-adjusted indirect comparisons (MAICs) for lisocabtagene maraleucel in the treatment of third-line or later (3L+) relapsed/refractory (R/R) mantle cell lymphoma (MCL)

## Aim of the study

The primary objective was to estimate the comparative efficacy and safety of lisocabtagene maraleucel (liso-cel) versus brexucabtagene autoleucel (brexu-cel), and pirtobrutinib in patients with third-line or later (3L+) relapsed or refractory (R/R) mantle cell lymphoma (MCL).

## Methodology

An unanchored matching-adjusted indirect comparisons (MAICs) were used to estimate populationadjusted relative treatment effects associated with liso-cel in the MCL cohort in TRANSCEND-NHL-001 trial compared to brexu-cel (CD19-directed genetically modified autologous T cell immunotherapy; ZUMA-2 trial) and pirtobrutinib (noncovalent, reversible, Bruton's tyrosine kinase inhibitor [BTKi]; BRUIN trial). For comparison versus brexu-cel, the outcomes included both efficacy and safety outcomes, while with pirtobrutinib comparison was feasible only for efficacy endpoints because of the

<div style=\"page-break-after: always\"></div>

presence of substantial differences in the safety profile and differences in the monitoring periods for AESIs.

## Diagnosis and main criteria for inclusion in the study

All participants were required to meet the inclusion/exclusion criteria specified in their respective trials (i.e.,TRANSCEND-NHL-001, ZUMA-2, and BRUIN). Furthermore, in conducting the MAICs, patients from the liso-cel trial who did not satisfy the inclusion/exclusion criteria of the comparator trials were excluded (to the best extent possible) prior to commencing the analysis.

## Criteria for evaluation and statistical considerations

Primary Endpoint: The outcomes of interest included efficacy outcomes (ORR, CRR, DOR, PFS, and OS) and safety outcomes (CRS, NT, corticosteroid, tocilizumab and/or vasopressor use for the management of CRS and NT, infections, any prolonged cytopenia, any prolonged thrombocytopenia, any prolonged neutropenia).

## Secondary Endpoints: Not applicable

Individual patient data (IPD) from the TRANSCEND-NHL-001 trial were adjusted to match the marginal distribution (e.g., proportions) of clinical factors among patients from the ZUMA-2 and BRUIN trials. Patients from TRANSCEND-NHL-001 were excluded from the IPD set if they did not meet the eligibility criteria specified in ZUMA-2 and BRUIN, particularly if they were identified as important effect modifiers or prognostic variables by clinical experts. IPD for patients who remained in the TRANSCEND-NHL-001 data set were weighted using a method-of-moments propensity score model.

## Results

## Table 40. Primary endpoint results

|                           | Estimate (95% CI)        | Estimate (95% CI)        | Estimate (95% CI)        | Estimate (95% CI)        |
|---------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                           | Naive (unadjusted)       | Primary MAIC scenario    | Naive (unadjusted)       | Primary MAIC scenario    |
| Overall response rate     | OR: 0.477 (0.173, 1.317) | OR: 0.791 (0.194, 3.220) | OR: 2.418 (1.427, 4.095) | OR: 2.756 (1.456, 5.218) |
| Complete response rate    | OR: 1.248 (0.620, 2.511) | OR: 1.389 (0.537, 3.596) | OR: 8.533 (4.738,15.368) | OR: 8.220 (4.222,16.004) |
| Duration of response      | HR: 1.617 (0.974, 2.687) | HR: 1.576 (0.825, 3.009) | HR: 1.157 (0.712, 1.881) | HR: 1.170 (0.687, 2.021) |
| Progression-free survival | HR: 1.536 (0.963, 2.449) | HR: 1.425 (0.776, 2.620) | HR: 0.689 (0.489, 0.970) | HR: 0.642 (0.426, 0.966) |
| Overall Survival          | HR: 1.436 (0.920, 2.240) | HR: 0.793 (0.403, 1.562) | HR: 1.180 (0.824, 1.689) | HR: 1.231 (0.814, 1.862) |

OR &gt; 1 and HR &lt;1 indicates favorable results for liso-cel vs brexu-cel/pirtobrutinib. Statistically significant results are bolded.

CI: confidence interval; HR: hazard ratio; MAIC: matching-adjusted indirect comparison; OR: odds ratio

<div style=\"page-break-after: always\"></div>

Table 41. Safety results

|                                       | Liso-cel vs Brexu-cel OR (95% CI)   | Liso-cel vs Brexu-cel OR (95% CI)   |
|---------------------------------------|-------------------------------------|-------------------------------------|
|                                       | Naive (unadjusted)                  | Primary MAIC scenario               |
| CRS, any grade                        | 0.154 (0.060, 0.394)                | 0.123 (0.041, 0.367)                |
| CRS, Grade>3                          | 0.067 (0.008, 0.535)                | 0.045 (0.001, 2.541)                |
| Corticosteroid use for CRSmanagement  | 0.403 (0.164, 0.987)                | 0.161 (0.027,0.973)                 |
| Tocilizumab usefor CRSmanagement      | 0.248 (0.126, 0.488)                | 0.122 (0.041, 0.363)                |
| Vasopressor usefor CRSmanagement      | 0.121 (0.026, 0.564)                | 0.081 (0.005, 1.470)                |
| iNT, any grade                        | 0.257 (0.132, 0.503)                | 0.221 (0.088, 0.556)                |
| iNT, Grade>3                          | 0.224 (0.092, 0.545)                | 0.134 (0.027, 0.659)                |
| Corticosteroid use for iNT management | 0.306 (0.144, 0.648)                | 0.167 (0.046, 0.607)                |
| Tocilizumab use for iNT management    | 0.032 (0.004, 0.246)                | 0.033 (0.001, 0.869)                |
| Infections, any grade                 | 0.429 (0.225, 0.821)                | 0.333 (0.135,0.818)                 |
| Infections, Grade≥3                   | 0.339 (0.156, 0.735)                | 0.245 (0.073, 0.826)                |
| Any prolonged cytopenia               | 0.517 (0.281, 0.951)                | 0.212 (0.077, 0.582)                |
| Any prolonged thrombocytopenia        | 0.423 (0.227, 0.790)                | 0.160 (0.052, 0.497)                |
| Any prolonged neutropenia             | 0.346 (0.180, 0.665)                | 0.142 (0.041, 0.496)                |

## 2.5.3. Discussion on clinical efficacy

## Rationale for dose selection

The main efficacy analysis came from the MCL cohort of the pivotal study 017001, in which data from patients treated with the dose level 1 (DL1S, 50 × 10 6 CAR+ T cells [25 × 10 6 CD8+ CAR+ T cells and 25 × 10 6 CD4+ CAR+ T cells in a single dose regimen] and the dose level 2 (DL2S, 100 × 10 6 CAR+ T cells [50 × 10 6 CD8+ CAR+ T cells and 50 × 10 6 CD4+ CAR+ T cells] in a single-dose regimen) were considered appropriate for supporting the proposed therapeutic dose of 100 × 10 6 CAR+ viable T cells (consisting of a target 1:1 ratio of CD4+ and CD8+ T cell components)). In fact, consistently with the experience in R/R LBCLs (see procedure  EMEA/H/C/004731/0000), the  DL2S  (i.e.  100  ×  10 6 )  was  eventually  chosen  by  the  steering committee as the recommended dose also for the MCL Cohort.

The ORR by IRC in the DL1S subgroup (N=6) of the liso-cel treated MCL efficacy analysis set was lower (33.3%) compared to the ORR in the DL2S subgroup (N=77, ORR 87.0%), hence uncertainties remain on the possibility that lower liso-cel doses might result in reduced efficacy. Dose-response data in the MCL cohort of study 017001 were, however, confounded by the fact that subjects in the DL1S group were more likely to present with prognostic factors associated with poor outcome (e.g. higher incidence of blastoid morphology, higher median number of previous lines of therapy and refractoriness status) compared with

<div style=\"page-break-after: always\"></div>

subjects in the DL2S cohort. Further, long-lasting remissions and a positive B/R balance could be observed across the whole dose range recommended in Section 4.2 of the SmPC. Finally, as specified by the MAH, post marketing data in the EU showed that Breyanzi has been manufactured so far to a target dose of 100 x 10 6 CAR+ viable T cells in ~99% of patients. The very limited number of patients expected to receive lisocel at doses lower than the target dose makes further requests to collect additional dose-response data in the post-approval setting unfeasible.

In conclusion, based on cumulative safety and efficacy data, the choice of 100 × 10 6 CAR+ T cells as target dose is considered appropriate. The dose regimen proposed for this extension of indication is in line with the current posology recommendations in section 4.2 of the SmPC for the approved indications of Breyanzi (i.e. target dose 100 x 10 6 CAR-positive viable T cells within an acceptance range of 44 to 120 x 10 6  CARpositive viable T cells).

## Design and conduct of clinical studies

The trial design of Study 017001 is in line with other registrational CAR-T trials (i.e. three distinct phases: pre-treatment, treatment and post-treatment, follow-up and possibility to participate in a LTFU study), with study schedules and duration of follow-up consistent with the purpose of the trial.

The single arm nature of study 017001 presents intrinsic limitations, mostly related to the absence of an active control arm, which brings uncertainties to efficacy assessments and results contextualisation. The absence of a standard of care when the trial was designed is acknowledged and the absence of control acceptable, considering the high unmet medical need in the claimed indication when the trial began.

ORR  by  IRC  according  to  the  2014  Lugano  criteria  was  the  primary  endpoint,  which  is  acceptable considering the design features of study 017001. ORR is a direct measure of the anti-tumour activity of liso-cel, yet its clinical relevance is limited, since the value of partial responses in the context of rapidly progressing malignancies is uncertain. Therefore, clinical benefit is better captured by the key secondary endpoint of CRR, since achieving complete remission is a pre-requisite to experience prolonged disease control. Duration of response (DOR), the other key secondary endpoint, is also considered a key measure to inform clinical benefit evaluations since, in the advanced setting targeted by the MAH, achieving longlasting  remission  with  conventional  treatments  is  unlikely.  DOR  evaluation  needs,  however,  to  be supported by a proper duration of follow-up: in respect to that, the first efficacy analysis (cut-off date 19-Jan-2023) corresponded to at least 6 months of follow-up from first objective response in all subjects, while the final analysis (cut-off date 16-May-2024) provided at least 24 months of follow-up, with all patients who either completed or discontinued the study.

No substantial differences were noted between the results obtained in the first and the final analysis and, although it cannot be considered exhaustive, the provided follow-up time can be considered sufficient to weight the efficacy of liso-cel, especially considering the aggressive behaviour of MCL in the R/R setting. Study 017001 was not originally developed using the estimand framework, as the original protocol was released in May -2015, prior to the publication of the draft version of the ICH E9(R1) addendum in Nov2019. The estimands for the primary and secondary endpoints were retrospectively described and were in  line  with  EMA  guidelines; for DOR, in the primary analysis the estimand framework was reported following the FDA censoring rule, yet a sensitivity analysis performed according to EMA requests was submitted.

PFS and OS data, which are usually considered the most relevant endpoints to inform clinical benefit evaluations in non-Hodgkin lymphomas, are only considered supportive for weighting the clinical benefit of liso-cel in MCL. In the absence of a randomised reference, in fact, disentangling the effect of the intervention from the possible impact of underlying tumour/patient characteristics (e.g. differences in

<div style=\"page-break-after: always\"></div>

tumour growth rates) on survival times is not possible, hampering reliable interpretations of the results. Similar considerations can also be applied to the evaluation of HRQoL and Hospital Resource Utilization.

Primary efficacy analysis in study 017001 was performed on subjects from the MCL cohort who had PETpositive disease before liso-cel administration, received liso-cel at the recommended dose regimen and had at least one post-infusion response assessment; this is acceptable to control possible confounding factors unrelated to liso-cel activity. However, results from all leukapheresed subjects, irrespectively on whether they actually received liso-cel, are considered more in line with the ITT principle and with real world clinical practice.

Sample size calculation for the primary analysis was based on the assumed thresholds for efficacy (i.e. ORR 40%, CRR 18%): this approach can be considered acceptable in the context of the exploratory nature of the study and the available treatment options at the time of study was designed, when the alternatives for BTKi exposed patients were limited. Notably, the statistical hypothesis for the definition of  the  primary  endpoint  was  set  on  literature  data  about  the  efficacy  of  lenalidomide  (alone  or combination  with  rituximab)  [Witzig  2017,  Andorsky  2016,  Wang  2015],  bortezomib+  rituximab [Chiappella 2009, 2015], obinutuzumab [Morschhauser 2013], or post-ibrutinib [Martin 2016]. To note, the validity of the assumptions can be maintained even considering that the target population (BTKi and anti-CD20  exposed  after  at  least  2  lines  of  therapy)  was  introduced  in  2019  (with  Amendment  7), although it is not completely adherent to the current therapeutic panorama, especially when the antiCD19 CART brexucabtagene autoleucel is taken into account. It is highlighted, however, that MCL is a heterogeneous condition with respect to clinical and biological features and, when the limits of a SAT design  are  taken  into  consideration  (see  e.g.  the  EMA  guidance  EMA/CHMP/458061/2024),  a  more conservative approach in the selection of the efficacy thresholds (e.g. considering the upper limit of the 95%CI for the ORR and CRR meta-analysis estimates) would have been preferred. It is acknowledged, however, that the high response rates eventually observed in the MCL cohort of study 017001 left no remaining concerns about clinical relevance. Further, as specified by the MAH, the initial sample size calculations  (N=50)  were  subsequently  increased  based  on  feedback  from  health  authorities  to  a minimum of N=70 evaluable subjects.

Two hypotheses (ORR ≤40% vs. ORR &gt; 40% and CRR ≤18% vs. &gt;18%) were sequentially tested at an overall 1-sided 0.025 level of significance. The overall Type-1 error was controlled using a Hierarchical Testing strategy, and only if the null hypothesis was rejected in the first hypothesis test, the second hypothesis testing could be performed. This is acceptable. Sensitivity analyses were performed to better define  the  robustness  of  results  obtained  with  the  primary  analysis.  Four  sensitivity  analyses  were performed: 1. using the Leukapheresed (ITT) set (n = 104), 2. based on responses adjudicated by Investigator, 3. using the Liso-cel- treated Efficacy Analysis Set (defined as all patients having received at least one dose of conforming liso-cel product and have baseline PET-positive disease present before liso-cel  administration  and  have  PET/CT  assessment  repeated  after  bridging  therapy  before  liso-cel administration; n = 83) and 4. assessing the impact of COVID-19 (as a post hoc analysis to evaluate the impact  of  COVID-19  pandemic  on  the  study).  In  addition,  a  post-hoc  modified  efficacy  analysis  set ('efficacy set') was also defined as all patients from the Liso-cel- treated Efficacy Analysis Set who have received prior treatment with at least 2 prior lines of systemic therapy including a BTKi and analyzed according to EMA censoring rules (n = 81), which is the dataset that is used for the presentation of efficacy  outcomes  in  the  SmPC.  All  the  sensitivity  analyses  were  deemed  supportive  for  the  initial purpose. In respect to the principal analysis, subjects in the Leukapheresed (ITT) Set who did not receive the  cell  product  was  considered  not  evaluable  (i.e.,  non-responder);  moreover,  for  PFS  and  OS evaluation, the date of the first leukapheresis served as the reference date instead of the date of the first liso-cel infusion. The pre-specified subgroups analyses, based on demographic (e.g. age categories, ethnic  groups,  gender)  and  prognostic/biological  features  (e.g.  TP53  and  KI67  status,  chemo-

<div style=\"page-break-after: always\"></div>

responsiveness, prior HSCT, CNS involvement) were deemed informative and in line with the clinical and biological features of R/R MCL.

At the time of the final analysis (data cut-off: 16-May-2024), with a longer on-study follow-up (median of 19.53 months), no formal hypothesis was tested.

Overall, the planned statistical methods used for the analyses of time-to-event and binary endpoints analyses were standard and acceptable and, despite the above mentioned limits, the current base of evidence is still in line with what has been previously considered adequate by the CAT/CHMP to conclude for a positive B/R with other CARTs in the clinical setting defined by the claimed indication.

## Extent of exposure and patient flow

All subjects in study 017001 were screened at 14 sites in the US: although the substantial uniformity in terms  of  guidelines  and  approved  treatments  between  US  and  EU  at  the  time  study  017001  was conducted is acknowledged, due to possible differences in treatment access or positioning (e.g. with respect to ASCT/alloHSCT) uncertainties on results generalizability to the EU setting cannot be excluded. The MAH agreed on amending the ongoing PASS JCAR017 -BCM-005 study to include the collection of data on EU subjects with R/R MCL treated with liso-cel.

In general, the disposition of patients is considered justified by the clinical/management complexity of cellular therapies like CAR-Ts in a rapidly evolving disease setting and disease characterised by poor response with conventional treatments: in particular, the observed high rate of study discontinuation due to death of participants (50%) is expected in an aggressive disease like MCL.

As  a  general  principle,  major  changes  in  the  study  protocol  of  an  ongoing  registrational  trial  are considered of potential regulatory concern: especially when involving the eligibility criteria, the definition of the primary analysis set and the SAP. However, it is also noted that the statistical hypotheses for rejecting the null hypothesis were not affected, as well as the estimated sample size and the total number of  subjects  enrolled  in  the  Primary  Analysis  Set  (N=75),  which  already  exceeded  the  number  of  50 patients estimated in the SAP. Further, the changes in the study population introduced are believed to not have had a significant impact on the integrity of the trial.

Most  of  the  subjects  in  the  Liso-cel-treated  Analysis  Set  received  treatment  during  the  COVID-19 pandemic, with 75% of the subjects treated from Jan-2020 to May-2022. The impact of the pandemic on study conduct was, apparently, negligible, since no major COVID-19-related protocol deviation was reported. The clinical impact of the pandemic was investigated in a dedicated sensitivity analysis.

Major  protocol  deviations  were  collected  in  6/88  subjects  (6.8%),  the  most  frequent  being  study treatment deviations (4 subjects, 4.5%). In general, the rate of deviations is considered low and without critical impact on the study conduction.

## Number analysed and baseline data

The wording of indication proposed by the MAH is considered adherent to the patients included in the Primary Analysis Set (PAS) used for the primary hypothesis testing. Overall, at the time of final analysis (data cut date of 16-MAY-2024), in the PAS a total of 75 patients were included, corresponding to 72% of the Leukapheresed Set (ITT). Compared to the primary analysis (data cut date of 19-JAN-2023), 1 additional subject was identified meeting the PAS criteria.

The demographic and baseline characteristics of all subjects in the PAS as reported in the sections above were representative of an R/R MCL population with moderate comorbidities and in line with the known epidemiology of MCL.

<div style=\"page-break-after: always\"></div>

Most subjects had at least one high risk feature and secondary CNS lymphoma involvement was not rare (active CNS disease at liso-cel infusion was present in 9.3% of patients). Overall, 65.3% of subjects were refractory to their most recent prior treatment and all (100%) received prior BTKi, with 54.7% being  refractory  to  BTKi  (40%  refractory  to  ibrutinib);  22.7%  of  subjects  were  also  refractory  to venetoclax.

As per the data presented in the sections above, all (100%) subjects received at least one prior alkylating agent and the median number of previous lines of therapy was 3 (2-11). The global number of patients who had received a prior ASCT was 29.3% and it is considered in line with the median age of subjects enrolled in the study; as expected, the global number of patients with a prior allogeneic SCT was low (5.3%). The median time from diagnosis to first liso-cel infusion for all subjects was 63.75 months (range 3.9 to 299.5 months) and it is considered in line with the disease-history of MCL. The high variability observed in terms of number of prior lines of therapy and time from diagnosis to liso-cel administration further highlights the significant clinical heterogeneity of MCL.

In general, demographics and baseline characteristics were similar between the PAS, the Liso-cel-treated Analysis Set, and the Leukapheresed Set.

The administration of a bridging therapy between leukapheresis and LDC administration was required in most  subjects  (65.3%).  In  principle,  the  need  for  bridging  therapy  in  most  patients  reflects  the aggressive  behavior  of  MCL,  given  the  disease's  tendency  to  present  systemic  recurrences  in  the advanced stages.

Overall, the manufacturing of liso-cel did not present critical issues able to affect the protocol's results. It  is  noted,  however,  that  in  some  cases  remarkable  delays  were  collected  (80  days  for  product availability), whose impact on treatment compliance and effectiveness is not completely characterised. While  the  occurrence  of  intercurrent  clinical  events  could  explain  the  longer  time  intervals  between product availability and administration, the reasons behind the delays in product availability are less clear.  Nevertheless,  considering  the  low  number  of  patients  experiencing  such  delay  this  does  not represent an issue for the final assessment of the data provided

The exposure to the liso-cel was in line with the intended use in terms of median total dose (99.6 × 10 6 range: 62 to 103 CAR+ viable T cells), median CD8 and CD4 component doses (49.8 × 10 6 , range: 22 to 56 and 49.4 × 10 6 , range: 35 to 52 CAR+ viable T cells, respectively) and median CD4:CD8 ratio (1.00, range: 0.8 to 1.8).

## Efficacy data and additional analyses

## Outcomes and estimation

The primary analysis was performed at a median follow up of 16.10 months for the MCL PAS Cohort (data cut date 19 Jan 2023). The primary endpoint of ORR was met in the PAS (ORR: 86.5% [95% CI: 76.5, 93.3] p value &lt; 0.0001), allowing to reject the cohort nu ll hypothesis of ORR ≤ 40%. The final analysis (data cut date 16 May-2024) reported a similar ORR of 86.7% [95% CI: 76.8, 93.4]. Most of the responses were represented by Complete Response (see Key secondary endpoint); Stable Disease (SD) was reported in 5 cases (6.7%) and Progression in 1 (1.3%). Notably, in 4 cases the Response was reported as Not Evaluable (5.3%) as no post liso-cel infusion scans were performed for these patients

Sensitivity analyses were applied to the primary endpoint in order to evaluate the robustness of the primary analysis, and showed consistent results (data cut date 16 May-2024):

- -In the Liso-cel treated Efficacy Analysis Set ,  the  overall  ORR was 83.1% (95% CI 73.390.5), with a total CR rate of 72.3% (95% CI 61.4-81.6). To note, in this analysis set were included subjects treated with two different levels of dose (DL1S: 50 x 10 6  CAR-positive viable

<div style=\"page-break-after: always\"></div>

T cells and  DL2S: 100 x 10 6  CAR-positive viable T cells, i.e. the recommended regimen) and reflects the range of acceptability (44-120 x 10 6  CAR-positive cell) reported in the SmPC of lisocel. To note, the ORR reported for the DL2S recommended regimen was far higher (ORR: 87.0%, 95%  CI:  77.4,  93.6)  than  that  reported  for  DL1S  (ORR:  33.3%,  95%  CI  4.4-77.7).  This inconsistency could result from the reduced sample size in the DL1S cohort (DL1S: N=6) and the  higher  frequency  of  adverse  prognostic  factors  like  blastoid  morphology,  higher  median number of previous lines and refractoriness status in comparison with the DL2S cohort, although a dose-response effect on response could not be definitively excluded. Overall, the results for DL1S should be interpreted with caution due to the small sample size of DL1S.

- -Investigator-assessed ORR in the PAS was 85.3% (95% CI: 75.3, 92.4) and was consistent with the IRC assessment; in general, this analysis is considered reliable, given the high rate of concordance (98.6%) between the IRC and Investigator assessments for BOR.
- IRC-assessed ORR in the Leukapheresed Set was 70.2% (95% CI: 60.4, 78.8), lower than the IRCassessed ORR in the PAS. This is an expected finding, since the Leukapheresed Set included all subjects who underwent leukapheresis, including those subjects who did not receive liso-cel (12 subjects) and those who received nonconforming product (4 subjects ).
- In the post-hoc defined modified Efficacy Analysis Set ('Efficacy Set') , which is used to present data in the SmPC, response rates were consistent: ORR of 82.7% (95% CI: 72.7, 90.2) and CRR of 71.6% (95% CI: 60.5, 81.1).

The  subgroup  analysis  for  the  primary  endpoint  showed  a  consistent  efficacy  of  liso-cel;  ORR  rates slightly below 80% but still clinically relevant were observed in patients with adverse prognostic factors such as prior HSCT, refractoriness to last therapy, mutated TP53 or general chemo-refractoriness and blastoid morphology, in absence of a clear trend of lack of efficacy in any of them. In general, a lower performance is expected in patients with adverse clinical/biological prognostic factors; however, in most of these cases, the small number of enrolled patients impaired the overall evaluation of the reported subgroup analysis. This is particularly evident for some categories of subjects like patients aged &lt; 65 years (N=15), Non-White (N=5), presence of CNS disease (N=6), KI67 &lt;30% (N=9). A trend towards reduced efficacy in subjects with high disease burden have been previously shown with immunotherapy, yet due to limited numbers in the post-hoc 'high-disease burden subgroup' (LDH &gt; 500 U/L: N=7; SPD &gt; 50 cm 2 : N=4, bulky disease N=2) no definitive conclusion could be drawn for liso-cel in the targeted indication.

The study also met its key secondary efficacy endpoint, rejecting the null hypothesis of CR rate ≤ 18% (p&lt;0.0001) in the MCL Cohort PAS; the IRC-assessed CR rate at the time of the primary analysis (data cut date 19 Jan 2023) was 74.3% (95% CI: 62.8, 83.8). The final analysis (data cut date 16 May-2024) reported  a  similar  CRR  of  74.7%  (95%  CI:  63.3,  84.0).  Similar  results  were  also  obtained  in  the sensitivity analyses applied to the secondary endpoint (Investigator assessment: 72.3%, 95% CI 61.481.6; Leukapheresed Set: 61.5%, 95% CI 51.5-70.9).

The subgroup analysis for CRR showed a trend similar to that reported for the ORR and this finding was expected, given that most of the response to Liso-cel were CR. In general, all the considerations made the primary endpoint in terms of sensitivity and subgroup analyses can be extended also to the secondary endpoint of CRR.

Given the single-arm design and the aim of pivotal trial 017001, the Duration of Response per IRC assumes a critical value to weight the clinical relevance of the antitumoral effect of liso-cel. In the PAS, the DOR was calculated for the 65 responders; the median IRC-assessed DOR at the time of the final analysis (data cut date 16 May-2024) was 11.3 months (95% CI: 5.7, 24.0). The KM plots for DOR showed how the majority of events occurred within the first 12 months after liso-cel infusion; the event

<div style=\"page-break-after: always\"></div>

rate seemed to slow down in the tails of the curves (although no clear plateau phase could be identified), likely reflecting the clinical and prognostic heterogeneity in MCL, yet late events could still be observed and heavy censoring after 21 months hampered the assessment of long-term benefit. Although the probability of continued response decreased from 62% (48.9-72.7) after 6 months to 39.4% (27.4-51.2) at 24 months, a subgroup of patients was still able to achieve durable remission with liso-cel despite the advanced setting of relapse. Most DoR events can be attributed to progression of disease (43.1%) or death (16.9%), with 2 patients censored because of start of a new anticancer therapy.  Achieving CR was associated with a longer duration of response, with a median IRC-assessed DOR of 14.5 months (95% CI: 7.0, 24.0) in subjects in CR compared to 2.2 months (95% CI: 1.5, 2.4) in subjects with a BOR of PR.  Responses were also rapidly achieved, with a median Time to Response of 0.95 months (range: 0.7 to 3.0). DOR results in the Efficacy Analysis Set were similar to those reported in the PAS, with a median value reached at 13.3 months (95% CI: 6.7-24), which was not unexpected considering that all but 6 subjects in this analysis came from the DL2S cohort. Similar results were also reported in the other sensitivity analyses (investigator-assessed median DOR in the PAS: 11.3 months, 95% CI: 5.7, 23.3; IRC-assessed median DOR in the Leukapheresed Set: 15.2 months (95% CI: 7.0, 24.0). Finally,  the  median  DOR  in  most  subgroups  was  consistent  with  that  observed  in  the  overall  PAS responder population, although these results should be interpreted with caution, given the small sample size in some subgroups. No substantial difference was noted when DoR was calculated according to the FDA or EMA censoring rules.

The results of the other time-to-event endpoints of PFS and OS should be considered as descriptive, since the absence of a control arm reduce their strength in terms of contextualization of the efficacy of the drug.  The sensitivity analyses for PFS were consistent with the primary analysis.

Similarly,  for  what  reported  for  DOR  and  PFS,  the  achievement  of  a  BOR  of  CR  correlated  with  a numerically longer median OS compared to subjects with a BOR of PR. Data reported in the EAS and in the Leukapheresed Set were consistent with the results in the primary analysis.

The majority (75%) of subjects in the MCL cohort of study 017001 received treatment during the COVID19  pandemic.  Seven  subjects  died  due  to  COVID  19:  6  subjects  who  achieved  CR  died  in  ongoing response within the first year post-liso-cel infusion (Day 72 to 325). Since these events impacted on the analysis of time to event endpoints, a sensitivity analysis where COVID 19-related events were censored as discontinued from study for DOR and PFS and as alive for OS was provided. These results can be considered similar to those in the PAS, with a median DOR of 15.2 months (95% CI: 6.7, 24.0), a median PFS of 12.3 months (95% CI: 6.1, 24.9) and a median OS of 36.3 months (95% CI: 16.5, NR). Based on the provided analyses, although COVID 19 influenced time to event endpoints, its impact is not considered critical for the interpretation of the trial's results.

The evaluation of Patient's Reported Outcome included subjects in the MCL Cohort Liso-cel-treated Set who had a baseline and at least one post baseline assessment that was analysable; the EORTC QLQC30, EQ-5D-5L, EQ-5D-5L VAS questionaries were used for the assessment. The compliance rate for all questionnaires decreased over time; to note, as reported by the MAH, noncompliance was mostly due to administrative and logistical delays around the implementation of the PROs in the study rather than to an explicit refusal of patients. The EORTC QLQ-C30, liso-cel consistently demonstrated improvements over time in evaluations of group-level mean change in the several primary domains.   The EQ-5D-5L Index Score group-level  mean remained consistent over the course of the study (from baseline to Month 24 post dose) for all subjects (total [DL1S+DL2S]) in the PRO/QoL (EQ 5D) Evaluable Set. With respect to the EQ-5D-5L VAS , liso-cel demonstrated clinically meaningful improvement for all subjects (total [DL1S+DL2S]) as the HRQoL measured by the EQ-5D-5L VAS improved from baseline to Month 2 (mean change [SD[ in VAS = 10.5 [22.31]), and the improvement remained consistent until Month 18. In general, despite the improvement in symptoms and QoL reported in questionnaires, the overall level of the evidence from the PROs was considered low, primarily because of the limits related to lack

<div style=\"page-break-after: always\"></div>

of controls and blinding. The supportive role of the provided PROs analysis for the global definition of the clinical benefit with liso-cel is, therefore, limited.

## Supportive Studies

To contextualize the results of the pivotal single arm trial, the MAH reported the results of 2 supportive studies a systematic literature review and an unanchored MAIC.

The aim of the systematic literature review (SLR) was to identify evidence on the clinical efficacy and safety of 3L+ treatment options for adult R/R MCL patients previously exposed to a BTKi.

Overall, the results from this SLR confirmed the presence of an unmet medical need for additional options in BTKi-pretreated R/R MCL patients in their third or subsequent line of therapy. The analysis of efficacy of the non-CAR-T therapies showed that the rate of ORR/CR was variable and largely influenced by the intensity (e.g. better results could be observed with the R-BAC regimen) and type of treatment (novel drugs like  pirtobrutinib  were  associated  with  better  outcomes).  As  expected,  the  efficacy  outcomes, especially in terms of depth and duration of responses were consistently better with brexu-cel compared to standard therapies, although data from real life experience showed increased variability compared to clinical trials, further highlighting the heterogeneity in the targeted condition.

The MAH also provided unanchored MAIC exercises to better contextualise the extent of benefit with lisocel: liso-cel compared favourably with pirtobrutinib in terms of ORR, CRR and PFS, yet no substantial differences were noted in terms of DOR and OS. Compared to brexu-cel, the point estimations were favourable to liso-cel only in terms of CRR and OS (it should be noted, however, that no comparison between liso-cel and brexu-cel was statistically significant. The intrinsic methodological limitations (e.g. the assumption that all variables with prognostic value should be accounted for in the model) and the limited sample size limited the reliability of the provided comparisons, especially when the significant clinical and biological heterogeneity of R/R MCL is taken into account.

Overall, although the results of the provided indirect comparison exercises provided some information to contextualise the extent of benefit observed with liso-cel in the uncontrolled study 017001, their role to  support  B/R  evaluations  is  necessarily  limited.  The  intrinsic  methodological  limitations  (e.g.  the assumption that all variables with prognostic value should be accounted for in the model) and the limited sample size limited the reliability of the provided comparisons, especially when the significant clinical and biological heterogeneity of R/R MCL is taken into account.

Furthermore, the applicant commits to collect further information on the mantle cell lymphoma patients which will be included in the ongoing post-authorization safety study (PASS) JCAR017-BCM-005 through the necessary adaptation of the protocol (in the RMP) to be submitted for assessment to the Agency within 2 months from receiving the commission decision on the current extension of indication.

## 2.5.4. Conclusions on the clinical efficacy

Efficacy data from the MCL cohort of pivotal study 017001 showed that treatment with liso-cel resulted in a clinically relevant rate of deep and durable responses in an advanced setting of relapse of MCL. In particular, a trend towards long-lasting disease control could be observed in a subgroup of patients who were able to achieve CR with liso-cel.

## 2.6. Clinical safety

## Introduction

For this proposed indication, the safety evaluation is primarily based on the safety data from Study 017001 (TRANSCEND  NHL-001)  as  of  data  cutoff  date  of  16-May-2024,  to  support  the  use  of

<div style=\"page-break-after: always\"></div>

lisocabtagene maraleucel (Breyanzi®; JCAR017;) for the treatment of adult patients with R/R MCL after at least 2 lines of systemic therapy, including a BTKi.

Safety data for liso-cel from the MCL Cohort (3L+ MCL; referred to as the R/R MCL Treated Set) of Study 017001 (n = 88 [DL1S + DL2S]) are presented side-by-side and pooled (n= 826) with safety data for liso-cel in 2L/3L+ LBCL and 2L+ FL.

For a comparison of the safety profile of liso-cel in the R/R MCL population to the known safety profile in the R/R LBCL population in the current SmPC, the supporting liso-cel monotherapy R/R LBCL studies from which 2L LBCL and 3L+ LBCL safety data were pooled and include:

- 3 studies for 2L R/R LBCL :
- -Study JCAR017-BCM-003 Arm B (hereafter referred to as 'Study BCM-003')
- -Study 017006
- -Study JCAR017-BCM-001 (hereafter referred to as 'Study BCM-001') Cohort 2
- ♦ 4 studies for 3L+ R/R LBCL:
- -Study BCM-001 Cohorts 1, 3, and 7
- -Study 017001 DLBCL Cohort
- -Study 017007
- -Study JCAR017-BCM-002 (hereafter referred to as 'Study BCM-002')

Data from each of the respective studies are summarized as:

- R/R MCL Treated Set: 3L+ MCL (017001 MCL Cohort)
- R/R FL Treated Set: 2L+ FL
- R/R LBCL Treated Set: 2L/3L+ LBCL

## Study 017001 in R/R MCL

The  MCL  Cohort  initially  included  subjects  with  R/R  MCL  after  at  least  1  prior  line  of  MCL  therapy. Following Study 017001 Protocol Amendment 07, subjects in the MCL Cohort were required to have received ≥ 2 prior lines of systemic MCL therapy and to have been previously treated with an alkylating agent, a BTKi and rituximab (or other CD20-targeted agents).

## Patient exposure

In Study 017001, in the MCL Cohort a total of 105 subjects were screened, 104 underwent leukapheresis, 93 received LDC, and 92 received CAR+ T cells drug product. Among the 92 who received CAR+ T cells drug product, 88 subjects received liso-cel which comprised the Liso-cel Treated Analysis Set (i.e., R/R MCL Treated Set). Four subjects received nonconforming products.

As of  the  16-May-2024 data cutoff date, the R/R MCL Treated Set had a longer median on-study follow-up time of 19.53 months ,  compared to 12.39 months in the R/R LBCL Treated Set. More subjects had completed the study in the R/R MCL Treated Set compared to the R/R LBCL Treated Set (45.5% vs 25.3%, respectively). In addition, a higher proportion of subjects enrolled in the LTFU study from the R/R MCL Treated Set compared to the R/R LBCL Treated Set (33% vs 18.3%). The most common reason for study discontinuation among both treated sets was death (Table 42).

<div style=\"page-break-after: always\"></div>

Table 42. Subject Disposition - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

|                                      | 3L+MCL N=88   | 2L+FL N = 130   | 2L/3L+ LBCL Total N=608   | 3L+MCLand 2L/3L+LBCL Total N = 696   | 3L+MCL 2L/3L+IBCL and2L+FL Total N=826   |
|--------------------------------------|---------------|-----------------|---------------------------|--------------------------------------|------------------------------------------|
| STUDY STATUS                         |               |                 |                           |                                      |                                          |
| ONGOING                              | 0             | 110 ( 84.6)     | 151 ( 24.8)               | 151 (21.7)                           | 261 ( 31.6)                              |
| COMPLETEDSTUDY                       | 40 ( 45.5)    | 1 (0.8)         | 154 ( 25.3)               | 194 ( 27.9)                          | 195 ( 23.6)                              |
| DISCONTINUED FROM STUDY              | 48 ( 54.5)    | 19 (14.6)       | 303 (49.8)                | 351 (50.4)                           | 370 ( 44.8)                              |
| ADVERSEEVENT                         | 0             | ( 0.8)          | 0                         | 0                                    | 1 (0.1)                                  |
| DEATH                                | 44 ( 50.0)    | （ 5.4)          | 237 (39.0)                | 281 (40.4)                           | 288 ( 34.9)                              |
| LOSTTOFOLLOW-UP                      | 0             | 1 ( 0.8)        | 5 ( 0.8)                  | 5 ( 0.7)                             | 6 0.7)                                   |
| OTHER (A)                            | 0             | 3 2.3)          | 23 3.8)                   | 23 3.3)                              | 26（ 3.1)                                 |
| STUDYTERMINATIONBYSPONSOR            | 0             | 0               | 0                         | 0                                    | 0                                        |
| SUBJECTWITHDREW CONSENT              | 4 (4.5)       | 7 5.4)          | 38 6.3)                   | 42 6.0)                              | 49 5.9)                                  |
| CONSENTEDTOTHEIONG-TERMFOLIOWUPSTUDY | 29 ( 33.0)    | 2( 1.5)         | 111 ( 18.3)               | 140 ( 20.1)                          | 142 ( 17.2)                              |
| SUBJECTSRECEIVEDRETREATMENT          | 2 (2.3)       | 0               | 19 ( 3.1)                 | 21 (3.0)                             | 21 ( 2.5)                                |

## Demographic and baseline characteristics

Demographics and baseline disease characteristics in the R/R MCL Treated Set were representative of a R/R high risk MCL population.

The median time from diagnosis to first liso-cel infusion for all R/R MCL subjects was 63.75 months (range: 3.9 to 299.5 months).

The median number of prior therapies in R/R MCL Treated Set was 3 (range: 1-11), reflecting a heavily pretreated population with advanced disease. Two subjects had received only 1 prior line of therapy for MCL, as allowed by the study protocol prior to Protocol Amendment 07.

In the R/R MCL Treated Set, 29 subjects (33.0%) had prior HSCT, where 26 (29.5%) subjects received prior autologous HSCT and 6 (6.8%) subjects received prior allogeneic HSCT.

Baseline characteristics of the R/R MCL population were reflective of MCL epidemiology. The majority (72.7%) of subjects in the R/R MCL Treated Set were ≥ 65 years old compared to 50.8% in the R/R LBCL Treated Set. 20.5% of R/R MCL subjects were ≥ 75 years old compared to 14.5% of subjects in the R/R LBCL Treated Set. There was no clinically meaningful difference in pre-LDC LDH or pre-LDC SPD between R/R MCL Treated Set and the R/R LBCL Treated Set.

For  additional  details  on  demographic  and  baseline  characteristics  of  Study  017001  MCL  Cohort Population, please refer to Clinical Efficacy part.

The proportion of subjects who received anticancer therapy for disease control (i.e., bridging therapy) in  the  R/R  MCL  Treated  Set  was  similar  to  that  in  the  R/R  LBCL  Treated  Set  (65.9%  vs  60.9%, respectively), reflective of a population with high disease burden and rapidly progressing disease.

In the R/R MCL Treated Set, the median time from last lymphodepleting chemotherapy (LDC) to liso-cel treatment was 4.0 days (range: 3 to 13 days), which was consistent with the protocol guidelines. The majority  of  subjects  in  the  R/R  MCL  (71.6%)  and  R/R  LBCL  (82.9%)  Treated  Sets  received  the  full specified  dose  of  fludarabine  and  cyclophosphamide  at  the  planned  time  with  no  missing  doses;  25 (28.4%) subjects in the R/R MCL  Treated Set received a reduced dose of fludarabine or cyclophosphamide that was mostly related to reduced CrCl.

## Liso-cel Dose

Subjects in the R/R MCL Treated Set received a median total liso-cel administered dose of 99.5 × 10 6 CAR+ viable T cells; the median CD8+ and CD4+ component doses were 49.7 × 10 6  and 49.4 × 10 6 CAR+ viable T cells, respectively, which was similar to the R/R LBCL Treated Set. All subjects in the R/R

<div style=\"page-break-after: always\"></div>

MCL Treated Set were dosed without delay or interruption, with the exception of 1 subject in which dosing was delayed beyond the specified window of 7 days after the completion of LDC due to an AE of hyperbilirubinemia (Grade 2) which was resolved at the time of liso-cel infusion.

## Adverse events

## Overall Safety Summary

The safety events were consistent with previously reported safety findings with liso-cel in R/R LBCL and in 2L+ FL ( Table 43 ).

Table 43. Overview of Treatment-emergent Adverse Events - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

|                                                 | 3L+ MCL N=88   | 2L+FL N = 130   | 2L/3L+ LBCL Total N= 608   | 3L+ ML and 2L/3L+LBCL Total N= 696   | 3L+ MCL 2L/3L+LBCL and2L+FL Total N= 826   |
|-------------------------------------------------|----------------|-----------------|----------------------------|--------------------------------------|--------------------------------------------|
| DURATION OF PERIOD (DAYS)，MEDIAN (RANGE)        | 90.0 (5-90)    | 90.0 (29-90)    | 90.0 (7-218)               | 90.0 (5-218)                         | 90.0 (5-218)                               |
| SUBJECTS WITHANYTEAE                            | 88 (100.0)     | 129 (99.2)      | 602 ( 99.0)                | 690 (99.1)                           | 819 (99.2)                                 |
| SUBJECTS WITHANY GRADE3-4TEAE                   | 72 ( 81.8)     | 99(76.2)        | 482 ( 79.3)                | 554 ( 79.6)                          | 653 (79.1)                                 |
| SUBJECIS WITH ANY GRADE 3-5 TEAE                | 76 (86.4)      | 100 (76.9)      | 497 ( 81.7)                | 573 (82.3)                           | 673 ( 81.5)                                |
| SUBJECTS WITHANY GRADE 5 TEAE                   | 4 (4.5)        | 1 (0.8)         | 15 (2.5)                   | 19 (2.7)                             | 20 (2.4)                                   |
| SUBJECTSWITHANYSERIOUSTEAE                      | 47( 53.4)      | 31 (23.8)       | 260 (42.8)                 | 307 (44.1)                           | 338 (40.9)                                 |
| SUBJECTSWITHANYLDC-RELATEDTEAE                  | 74 (84.1)      | 98 (75.4)       | 498 ( 81.9)                | 572 (82.2)                           | 670 ( 81.1)                                |
| SUBJECTSWITHANYLDC-RELATEDGRADE3-4TEAE          | 57 ( 64.8)     | 81 (62.3)       | 419 ( 68.9)                | 476 ( 68.4)                          | 557 ( 67.4)                                |
| SUBJECTSWITHANYLDC-RELATEDGRADE3-5TEAE          | 59 ( 67.0)     | 81 ( 62.3)      | 427 (70.2)                 | 486 ( 69.8)                          | 567 (68.6)                                 |
|                                                 | 2 (2.3)        | 0               | 8 (1.3)                    | 10 (1.4)                             | 10 (1.2)                                   |
| SUBJECTS WITHANY LDC-RELATED SERIOUS TEAE       | 13 ( 14.8)     | 8 (6.2)         | 67 (11.0)                  | 80 (11.5)                            | 88 (10.7)                                  |
| SUBJECTSWITHANYJCARO17-RELATEDTEAE              | 77( 87.5)      | 115 ( 88.5)     | 486 ( 79.9)                | 563 ( 80.9)                          | 678 ( 82.1)                                |
| SUBJECTSWITHANYJCAR017-RELATEDGRADE3-4TEAE      | 40 ( 45.5)     | 80 ( 61.5)      | 277 ( 45.6)                | 317 ( 45.5)                          | 397 (48.1)                                 |
| SUBJECIS WITH ANY JCAR017-RELATED GRADE 3-5TEAE | 43 ( 48.9)     | 81 ( 62.3)      | 285 ( 46.9)                | 328 ( 47.1)                          | 409 ( 49.5)                                |
| SUBJECTS WITHANYJCAR017-RELATEDGRADE5TEAE       | 3(3.4)         | 1 (0.8)         | 8 (1.3)                    | 11 (1.6)                             | 12 (1.5)                                   |
| SUBJECTSWITHANYJCARO17-RELATEDSERIOUSTEAE       | 34 ( 38.6)     | 24 ( 18.5)      | 181 ( 29.8)                | 215 ( 30.9)                          | 239 (28.9)                                 |

## Treatment Emergent Adverse Events (TEAEs)

In the R/R MCL Treated Set, the most frequently occurring TEAEs by SOC are reported in the Table 44 .

Table 44.Treatment-emergent Adverse Events by System Organ Class and Preferred Term Reported in ≥ 10% of MCL or LBCL Subjects - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

| System Organ Class Preferred Tenm                    | 3L+ MCL N=88 n (%)   | 2L+FL N = 130 n (%)   | 2L/3L+ LBCL Total N= 608 n (%)   | 3L+MCLand 2L/3L+ LBCL Total N= 696 n (%)   | 3L+ MCL 2L/3L+IBCL and 2L+FL Total N= 826 n (%)   |
|------------------------------------------------------|----------------------|-----------------------|----------------------------------|--------------------------------------------|---------------------------------------------------|
| SUBJECTS WITH ANY TEAE                               | 88 (100.0)           | 129 ( 99.2)           | 602 (99.0)                       | 690 ( 99.1)                                | 819 (99.2)                                        |
| Blood and lymphatic system clisorders                | 68 (77.3)            | 100 (76.9)            | 494 4(81.3)                      | 562 ( 80.7)                                | 662 (80.1)                                        |
| Neutropenia                                          | 52 59.1)             | 88 (67.7)             | 409 (67.3)                       | 461 (66.2)                                 | 549 66.5)                                         |
| Anaemia                                              | 39 44.3)             | 52 (40.0)             | 275 45.2)                        | 314 (45.1)                                 | 366 44.3)                                         |
| Thrcmbocytopenia                                     | 26 29.5)             | 38 (29.2)             | 228 (37.5)                       | 254 (36.5)                                 | 292 (35.4)                                        |
| Leukopenia                                           | 6 6.8)               | 18 (13.8)             | 140 23.0)                        | 146 (21.0)                                 | 164 (19.9)                                        |
| Lymphopenia                                          | 6 6.8)               | 19 (14.6)             | 69 (11.3)                        | 75 (10.8)                                  | 94 (11.4)                                         |
| General disorders and acministration site conditions | 59 ( 67.0)           | 58 ( 44.6)            | 386 ( 63.5)                      | 445 ( 63.9)                                | 503 (60.9)                                        |
| Fatigue                                              | 31 ( 35.2)           | 20 ( 15.4)            | 205 (33.7)                       | 236 (33.9)                                 | 256 ( 31.0)                                       |
| Pyrexia                                              | 15 ( 17.0)           | 21 (16.2)             | 120 (19.7)                       | 135 (19.4)                                 | 156 (18.9)                                        |
| Oeclema peripheral                                   | 15 (17.0)            | 6( 4.6)               | 76 (12.5)                        | 91 (13.1)                                  | 97(11.7)                                          |
| Chills                                               | 10 (11.4)            | 4( 3.1)               | 44 (7.2)                         | 54 (7.8)                                   | 58 (7.0)                                          |
| Gastrointestinal cisorders                           | 46 ( 52.3)           | 61 ( 46.9)            | 378 3(62.2)                      | 424  (60.9)                                | 485 ( 58.7)                                       |
| Nausea                                               | 16 (18.2)            | 12 9.2)               | 164 ( 27.0)                      | 180 (25.9)                                 | 192 ( 23.2)                                       |
| Diarrhoea                                            | 15 17.0)             | 22 (16.9)             | 127 (20.9)                       | 142 (20.4)                                 | 164 (19.9)                                        |
| Constipation                                         | 12 13.6)             | 27 (20.8)             | 121 (19.9)                       | 133 (19.1)                                 | 160 (19.4)                                        |
| Vemiting                                             | 5 5.7)               | 5 3.8)                | 88 (14.5)                        | 93 (13.4)                                  | 98 3 (11.9)                                       |
| Abdlcminal pain                                      | 7 8.0)               | 9 （ 6.9)              | 70 ( 11.5)                       | 77 (11.1)                                  | 86 (10.4)                                         |

Assessment report EMADOC-1700519818-2456442

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Tenm               | 3L+MCL N=88 n (%)   | 2L+FL N = 130 n (%)   | 2L/3L+ IBCL Total N= 608 n (%)   | 3L+MCL and 2L/3L+LBCL Total N = 696 n (%)   | 3L+MCL 2L/3L+LBCL and 2L+ FL Total N = 826 n (%)   |
|-------------------------------------------------|---------------------|-----------------------|----------------------------------|---------------------------------------------|----------------------------------------------------|
| Nervous system disorders                        | 42 (47.7)           | 56 ( 43.1)            | 352 (57.9)                       | 394 (56.6)                                  | 450 (54.5)                                         |
| Headache                                        | 20 (22.7)           | 38 (29.2)             | 154 25.3)                        | 174 25.0)                                   | 212 (25.7)                                         |
| Dizziness                                       | 6 6.8)              | 6 (4.6)               | 101 (16.6)                       | 107 (15.4)                                  | 113 (13.7)                                         |
| Tremor                                          | 10 (11.4)           | 19 (14.6)             | 82 (13.5)                        | 92 (13.2)                                   | 111 (13.4)                                         |
| Metabolism andl nutrition clisorders            | 56 (63.6)           | 32 (24.6)             | 292 48.0)                        | 348 ( 50.0)                                 | 380 46.0)                                          |
| Decreased appetite                              | 18 (20.5)           | 7 5.4)                | 124 20.4)                        | 142 20.4)                                   | 149 18.0)                                          |
| Hypokalaemia                                    | 21 (23.9)           | 9 6.9)                | 100 16.4)                        | 121 (17.4)                                  | 130 15.7)                                          |
| Hypomagmesaemia                                 | 13 (14.8)           | 4 3.1)                | 86 14.1)                         | 66 (14.2)                                   | 103 12.5)                                          |
| Hypophosphataemia                               | 15 (17.0)           | 2 1.5)                | 57 9.4)                          | 72 (10.3)                                   | 74 9.0)                                            |
| Hyponatraemia                                   | 9 (10.2)            | 4 3.1)                | 32 5.3)                          | 41（ 5.9)                                    | 45 5.4)                                            |
| Hypocalcaemia                                   | 11 (12.5)           | 1.5)                  | 13 2.1)                          | 24( 3.4)                                    | 26 3.1)                                            |
| Inmune system dlisorders                        | 56 (63.6)           | 77 (59.2)             | 283 46.5)                        | 339 (48.7)                                  | 416 （ 50.4)                                        |
| Cytokine release symdrome                       | 54 (61.4)           | 75 ( 57.7)            | 254 41.8)                        | 308 (44.3)                                  | 383 （ 46.4)                                        |
| Hypoganmaglobulinaemia                          | 6 6.8)              | 3 (2.3)               | 61 (10.0)                        | 67（ 9.6)                                    | 70 8.5)                                            |
| Musculoskeletal and connective tissue disorders | 39 (44.3)           | 40 ( 30.8)            | 244 (40.1)                       | 283 ( 40.7)                                 | 323 3(39.1)                                        |
| Arthralgia                                      | 10 (11.4)           | 11 (8.5)              | 66 (10.9)                        | 76 (10.9)                                   | 87 (10.5)                                          |
| Back pain                                       | 13 (14.8)           | 9 （ 6.9)              | 65 (10.7)                        | 78 (11.2)                                   | 87 ( 10.5)                                         |
| Pain in extremity                               | 6 (10.2)            | 3( 2.3)               | 6.7)                             | 50 (7.2)                                    | 53( 6.4)                                           |
| Respiratory, thoracic and mediastinal disorders | 26 (29.5)           | 21 (16.2)             | 233 ( 38.3)                      | 259 (37.2)                                  | 280 ( 33.9)                                        |
| Cough                                           | 6 (10.2)            | 9 (6.9)               | 91 (15.0)                        | 100 ( 14.4)                                 | 109 (13.2)                                         |
| Vascular disorders                              | 27 (30.7)           | 22 (16.9)             | 184 (30.3)                       | 211 (30.3)                                  | 233 (28.2)                                         |
| Hypotension                                     | 11 (12.5)           | 10 (7.7)              | 97 (16.0)                        | 108 (15.5)                                  | 118 (14.3)                                         |
| Hypertension                                    | 9 (10.2)            | 6 (4.6)               | 58( 9.5)                         | 67 9.6)                                     | 73 8.8)                                            |
| Psychiatric cisorders                           | 27 ( 30.7)          | 19 ( 14.6)            |                                  |                                             |                                                    |
| Inscmmia                                        | 11 (12.5)           | 7                     | 187 ( 30.8) 67                   | 214 ( 30.7) 78 (11.2)                       | 233 (28.2) 85 (10.3)                               |
| Confusional state                               | 14 ( 15.9)          | (5.4) 3 (2.3)         | (11.0) 66 (10.9)                 | 80 ( 11.5)                                  | 83 (10.0)                                          |
| Anxiety                                         | 11 ( 12.5)          | 2 (1.5)               | 40( 6.6)                         | 51 (7.3)                                    | 53 ( 6.4)                                          |

A subject was counted only once for multiple events within a PT/SOC.

Table was sorted by SOC and PT in descending order of incidence in the Overall Total column.

## Grade 3 and Higher TEAEs

Overall, the types and frequency of the most common Grade ≥ 3 TEAEs reported in ≥ 2% of subjects were similar between the R/R MCL and the R/R LBCL Treated Sets. In the R/R MCL Treated Set, the most frequently occurring Grade ≥ 3 TEAEs by SOC are reported in t he Table 45 .

Table 45. Grade 3 or Higher Treatment-emergent Adverse Events by System Organ Class and Preferred Term Reported in ≥ 2% of MCL or LBCL Subjects - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

| System Organ Class Preferred Term     | 3L+MCL N = 88 n (%)   | 2L+FL N = 130 n (%)   | 2L/3L+IBCL Total N= 608 n (%)   | 3L+MCLand 2L/3L+IBCL Total N= 696 n (%)   | 3L+ MCL, 2L/3L+ IBCL and 2L+FL Total N = 826 n (%)   |
|---------------------------------------|-----------------------|-----------------------|---------------------------------|-------------------------------------------|------------------------------------------------------|
| SUBJECTS WITHANY GRADE3 OR HIGHERTEAE | 76 (86.4)             | 100 ( 76.9)           | 497 ( 81.7)                     | 573 (82.3)                                | 673 ( 81.5)                                          |
| Blood and lymphatic system disorders  | 64 72.7)              | 91 70.0)              | 460 75.7)                       | 524 75.3)                                 | 615 (74.5)                                           |
| Neutropenia                           | 49 55.7)              | 79 60.8)              | 388 63.8)                       | 437 62.8)                                 | 516 62.5)                                            |
| Anaemia                               | 33 37.5)              | 13 10.0)              | 203 33.4)                       | 236 33.9)                                 | 249 30.1)                                            |
| Thrcmbocytopenia                      | 22 25.0)              | 15 11.5)              | 177 29.1)                       | 199 28.6)                                 | 214 25.9)                                            |
| Leukopenia                            | 6 6.8)                | 15 11.5)              | 127 20.9)                       | 133 19.1)                                 | 148 17.9)                                            |
| Lymphopenia                           | 5 5.7)                | 16 (12.3)             | 63 10.4)                        | 68 9.8)                                   | 84 10.2)                                             |
| Febrile neutropenia                   | 4 4.5)                | 7 (5.4)               | 46 7.6)                         | 50 7.2)                                   | 57 6.9)                                              |
| Metabolism andl nutrition clisorders  | 21 (23.9)             | 2 1.5)                | 80 (13.2)                       | 101 (14.5)                                | 103 12.5)                                            |
| Hypophosphataemia                     | 8 9.1)                | 0                     | 27 4.4)                         | 35 5.0)                                   | 35 4.2)                                              |
| Hypokalaemia                          | 7 8.0)                | 0                     | 15 2.5)                         | 22 3.2)                                   | 22 2.7)                                              |
| Hyponatraemia                         | 3 3.4)                | 0                     | 16 2.6)                         | 19 2.7)                                   | 19 2.3)                                              |
| Decreased appetite                    | 4 4.5)                | 0                     | 12 2.0)                         | 16 2.3)                                   | 16 1.9)                                              |
| Hyperglycaemia                        | 2 2.3)                | 1 （ 0.8)              | 5 0.8)                          | 7 1.0)                                    | 8 1.0)                                               |
| Hypocalcaemia                         | 3 3.4)                | 0                     | 4 0.7)                          | 7 1.0)                                    | 7 0.8)                                               |
| Tumour lysis_syncrome                 | 2 2.3)                | 0                     | 2 0.3)                          | 4 0.6)                                    | 4 0.5)                                               |
| Hyperuricaemia                        | 2 2.3)                | 0                     | 0                               | 2 0.3)                                    | 2 0.2)                                               |
| Infections andl infestations          | 13 (14.8)             | 7 5.4)                | 73 12.0)                        | 86 12.4)                                  | 93 11.3)                                             |
| Pneumonia                             |                       | 1 0.8)                | 17 2.8)                         | 17 2.4)                                   | 18 2.2)                                              |
| Urinary tract infection               | 03 3.4)               | 0                     | 6 1.0)                          | 9 1.3)                                    | 9 1.1)                                               |
| Upper respiratory tract infection     | 22 2.3)               | 0                     | 2 0.3)                          | 4 0.6)                                    | 4 0.5)                                               |
| Staphylococcal bacteraemia            | 2.3)                  | 0                     | 1 0.2)                          | 3 0.4)                                    | 3 0.4)                                               |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Tenm                      | 3L+MCL N=88 n (%)   | 2L+FL N = 130 n (%)   | 2L/3L+IBCL Total N = 608 n (%)   | 3L+MCL and 2L/3L+IBCL Total N= 696 n (%)   | 3L+ MCL, 2L/3L+IBCL and 2L+ FL Total N=826 n (%)   |
|--------------------------------------------------------|---------------------|-----------------------|----------------------------------|--------------------------------------------|----------------------------------------------------|
| Nervous system clisordlers                             | 7 8.0)              | ５１２0 3.8)             | 62 (10.2)                        | 69 9.9)                                    | 74 9.0)                                            |
| Encephalopathy                                         | 3.4)                | 0.8)                  | 3.0)                             | 3.0)                                       | 972                                                |
| Symcope                                                |                     | 1.5)                  | 2.9)                             | 2.0)                                       |                                                    |
| Somnolence                                             | ３２２                 |                       | 13:2:4 0.7)                      | 9.矶记8 0.9)                                 |                                                    |
| Gastrointestinal clisorders                            |                     | 21 1.5)               | 7.4)                             | 7.2)                                       | ±  .3                                              |
| Abdlominal pain                                        |                     | 0.8)                  | 1.3)                             | 50 1.4)                                    |                                                    |
| Nausea                                                 | 522 2.3)            | 0                     | 1.0)                             | 8 1.1)                                     | 8 1.0)                                             |
| Vascular disorders                                     | ４３０ 4.5)            | 3.1)                  | 6.9)                             | 6.6)                                       | 6.1)                                               |
| Hypertension                                           | 3.4)                | 1.5)                  | 3.5)                             | 3.4)                                       | 3.1)                                               |
| Hypotension                                            |                     | ４２０                   | 忆币 2.6)                          | 2.3)                                       | 1.9)                                               |
| Psychiatric clisorders                                 | ５２２ 5.7)            | 2.3)                  | 5.3)                             | 37 5.3)                                    | 40 4.8)                                            |
| Confusional state                                      | 2.3)                | 0.8)                  | 310 1.6)                         | 12 1.7)                                    | 13 1.6 6)                                          |
| Delirium                                               | ( 2.3)              | ３１０                   | 4 0.7)                           | 6 0.9)                                     | 6 0.7)                                             |
| Respiratory, thoracic and mediastinal cisorders        | 2 2.3)              | 1 0.8)                | 27 4.4)                          | 29 4.2)                                    | 30 3.6)                                            |
| Hypoxia                                                | 2 ( 2.3)            | 1 0.8)                | 6 1.0)                           | 8 1.1)                                     | 9 1.1)                                             |
| General clisorders and acministration site conclitions | 3.4)                | 1 0.8)                | 22 ( 3.6)                        | 25 3.6)                                    | 26 ( 3.1)                                          |
| Fatigue                                                | 2 ( 2.3)            | 0                     | 6 （ 1.0)                         | 8 1.1)                                     | 8 1.0)                                             |
| Cardiac disorders                                      | 6 6.8)              | 1.5)                  | 14 ( 2.3)                        | 20 2.9)                                    | 22 2.7)                                            |
| Atrial fibrillation                                    | 2.3)                | 0                     | 4 ( 0.7)                         | 6 0.9)                                     | 6 0.7)                                             |

Table was sorted by SOC and PT in descending order of incidence in the Overall Total column.

Asubjectwas countedonlyonceformultipleeventswithin aPT/SOC.

## TEAEs Related to Liso-cel

Overall, the type and frequency of the most commonly reported liso-cel-related TEAEs reported in ≥ 10% of subjects were similar between the R/R MCL and the R/R LBCL Treated Sets. In the R/R MCL Treated Set, the most frequently occurring liso-cel-related TEAEs by SOC are reported in the Table 46 .

Table 46. Liso-cel Related Treatment-emergent Adverse Events by System Organ Class and Preferred Term Reported in ≥ 10% of MCL or LBCL Subjects - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

| System Organ Class Preferred Term                     | 3L+MCL N=88 n (%)   | 2L+FL N = 130 n (%)   | 2L/3L+ LBCL Total N = 608 n (%)   | 3L+MCLand 2L/3L+LBCL Total N = 696 n (%)   | 3L+ML, 2L/3L+IBCL and2L+FL Total N = 826 n (%)   |
|-------------------------------------------------------|---------------------|-----------------------|-----------------------------------|--------------------------------------------|--------------------------------------------------|
| SUBJECTSWITHANYLISO-CELRELATEDTEAE                    | 77 ( 87.5)          | 115 (88.5)            | 486 (79.9)                        | 563 80.9)                                  | 678 82.1)                                        |
| Inmne_ system dlisorclers                             | 56 (63.6)           | 77 59.2)              | 274 45.1)                         | 330 47.4)                                  | 407 49.3)                                        |
| Cytokine release symclrome                            | 54 ( 61.4)          | 75 ( 57.7)            | 254 41.8)                         | 308 44.3)                                  | 383 (46.4)                                       |
| Blood andl lymphatic system disorders                 | 38 (43.2)           | 80 61.5)              | 264 43.4)                         | 302 43.4)                                  | 382 46.2)                                        |
| Neutropenia                                           | 31 (35.2)           | 70 53.8)              | 193 31.7)                         | 224 32.2)                                  | 294 35.6)                                        |
| Anaemia                                               | 11 (12.5)           | 38 29.2)              | 124 20.4)                         | 135 19.4)                                  | 173 20.9)                                        |
| Thrombocytopenia                                      | 10 (11.4)           | 27 20.8)              | 122 20.1)                         | 132 19.0)                                  | 159 19.2)                                        |
| Leukopenia                                            | 2 (2.3)             | 11 8.5)               | 68 11.2)                          | 70 （ 10.1)                                 | 81 9.8)                                          |
| Nervous system clisorclers                            | 28 (31.8)           | 29 22.3)              | 197 32.4)                         | 225 32.3)                                  | 254 30.8)                                        |
| Headache                                              | 14 ( 15.9)          | 13 (10.0)             | 64 (10.5)                         | 78 (11.2)                                  | 91 (11.0)                                        |
| General clisorders and acministration site conditions | 32 (36.4)           | 41 ( 31.5)            | 198 (32.6)                        | 230(33.0)                                  | 271 (32.8)                                       |
| Fatigue                                               | 18 (20.5)           | 17 (13.1)             | 96 (15.8)                         | 114 (16.4)                                 | 131 (15.9)                                       |
| Pyrexia                                               | 11 ( 12.5)          | 17 (13.1)             | 76 (12.5)                         | 87 （ 12.5)                                 | 104 (12.6)                                       |
| Psychiatric cisorcers                                 | 17 (19.3)           | 10 7.7)               | 84 (13.8)                         | 101 (14.5)                                 | 111 (13.4)                                       |
| Confusional state                                     | 14 ( 15.9)          | 2 1.5)                | 53 8.7)                           | 67 9.6)                                    | 69( 8.4)                                         |

Table was sorted by SOC and PT in descending order of incidence in the Overall Total column.

AsubjectwascountedonlyonceformultipleeventswithinaPT/SoC.

The overall types and frequency of the most commonly reported liso-celrelated Grade ≥ 3 TEAEs reported in ≥ 2% of subjects were similar between the R/R MCL and the R/R LBCL Treated Sets ( Table 47 ).

Table 47. Liso-cel Related Grade 3 or Higher Treatment-emergent Adverse Events by System Organ Class and Preferred Term Reported in ≥ 2% of MCL or LBCL Subjects - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Tenm                    | 3L+MCL N=88 n (%)   | 2L+FL N = 130 n (%)   | 2L/3L+ LBCL Total N= 608 n (%)   | 3L+ MCL and 2L/3L+LBCL Total N= 696 n (%)   | 3L+ML, 2L/3L+ LBCL and 2L+ FL Total N= 826 n (%)   |
|------------------------------------------------------|---------------------|-----------------------|----------------------------------|---------------------------------------------|----------------------------------------------------|
| SUBJECTS WITHANY LISO-CELRELATEDGRADE3OR HIGHER TEAE | 43 ( 48.9)          | 81 (62.3)             | 285 ( 46.9)                      | 328 ( 47.1)                                 | 409( 49.5)                                         |
| Blood and lymphatic system dlisordlers               | 32 (36.4)           | 73 56.2)              | 240 ( 39.5)                      | 272 (39.1)                                  | 345 ( 41.8)                                        |
| Neutropenia                                          | 27 (30.7)           | 62 47.7)              | 181 （ 29.8)                      | 208 29.9)                                   | 270 (32.7)                                         |
| Thrombocytopenia                                     | 9 (10.2)            | 10 7.7)               | 96  (15.8)                       | 105 (15.1)                                  | 115 ( 13.9)                                        |
| Anaemia                                              | 6 (10.2)            | 10 7.7)               | 87 (14.3)                        | 96 13.8)                                    | 106 (12.8)                                         |
| Leukopenia                                           | 2 2.3)              | 7 5.4)                | 56 9.2)                          | 58 8.3)                                     | 65 7.9)                                            |
| Lymphopenia                                          | 1 1.1)              | 15 11.5)              | 35 5.8)                          | 36 5.2)                                     | 51 6.2)                                            |
| Febrile neutropenia                                  | 1 1.1)              | 6 4.6)                | 28 4.6)                          | 29 4.2)                                     | 35 4.2)                                            |
| Nervous system clisorders                            | 6 6.8)              | 3 2.3)                | 41 6.7)                          | 47 6.8)                                     | 50 6.1)                                            |
| Encephalopathy                                       | 3 3.4)              | 1 0.8)                | 16 2.6)                          | 19 2.7)                                     | 20 2.4)                                            |
| Sommolence                                           | 2 2.3)              | 0                     | 4 （ 0.7)                         | 6 0.9)                                      | 6 ( 0.7)                                           |
| Psychiatric disorders                                | 4 4.5)              | 2.3)                  | 24 3.9)                          | 28 4.0)                                     | 31 3.8)                                            |
| Confusional state                                    | 2 2.3)              | 1 0.8)                | 9 1.5)                           | 11 1.6)                                     | 12 1.5)                                            |
| Delirium                                             | 2 2.3)              | 0                     | 4 0.7)                           | 6 0.9)                                      | 6 0.7)                                             |
| Metalbolism andl nutrition clisorders                | 7 8.0)              | 0                     | 11 1.8)                          | 18 2.6)                                     | 18 2.2)                                            |
| Decreased appetite                                   | 2 2.3)              | 0                     | 2 0.3)                           | 4 0.6)                                      | 4 0.5)                                             |
| Tumour lysis symclrome                               | 2 2.3)              | 0                     | 1 0.2)                           | 3 0.4)                                      | 3 0.4)                                             |

Table was sorted by SOC and PT in descending order of incidence in the Overall Total column.

Asubjectwas countedonly onceformultiple eventswithinaPT/SOC.

## Post-treatment-emergent Period Adverse Events

AEs in the posttreatment emergent period (≥ 91 days after liso -cel infusion) were numerically higher in R/R MCL Treated Set Compared to R/R LBCL Treated Set (54.9% vs 45.4%, respectively) ( Table 48 ).

Table 48. Overview of Adverse Events - Post-treatment-emergent Period - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

|                                                | 3L+MCL N=82    | 2L+FL N = 129   | 2L/3L+IBCL Total N = 559   | 3L+ MCL and 2L/3L+ LBCL Total N = 641   | 3L+MCL 2L/3L+ LBCL and 2L+ FL Total N = 770   |
|------------------------------------------------|----------------|-----------------|----------------------------|-----------------------------------------|-----------------------------------------------|
| DURATION OF FERIOD (DAYS)，MEDIAN (RANGE)       | 620.0 (3-686)  | 739.0 (25-1042) | 359.0 (2-1287)             | 388.0 (2-1287)                          | 469.5 (2-1287)                                |
| SUBJECTS WITH ANY AE                           | 45 (54.9)      | 46 ( 35.7)      | 254 ( 45.4)                | 299 (46.6)                              | 345 ( 44.8)                                   |
| SUBJECTS WITH ANY GRAIE 3-4 AE                 | 20 (24.4)      | 22 (17.1)       | 124 ( 22.2)                | 144 (22.5)                              | 166 ( 21.6)                                   |
| SUBJECTSWITHANY GRAIE 3-5AE                    | 25 ( 30.5)     | 25 ( 19.4)      | 143 ( 25.6)                | 168 (26.2)                              | 193 ( 25.1)                                   |
| SUBJECTS WITH ANY GRAIE 5AE                    | 5 6.1)         | 3 (2.3)         | 19 (3.4)                   | 24 (3.7)                                | 27 (3.5)                                      |
| SUBJECTS WITH ANY SERIOUSAE                    | 23 (28.0)      | 21 (16.3)       | 85 (15.2)                  | 108 (16.8)                              | 129 (16.8)                                    |
| SUBJECTS WITHANY LDC-RELAIEDAE                 | 17 (20.7)      | 11 ( 8.5)       | 89 ( 15.9)                 | 106 ( 16.5)                             | 117 ( 15.2)                                   |
| SUBJECTS WITH ANY LDC-RELATED GRAIE 3-4 AE     | 9 (11.0)       | 3.1)            | 51 (9.1)                   | 60 (9.4)                                | 64 ( 8.3)                                     |
| SUBJECTS WIIHANY IDC-RELAIEDGRAIE 3-5AE        | 10 (12.2)      | 5( 3.9)         | 56 ( 10.0)                 | 66 (10.3)                               | 71( 9.2)                                      |
| SUBJECTS WITHANY IDC-RELATED GRAIE 5AE         | 1 1.2)         | 1（ 0.8)         | 5 (0.9)                    | 6 (0.9)                                 | 7 0.9)                                        |
| SUBJECTS WIIH ANY LDC-REIATEDSERIOUS AE        | 5 6.1)         | 3( 2.3)         | 25 (4.5)                   | 30（ 4.7)                                | 33( 4.3)                                      |
|                                                | 3L+ MCL N = 82 | 2L+FL N = 129   | 2L/3L+ LBCL Total N = 559  | 3L+MCLand 2L/3L+LBCL Total N = 641      | 3L+MCL 2L/3L+ LBCL and 2L+ FL Total N = 770   |
| SUBJECTSWITHANYJCAR017-RELATEDAE               | 16 ( 19.5)     | 31 ( 24.0)      | 111 ( 19.9)                | 127 ( 19.8)                             | 158 ( 20.5)                                   |
| SUBJECTS WITH ANY JCAR017-RELATED GRAIE 3-4 AE | 7 8.5)         | 15 (11.6)       | 56 (10.0)                  | 63 9.8)                                 | 78 10.1)                                      |
| SUBJECTSWITHANYJCAR017-RELATEDGRAIE3-5AE       | 8 9.8)         | 16 ( 12.4)      | 60 (10.7)                  | 68 (10.6)                               | 84 (10.9)                                     |
| SUBJECTS WITH ANY JCARO17-RELATED GRAIE 5 AE   | 1.2)           | 1 0.8)          | 4 0.7) 22                  | 5 0.8)                                  | 6 0.8) 37                                     |
| SUBJECTS WITHANY JCARO17-REIATEDSERIOUSAE      | 5 6.1)         | 10 7.8)         | 3.9)                       | 27 4.2)                                 | 4.8)                                          |

The most severe grade was used for AEs that occurred more than once in an individual subject during the period.

Post-treatment-emergent period started from 91 dayspost final liso-cel infusion or initiation of subsequent anticancertherapy/product retreatmentif subject initiated subsequent anticancer therapy/product retreatment prior to Study Day 91.

In the R/R MCL Treated Set, the most frequently occurring post-treatment-emergent period AEs by SOC were Blood and lymphatic system disorders as well as Neoplasms benign, malignant and unspecified (17.1% each), and Infections and infestations (13.4%). The most frequently occurring post-treatmentemergent period AEs by PT were thrombocytopenia (7.3%) and neutropenia and anaemia (6.1% each) ( Table 49 ).

<div style=\"page-break-after: always\"></div>

Table 49. Adverse Events by System Organ Class and Preferred Term Reported in ≥ 5% of MCL or LBCL Subjects - Post-treatment-emergent Period - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

| System Organ Class Preferred Tenm        | 3L+MCL N = 82 n (%)   | 2L+FL N = 129 n (%)   | 2L/3L+IBCL Total N = 559 n (%)   | 3L+MCLand 2L/3L+ LBCL Total N = 641 n (%)   | 3L+MCL, 2L/3L+IBCL and 2L+ FL Total N = 770 n (%)   |
|------------------------------------------|-----------------------|-----------------------|----------------------------------|---------------------------------------------|-----------------------------------------------------|
| SUBJECTSWITHANYAEPOST-TREATMENT-EMERGENT | 45 ( 54.9)            | 46 ( 35.7)            | 254 ( 45.4)                      | 299 (46.6)                                  | 345 ( 44.8)                                         |

PERIOD

| SystemOrgan_Class Preferred Tenm                     | 3L+MCL N = 82 n (%)   | 2L+FL N = 129 n (%)   | 2L/3L+LBCL Total N = 559 n (%)   | 3L+ MCL and 2L/3L+ IBCL Total N = 641 n (%)   | 3L+ MCL, 2L/3L+LBCL and2L+FL Total N = 770 n (%)   |
|------------------------------------------------------|-----------------------|-----------------------|----------------------------------|-----------------------------------------------|----------------------------------------------------|
| Blood and lymphatic system disorders                 | 14 (17.1)             | 18 (14.0)             | 133 23.8)                        | 147 22.9)                                     | 165 (21.4)                                         |
| Neutropenia                                          | 5 6.1)                | 13 (10.1)             | 66 11.8)                         | 71 11.1)                                      | 84 (10.9)                                          |
| Thrombocytopenia                                     | 6 7.3)                | 3 2.3)                | 54 9.7)                          | 60 9.4)                                       | 63 8.2)                                            |
| Anaemia                                              | 5 6.1)                | 1 0.8)                | 55 9.8)                          | 60 9.4)                                       | 61 7.9)                                            |
| General disorders and administration site conditions | 4 （ 4.9)              | 3( 2.3)               | 49 8.8)                          | 53 8.3)                                       | 56( 7.3)                                           |
| Fatigue                                              | 0                     | 1 （ 0.8)              | 29（ 5.2)                         | 29（ 4.5)                                      | 30(3.9)                                            |

Post-treatment-emergent period started from 91 days post final liso-cel infusion or initiation of subsequent anticancer therapy/product retreatment if subject initiated

TablewassortedbySOC andPTindescendingorder ofincidencein theOverall Total column.

A subject was counted only oncefor multipleevents within a PT/SOC.

Overall, the frequency of the most commonly reported Grade ≥ 3 post -treatment-emergent period AEs was similar between the R/R MCL and the R/R LBCL Treated Sets (30.5% vs 25.6%, respectively) ( Table 50 ).

Table 50. Grade 3 or Higher Adverse Events by System Organ Class and Preferred Term Reported in ≥ 2% of MCL or LBCL Subjects - Post-treatment-emergent Period - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

| System Organ Class Preferred Term                                    | 3L+ML N = 82 n (%)   | 2L+FL N = 129 n (%)   | 2L/3L+ IBCL Total N = 559 n (%)   | 3L+ MCL and 2L/3L+IBCL Total N = 641 n (%)   | 3L+MCL, 2L/3L+IBCL and2L+FL Total N = 770 n (%)   |
|----------------------------------------------------------------------|----------------------|-----------------------|-----------------------------------|----------------------------------------------|---------------------------------------------------|
| SUBJECTS WITH ANY GRADE 3 OR HIGHER AE FOST TREATMENT-EMERGENTPERIOD | 25 ( 30.5)           | 25 ( 19.4)            | 143 ( 25.6)                       | 168 ( 26.2)                                  | 193 ( 25.1)                                       |
| Blood andl lymphatic system clisorders                               | 10 12.2)             | 10 7.8)               | 97 (17.4)                         | 107 (16.7)                                   | 117 (15.2)                                        |
| Neutropenia                                                          | 4 4.9)               | 10 7.8)               | 51 9.1)                           | 55 （ 8.6)                                    | 65 8.4)                                           |
| Anaemia                                                              | 2 2.4)               | 1 0.8)                | 41 ( 7.3)                         | 43 6.7)                                      | 44 5.7)                                           |
| Thrombocytopenia                                                     | 4 4.9)               | 2 1.6)                | 35 6.3)                           | 39 6.1)                                      | 41 5.3)                                           |
| Febrile neutropenia                                                  | 1 1.2)               | 0                     | 15 2.7)                           | 16 ( 2.5)                                    | 16 2.1)                                           |
| Leukopenia                                                           | 0                    | 0                     | 14 2.5)                           | 14 ( 2.2)                                    | 14 1.8)                                           |
| Lynphopenia                                                          | 2 2.4)               | 0                     | 11 2.0)                           | 13( 2.0)                                     | 13 1.7)                                           |
| Infections and infestations                                          | 6 7.3)               | 6 4.7)                | 28 5.0)                           | 34( 5.3)                                     | 40( 5.2)                                          |
| COVID-19                                                             | 4 4.9)               | 2 1.6)                | 3 ( 0.5)                          | 7 ( 1.1)                                     | 9 1.2)                                            |
| COVID-19 pneumonia                                                   | 2 2.4)               | 2 1.6)                | 2 0.4)                            | 4( 0.6)                                      | 6 ( 0.8)                                          |
| Neoplasms benigm, maligmant andl unspecified (incl cysts and polyps) | 8( 9.8)              | 7( 5.4)               | 19 3.4)                           | 27( 4.2)                                     | 34( 4.4)                                          |
| Myelodysplastic syncrcme                                             | 2( 2.4)              | 1( 0.8)               | 10 1.8)                           | 12 ( 1.9)                                    | 13 ( 1.7)                                         |
| Metabolism andl nutrition disorders                                  | 2.4)                 | 0                     | 13 2.3)                           | 15 2.3)                                      | 15 ( 1.9)                                         |
| Hypokalaemia                                                         | 2( 2.4)              | 0                     | 2( 0.4)                           | 4( 0.6)                                      | 4( 0.5)                                           |

Post-treatment-emergent period started from 91 days post final liso-cel infusion or initiation of subsequent anticancer therapy/product retreatmentif subject initiated

Table was sorted by SOC and PT in descending order of incidence in the Overall Total column.

A subject was counted only once for multiple events within a PT/SOC.

## COVID-19 Infections

The majority of the subjects in the MCL Cohort (75%) were treated during the COVID-19 pandemic. In the R/R MCL Treated Set, treatment-emergent COVID-19 infections occurred in 2 (2.3%) subjects, of which 1 was a fatal COVID-19 pneumonia. In the 2L/3L+ LBCL population, treatment-emergent COVID19 infections occurred in 8 (1.3%) subjects, of which 2 were fatal.

<div style=\"page-break-after: always\"></div>

In the post-treatment-emergent period, the overall incidence of SOC Infections and infestations was 13.4% in the R/R MCL Treated Set and 10.9% in the R/R LBCL Treated Set, while the frequency of Grade ≥ 3 post-treatment-emergent period infection and infestation AEs was 7.3% and 5.0%, respectively. Notably, in the R/R MCL Treated Set, all of the Grade ≥ 3 post-treatment infections and infestations AEs reported were COVID-19 related AEs (6 of 6), as opposed to 5 out of 28 subjects with COVID-19 related AEs in the 2L/3L+ LBCL population.

## Serious adverse event/deaths/other significant events

## Deaths

In the R/R MCL Liso-cel-treated Analysis Set (n= 88), 46 (52.3%) subjects died any time after the first liso-cel infusion. Of these subjects, most (29 [33.0%]) died due to disease progression, with 22 (25.0%) deaths occurring after 90 days post liso-cel infusion ( Table 51 ).

Table 51. Summary of Deaths - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

|                                                                              | 3L+ MCL N= 88   | 2L+FL N = 130   | 2L/3L+IBCL Total N= 608   | 3L+ ML and 2L/3L+ LBCL Total N = 696   | 3L+MCL 2L/3L+ LBCL and 2L+FL Total N= 826   |
|------------------------------------------------------------------------------|-----------------|-----------------|---------------------------|----------------------------------------|---------------------------------------------|
| DEATHS OCCURREDAFTERFIRSTLISO-CELINFUSION                                    | 46 ( 52.3)      | 13 ( 10.0)      | 258 ( 42.4)               | 304 (43.7)                             | 317 (38.4)                                  |
| PRIMARY CAUSE OF DEATH                                                       |                 |                 |                           |                                        |                                             |
| DISEASE PROGRESSION                                                          | 29 ( 33.0)      | 7 5.4)          | 206 (33.9)                | 235 ( 33.8)                            | 242 ( 29.3)                                 |
| ADVERSE EVENT                                                                | 5 5.7)          | 3 2.3)          | 23 3.8)                   | 28 4.0)                                | 31 3.8)                                     |
| COVID-19                                                                     | 7 8.0)          | 2 1.5)          | 9 1.5)                    | 16 (2.3)                               | 18 (2.2)                                    |
| UNKNOWN                                                                      | 1 1.1)          | 0               | 6 1.0)                    | 7 (1.0)                                | 7(0.8)                                      |
| OTHER (A)                                                                    | 4 4.5)          | 1 0.8)          | 14 2.3)                   | 18 (2.6)                               | 19 (2.3)                                    |
| DEATHSOCCURREDAFTERFIRSTLISO-CELINFUSION ANDWITHIN3ODAYSFOSTLISO-CELINFUSION | 4( 4.5)         | 1( 0.8)         | 12 ( 2.0)                 | 16 (2.3)                               | 17 (2.1)                                    |
| PRIMARYCAUSEOFDEATH                                                          |                 |                 |                           |                                        |                                             |
| DISEASEPROGRESSION                                                           | 3 3.4)          | 0               | 7 1.2)                    | 10 1.4)                                | 10                                          |
| ADVERSE EVENT                                                                | 1 1.1)          | 1 0.8)          | 5 0.8)                    | 6 0.9)                                 | 0.8) 0                                      |
| COVID-19                                                                     | 0               | 0               | 0                         | 0                                      |                                             |
| UNKNOWN                                                                      | 0               | 0               | 0                         | 0                                      | 0                                           |
| OTHER (A)                                                                    | 0               | 0               | 0                         | 0                                      | 0                                           |
| DEATHS OCCURRED BEIWEEN 31AND 90 DAYS FOST LISO-CEL INFUSION                 | 8（ 9.1)         | 0               | 45 (7.4)                  | 53 (7.6)                               | 53 (6.4)                                    |
| PRIMARYCAUSE OFDEATH                                                         |                 |                 |                           |                                        |                                             |
| DISEASEPROGRESSION                                                           | 4 4.5)          | 0               | 31 5.1)                   | 35 5.0)                                | 35 ( 4.2)                                   |
| ADVERSE EVENT                                                                | 3 3.4)          | 0               | 9 1.5)                    | 12 1.7)                                | 12 1.5)                                     |
| COVID-19                                                                     | 1 1.1)          | 0               | 2 0.3)                    | 3 0.4)                                 | 3 0.4)                                      |
| UNKNOWN                                                                      | 0               | 0               | 2 0.3)                    | 2 0.3)                                 | 2 0.2)                                      |
| OTHER (A)                                                                    | 0               | 0               | 1 0.2)                    | 1 0.1)                                 | 1 0.1)                                      |
| DEATHSOCCURREDFROM91DAYSPOSTLISO-CEL INFUSIONUNTILTHEENDOFSTUDY              | 34 ( 38.6)      | 12 ( 9.2)       | 201 ( 33.1)               | 235 ( 33.8)                            | 247 (29.9)                                  |
| PRIMARYCAUSEOFDEATH                                                          |                 |                 |                           |                                        |                                             |
| DISEASE PROGRESSION                                                          | 22 (25.0)       | 7 5.4)          | 168 27.6)                 | 190 (27.3)                             | 197 (23.8)                                  |
| ADVERSE EVENT                                                                | 1 1.1)          | 2 1.5)          | 9 1.5)                    | 10 1.4)                                | 12 1.5)                                     |
| COVID-19                                                                     | 6 6.8)          | 2 1.5)          | 7 1.2)                    | 13 1.9)                                | 15 1.8)                                     |
| UNKNOWN                                                                      | 1 1.1)          | 0               | 4 0.7)                    | 5 0.7)                                 | 5 0.6)                                      |
| OTHER (A)                                                                    | 4 4.5)          | 1 0.8)          | 13 2.1)                   | 17 2.4)                                | 18 2.2)                                     |

(A) Events listed as Other for the MCL Cohort include GVHD, respiratory failure of unknown origin, motor vehicle accident, complications from lung cancer and failure to thrive. Refer to Listing 2.7.5 in Appendix 2 for details.

Asofthedatacutoffdate(RefTable1.1-1)

In the R/R MCL Treated Set, of the 5 subjects died due to AE, 4 (4.5%) died due to Grade 5 TEAEs (compared with 2.5% of subjects in the R/R LBCL Treated Set ( Table 52 ). Grade 5 TEAEs in the R/R MCL Treated Set in R/R MCL Treated Set included COVID-19 pneumonia, cryptococcal meningoencephalitis, cardio-respiratory  arrest,  and  tumor  lysis  syndrome.  Of  all  4  cases,  3  seems  related  to  the  liso-cel treatment and only one death case caused by cardio-respiratory arrest is reported to be unrelated to liso-cel treatment.

<div style=\"page-break-after: always\"></div>

Table 52. Grade 5 TEAEs by System Organ Class and Preferred Term - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+LBCL

| System Organ Class Preferred Term                       | 3L+MCL N=88 n (%)   | 2L+FL N = 130 n (%)   | 2L/3L+ LBCL Total N= 608 n (%)   | 3L+ MCL and 2L/3L+LBCL Total N= 696 n (%)   | 3L+ MCL, 2L/3L+ LBCL and 2L+ FL Total N = 826 n (%)   |
|---------------------------------------------------------|---------------------|-----------------------|----------------------------------|---------------------------------------------|-------------------------------------------------------|
| SUBJECTS WITH ANY GRADE 5 TEAE                          | 4( 4.5)             | 1（ 0.8)               | 15 ( 2.5)                        | 19 (2.7)                                    | 20（ 2.4)                                              |
| Infections and infestations                             | 2 2.3)              | 0                     | 7 1.2)                           | 9 1.3)                                      | 9 1.1)                                                |
| COVID-19 pneumonia                                      | 1 1.1)              | 0                     | 1 0.2)                           | 2 0.3)                                      | 2 0.2)                                                |
| COVID-19                                                | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Candida sepsis                                          | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Cryptococcal meningoencephalitis                        | 1 1.1)              | 0                     | 0                                | 1 0.1)                                      | 1 0.1)                                                |
| Pneumonia                                               | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Progressive multifocal leukoencephalopathy              | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Septic shock                                            | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Staphylococcal sepsis                                   | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Respiratory, thoracic and meciastinal disorders         | 0                   | 0                     | 3 0.5)                           | 3 0.4)                                      | 3 0.4)                                                |
| Diffuse alveolar damage                                 | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Pulmonary haemorrhage                                   | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Respiratory failure                                     | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Cardiac disorders                                       | 1 1.1)              | 0                     | 1 0.2)                           | 2 0.3)                                      | 21 0.2)                                               |
| Cardio-respiratory arrest                               | 1 1.1)              | 0                     | 0                                | 1 0.1)                                      | 0.1)                                                  |
| Cardlicmyopathy                                         | 0                   | 0                     | 1 0.2)                           | 1 （ 0.1)                                    | 1 0.1)                                                |
| Inmune system cisorders                                 | 0                   | 0.8)                  | 1 0.2)                           | （ 0.1)                                      | 0.2)                                                  |
| Haemophagocytic lymphohistiocytosis                     | 0                   | 0.8)                  | 1 0.2)                           | 1 0.1)                                      | 22 0.2)                                               |
| Metabolism and nutrition cisorders                      | 1 1.1)              | 0                     | 1 0.2)                           | 2 0.3)                                      | 2 0.2)                                                |
| Failure to thrive                                       | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 0.1)                                                  |
| Tumour lysis symcrcme                                   | 1 1.1)              | 0                     | 0                                | 1 （ 0.1)                                    | 11 0.1)                                               |
| General clisorcders and acministration site conclitions | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Multiple organ dysfunction symdrome                     | 0                   | 0                     | 1 0.2)                           | 1 0.1)                                      | 1 0.1)                                                |
| Nervous system cisordlers                               | 0                   | 0                     | 1 1                              | 1 0.1) 1                                    | 0.1)                                                  |
| Leukoencephalopathy                                     | 0                   | 0                     | 0.2) 0.2)                        | 0.1)                                        | 0.1)                                                  |

TablewassortedbySOCandPTindescendingorderofincidenceintheOverall Total column.

A subject was counted only once for multiple events within a PT/SOC.

## Treatment-emergent Serious Adverse Events

The overall types and frequency of treatment-emergent SAEs were similar between the R/R MCL and the R/R LBCL Treated Sets ( Table 53 ).

Table 53. Treatment-emergent SAEs by System Organ Class and Preferred Term Reported in ≥ 2% of MCL or LBCL Subjects - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

| System Organ Class Preferred Temm      | 3L+MCL N=88 n (%)   | 2L+FL N = 130 n (%)   | 2L/3L+LBCL Total N=608 n (%)   | 3L+MCLand 2L/3L+LBCL Total N=696 n (%)   | 3L+MCL, 2L/3L+IBCL and2L+FL Total N=826 n (%)   |
|----------------------------------------|---------------------|-----------------------|--------------------------------|------------------------------------------|-------------------------------------------------|
| SUBJECTSWITHANYSERIOUSTEAE             | 47 ( 53.4)          | 31 (23.8)             | 260 (42.8)                     | 307 ( 44.1)                              | 338 (40.9)                                      |
| Immne system dlisorders                | 21 (23.9)           | 13 (10.0)             | 101 (16.6)                     | 122 (17.5)                               | 135 ( 16.3)                                     |
| Cytokine release symclrome             | 21 ( 23.9)          | 12（ 9.2)              | 100 (16.4)                     | 121 (17.4)                               | 133 ( 16.1)                                     |
| Nervous system cisorders               | 8 9.1)              | 7 5.4)                | 78 3(12.8)                     | 86 (12.4)                                | 93 (11.3)                                       |
| Aphasia                                | 1 （ 1.1)            | 5 3.8)                | 17 ( 2.8)                      | 18 2.6)                                  | 23 2.8)                                         |
| Encephalopathy                         | 2 2.3)              |                       | 20 （ 3.3)                      | 22 3.2)                                  | 22 2.7)                                         |
| Tremor                                 | 0                   | 3 （ 2.3)              | 14 2.3)                        | 14 2.0)                                  | 17 2.1)                                         |
| Infections and infestations            | 9 10.2)             | 7 5.4)                | 61 (10.0)                      | 70 ( 10.1)                               | 77 9.3)                                         |
| Pneumonia                              |                     | 1 0.8)                | 13 （ 2.1)                      | 13 1.9)                                  | 14 1.7)                                         |
| Upper respiratory tract infection      | 2 2.3)              | 0                     | 2 0.3)                         | 4 0.6)                                   | 4 0.5)                                          |
| Blood and lymphatic system clisordlers | 2 2.3)              | 5 3.8)                | 48 7.9)                        | 50 7.2)                                  | 55 6.7)                                         |
| Febrile neutropenia                    | 1 1.1)              | 4 3.1)                | 22 3.6)                        | 23 3.3)                                  | 27 3.3)                                         |
| Neutropenia                            | 0                   | 1 0.8)                | 19 3.1)                        | 19 2.7)                                  | 20 2.4)                                         |
| Thrombocytopenia                       | 1 1.1)              | 0                     | 17 2.8)                        | 18 2.6)                                  | 18 2.2)                                         |

<div style=\"page-break-after: always\"></div>

| System OrganClass Preferred Tenmm                     | 3L+MCL N=88 n (%)   | 2L+FL N = 130 n (%)   | 2L/3L+IBCL Total N=608 n (%)   | 3L+MLand 2L/3L+LBCL Total N= 696 n (%)   | 3L+MCL, 2L/3L+LBCL and 2L+FL Total N = 826 n (%)   |
|-------------------------------------------------------|---------------------|-----------------------|--------------------------------|------------------------------------------|----------------------------------------------------|
| Psychiatric disordlers                                | 7 ( 8.0)            | 5 (3.8)               | 39 6.4)                        | 46 6.6)                                  | 51( 6.2)                                           |
| Confusional state                                     | 5 ( 5.7)            | 2 1.5)                | 19 3.1)                        | 24 3.4)                                  | 26 3.1)                                            |
| Mentalstatus changes                                  | 2 ( 2.3)            | 0                     | 6 1.5)                         | 11 1.6)                                  | 11 1.3)                                            |
| Generalclisordlers andacministration site condlitions | 4 ( 4.5)            | 3.1)                  | 29 4.8)                        | 33 4.7)                                  | 37 4.5)                                            |
| Pyrexia                                               | 3 3.4)              | 2.3)                  | 21 3.5)                        | 24 3.4)                                  | 27 3.3)                                            |
| Respiratory, thoracic and mecliastinal cisorders      | 2 ( 2.3)            | 1 ( 0.8)              | 19 3.1)                        | 21 3.0)                                  | 22 2.7)                                            |
| Pleural effusion                                      | 2 ( 2.3)            | 0                     | 2 ( 0.3)                       | 4 0.6)                                   | 4 ( 0.5)                                           |
| Metabolism andnutrition disorders                     | 4 4.5)              | 0                     | 12 (2.0)                       | 16 2.3)                                  | 16 1.9)                                            |
| Decreased appetite                                    | 2 2.3)              | 0                     | 2 (0.3)                        | 4 ( 0.6)                                 | 4 ( 0.5)                                           |

TablewassortedbySOC andPTindescendingorderofincidenceintheOverallTotal column

AsubiectwascountedonlvonceformultipleeventswithinaPT/SOC.

## Other Significant Adverse Events of Special Interest

The profile of reported AESIs in the R/R MCL Liso-cel-treated Analysis Set was consistent with the known profile for R/R LBCL.

Table 54. Treatment-emergent AESIs by Grade - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

|                               | 3L+MCL N= 88   | 2L+FL N = 130   | 2L/3L+IBCL Total N= 608   | 3L+MCLand 2L/3L+IBCL Total N= 696   | 3L+ MCL 2L/3L+LBCL and 2L+FL Total N= 826   |
|-------------------------------|----------------|-----------------|---------------------------|-------------------------------------|---------------------------------------------|
| CRS                           | 54 （ 61.4)     | 75 (57.7)       | 254 ( 41.8)               | 308 (44.3)                          | 383 （ 46.4)                                 |
| GRADE 1-2                     | 310g ( 60.2)   | 74 ( 56.9)      | 244 40.1)                 | 297 42.7)                           | 371 44.9)                                   |
| GRADE 3-4                     | 1.1)           | ( 0.8)          | 10 1.6)                   | 11 ( 1.6)                           | 12 1.5)                                     |
| GRADE 5                       |                | 10              | 0                         | 0                                   | 0                                           |
| SAE                           | 21 (23.9)      | 12 9.2)         | 100 (16.4)                | 121 (17.4)                          | 133 (16.1)                                  |
| NT                            | 27 30.7)       | 21 (16.2)       | 151 (24.8)                | 178 ( 25.6)                         | 199 24.1)                                   |
| GRADE 1-2                     | 19 ( 21.6)     | 17 ( 13.1)      | 100 （ 16.4)               | 119 17.1)                           | 136 16.5)                                   |
| GRADE 3-4                     | ( 9.1)         | 4 （ 3.1)        | 51 8.4)                   | 59 8.5)                             | 63 7.6)                                     |
| GRADE 5                       |                |                 | 0                         | 0                                   | 0                                           |
| SAE                           | ( 12.5)        | 7 5.4)          | 76 (12.5)                 | 87 ( 12.5)                          | 94 (11.4)                                   |
| INFUSION RELATED REACTION     | 2.3)           |                 | 6 1.0)                    | 1.1)                                | 8 ( 1.0)                                    |
| GRADE 1-2                     | （（ 2.3)        | 0               | ６000 ( 1.0)               | 1.1)                                | 1.0)                                        |
| GRADE 3-4                     |                | 0               |                           |                                     |                                             |
| GRADE 5                       | 2200:          | 0               |                           | ８８00１                               | 00                                          |
| SAE                           | 1 1.1)         | 0               |                           | 0.1)                                | 1 ( 0.1)                                    |
| MACROPHAGEACTIVATIONSYNDROME  |                | 1 0.8)          | 4 0.7)                    | 4 0.6)                              | 5 0.6)                                      |
| GRADE 1-2                     |                | 0               | 0.2)                      | 0.1)                                | 1 0.1)                                      |
| GRADE 3-4                     | 0              | 0               | 0.3)                      | 0.3)                                | 22 0.2)                                     |
| GRADE 5                       |                | 1 0.8)          | ( 9.2)                    | 0.1)                                | 0.2)                                        |
| SAE                           | 0              | 1 0.8)          | 1213 ( 0.5)               | １２13 0.4)                           | 4 0.5)                                      |
| TUMOR LYSIS SYNDROME          | ２０１１１ 2.3)     | 0               | 2 ( 0.3)                  | 4 ( 0.6)                            | 4 ( 0.5)                                    |
| GRADE 1-2                     |                | 0               |                           |                                     |                                             |
| GRADE 3-4                     | 1.1)           |                 | 0200 0.3)                 | 0.4)                                | 3 0.4)                                      |
| GRADE 5                       | 1.1)           |                 |                           | 0.1)                                | 1 0.1)                                      |
| SAE                           | 1.1)           | 000             |                           | 0３1１ 0.1)                           | 1 0.1)                                      |
| GRADE>=3INFECTIONS            | 13 ( 14.8)     | 7 5.4)          | 73 （ 12.0)                | 86 12.4)                            | 93 11.3)                                    |
| GRADE 3-4                     | 11 ( 12.5)     | 7 5.4)          | 66 ( 10.9)                | 77 ( 11.1)                          | 84 ( 10.2)                                  |
| GRADE 5                       | 2 ( 2.3)       | 0               | 7 1.2)                    | 9 1.3)                              | 6 ( 1.1)                                    |
| GRADE>=3 BACTERIAL INFECTIONS | 440 4.5)       | 1:3)            |                           | T昭 43                               | 31 3.8)                                     |
| GRADE 3-4                     | 4.5)           | 220             |                           |                                     | 19:8                                        |
| GRADE 5                       |                |                 |                           | 0.1)                                | 1 0.1)                                      |
| GRADE >= 3 FUNGAL INFECTIONS  | 1 1.1)         | 0               | 0.8)                      | 0.9)                                | 0.7)                                        |
| GRADE 3-4                     |                |                 | ５４１ 0.73                  | 0.6)                                | 0.5 5)                                      |
| GRADE 5                       | 1 1.1)         | 0               | 0.2)                      | ６４２ 0.3)                            | ６４２ ( 0.2)                                  |

<div style=\"page-break-after: always\"></div>

L

|                                                   | 3L+ML N=88   | 2L+FL N = 130   | 2L/3L+ LBCL Total N=608   | 3L+MCLand 2L/3L+ LBCL Total N= 696   | 3L+ MCL 2L/3L+LBCL and2L+FL Total N=826   |
|---------------------------------------------------|--------------|-----------------|---------------------------|--------------------------------------|-------------------------------------------|
| GRADE >= 3 VIRAL INFECTIONS GRADE 3-4             | 4 4.5)       | 1 0.8)          | 10 1.6)                   | 14 2.0)                              | 15 1.8)                                   |
|                                                   | 3１ 3.4)      | 0.8)            | 7 1.2)                    | 10 1.4)                              | 11 1.3)                                   |
| GRADE 5                                           | 1.1)         | 10              | 3 0.5)                    | 4 0.6)                               | 4 0.5)                                    |
| GRADE 3-4                                         | ５５0 5.7)     | 5 3.8)          | 43 7.1)                   | 48 6.9)                              | 53 6.4)                                   |
|                                                   | ( 5.7)       | 50 3.8)         | 41 ( 6.7)                 | 46 6.6)                              | 51 6.2)                                   |
| GRADE 5                                           |              |                 | 2 0.3)                    | 2 0.3)                               | 2 0.2)                                    |
| GRADE>=3 CYTOPENIA(A)FROM                         | 75 (85.2)    | 103 ( 79.2)     | 545 (89.6)                | 620 (89.1)                           | 723 ( 87.5)                               |
| DAY 1 THROUGH DAY 29 OR 35(B) GRADE>=3ATDAY29OR35 | 35 (39.8)    | 29 (22.3)       | 217 (35.7)                | 252 36.2)                            | 281 (34.0)                                |
| GRADE <= 2 AT DAY 29 OR 35                        | 32 (36.4)    | 64 49.2)        | 273 44.9)                 | 305 43.8)                            | 369 44.7)                                 |
| UNKNOWNATDAY29OR35                                | 8 9.1)       | 10 7.7)         | 55 9.0)                   | 63 9.1)                              | 73 8.8)                                   |

(A) Prolonged cytopenia was defined as Grade ≥3 laboratory results of decreased hemoglobin, decreased neutrophil count, or decreased platelet count.

(B) Visit considered at Day 35 (+/- 6 days) after liso-cel infusion for BCM-003, and at Day 29 (+/- 2 days) after liso-cel infusion in other studies.

AsubjectwascountedonlyonceformultipleeventswithinaPT/SoC.

Infectionincludedgrade3orhigherTEAEsfromInfectionsandinfestationsSOC,byAEHLGT.

The most severe grade was used for AEs that occur more than once in an individual subject during the period.

If multiple test results are available in the window, the maximum grade is selected.

Results after the initiation of subsequent anticancer therapy or product retreatment are excluded.

Table 55. Second Primary Malignancies, Hypogammaglobulinemia, and Autoimmune Disorders in the Treatment-emergent and Post-treatment-emergent Periods - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

| TREATMENT-EMERGENTPERIOD        | 3L+MCL N=88   | 2L+FL N = 130   | 2L/3L+IBCL Total N= 608   | 3L+MCLand 2L/3L+LBCL Total N= 696   | 3L+ MCL 2L/3L+ LBCL and2L+FL Total N= 826   |
|---------------------------------|---------------|-----------------|---------------------------|-------------------------------------|---------------------------------------------|
| SUBJECTS WITH AESI (ANY GRADE)  |               |                 |                           |                                     |                                             |
| SECONDPRIMARYMALIGNANCY(A)      | 3.4)          | 2(1 1.5)        | 8 (1.3)                   | 11 (1.6)                            | 13 (1.6)                                    |
| HYPOGAMMAGLOBULINAFMIA          | 6.8)          | 5 (3.8)         | 65 (10.7)                 | 71 (10.2)                           | 76 (9.2)                                    |
| AUIOIMMUNE DISORDERS (A)        | 0             | 0               | 0                         | 0                                   | 0                                           |
| SUBJECTS WITH AESI (GRADE >= 3) |               |                 |                           |                                     |                                             |
| SECOND PRIMARY MALIGNANCY (A)   | 2 （ 2.3)      | 2 (1.5)         | 4 0.7)                    | 6（ 0.9)                             | 8 (1.0)                                     |
| HYPOGAMMAGLOBULINAFMIA          | 0             | 0               | 1 0.2)                    | 1( 0.1)                             | 1 ( 0.1)                                    |
| AUIOIMMUNE DISORDERS (A)        | 0             | 0               | 0                         | 0                                   | 0                                           |
| POSt-TREATMFNT-EMFRGENTPERIOD   | 3L+MCL N= 82  | 2L+FL N = 129   | 2L/3L+ LBCL Total N = 559 | 3L+MCLand 2L/3L+IBCL Total N = 641  | 3L+ MCL 2L/3L+IBCL and 2L+ FL Total N = 770 |
| SUBJECTS WITH AESI (ANY GRADE)  |               |                 |                           |                                     |                                             |
| SECOND PRIMARY MALIGNANCY (A)   | 14 ( 17.1)    | 8(6.2)          | 29（ 5.2)                  | 43（6 6.7)                           | 51 (6.6)                                    |
| HYPOGAMMAGLOBULINAFMIA          | 4 (4.9)       | 3 (2.3)         | 27（ 4.8)                  | 31（ 4.8)                            | 34 (4.4)                                    |
| AUIOIMMUNE DISORDERS (A)        | 0             | 0               | 0                         | 0                                   | 0                                           |
| SECOND PRIMARY MALIGNANCY (A)   | 8( 9.8)       | 5 (3.9)         | 19 ( 3.4)                 | 27 (4.2)                            | 32（ 4.2)                                    |
| HYPOGAMMAGLOBULINAFMIA          | 0             | 1 ( 0.8)        | 0                         | 0                                   | 1 (0.1)                                     |
| AUIOIMMUNE DISORDERS (A)        | 0             | 0               | 0                         | 0                                   | 0                                           |

(A)Basedonadjudicatedresults.

Post-treatment-emergent period started from 91 days post final liso-cel infusion or initiation of subsequent anticancer therapy/product retreatment if subject initiated subsequent anticancertherapy/productretreatmentpriortoStudyDay91.

<div style=\"page-break-after: always\"></div>

## Cytokine Release Syndrome

Table 56. Treatment-emergent CRS Symptoms by Grade in ≥ 10% of Subjects - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

|                                                       | 3L+MCL N=88   | 2L+FL N = 130   | 2L/3L+IBCL Total N = 608   | 3L+MCLand 2L/3L+LBCL Total N= 696   | 3L+ MCL 2L/3L+ LBCL and 2L+FL Total N= 826   |
|-------------------------------------------------------|---------------|-----------------|----------------------------|-------------------------------------|----------------------------------------------|
| SUBJECTSWITHTREATMENT-EMERGENT CRSSYMPTOMS(ANYGRADE)  | 54 ( 61.4)    | 75 ( 57.7)      | 254 ( 41.8)                | 308 (44.3)                          | 383 (46.4)                                   |
| SUBJECTSWITHTREATMENT-EMERGENT CRS SYMPTOMS（GRADE>=3) | 8.0)          | 2( 1.5)         | 42( 6.9)                   | 49 (7.0)                            | 51 (6.2)                                     |
| FEVER                                                 | 53 (60.2)     | 74 (56.9)       | 243 ( 40.0)                | 296 ( 42.5)                         | 370 ( 44.8)                                  |
| GRADE 1-2                                             | 53 (60.2)     | 74 (56.9)       | 231 ( 38.0)                | 284 ( 40.8)                         | 358 (43.3)                                   |
| GRADE 3-4                                             | 0             | 0               | 12 (2.0)                   | 12( (1.7)                           | 12 (1.5)                                     |
| GRADE 5                                               | 0             | 0               | 0                          | 0                                   | 0                                            |
| HYPOTENSION                                           | 19 (21.6)     | 18 (13.8)       | 98 (16.1)                  | 117 (16.8)                          | 135 ( 16.3)                                  |
| GRADE 1-2                                             | 16 5 (18.2)   | 16 (12.3)       | 84 (13.8)                  | 100( (14.4)                         | 116 (14.0)                                   |
| GRADE 3-4                                             | 3 3.4)        | 2 (1.5)         | 14 (2.3)                   | 17 (2.4)                            | 19 (2.3)                                     |
| GRADE 5                                               | 0             | 0               | 0                          | 0                                   | 0                                            |
| TACHYCARDIA                                           | 9 (10.2)      | 1 (0.8)         | 65 (10.7)                  | 74 (10.6)                           | 75( 9.1)                                     |
| GRADE 1-2                                             | 6 (10.2)      | 1（ 0.8)         | 64 ( 10.5)                 | 73 (10.5)                           | 74( 9.0)                                     |
| GRADE 3-4                                             | 0             | 0               | 1 (0.2)                    | 1 (0.1)                             | 1（ 0.1)                                      |
| GRADE 5                                               | 0             | 0               | 0                          | 0                                   | 0                                            |
| HYPOXIA                                               | 10 ( 11.4)    | 3（ 2.3)         | 44 ( 7.2)                  | 54 ( 7.8)                           | 57( 6.9)                                     |
| GRADE 1-2                                             | 7 8.0)        | 3（ 2.3)         | 28( 4.6)                   | 35 5.0)                             | 38( 4.6)                                     |
| GRADE 3-4                                             | 3 3.4)        | 0               | 16 ( 2.6)                  | 19 2.7)                             | 19( 2.3)                                     |
| GRADE 5                                               | 0             | 0               | 0                          | 0                                   | 0                                            |

A CRS symptom that started from start of product infusion through and including 90 days post product infusion was considered treatment-emergent.

Grouped term Fever includes PTs Pyrexia; grouped term Hypotension includes PTs Hypotension and Orthostatic hypotension.

A subject was counted only oncefor multiple events within a preferred term or grouped term.

The table summarizes data collected on the CRS Symptom eCRF.

The most severegradewas usedfor AEs that occurredmore than once in an individual subject during theperiod.

Table 57. Time to Onset and Time to Resolution of Treatment-emergent CRS - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

|                                                   | 3L+ MCL N= 88   | 2L+FL N = 130   | 2L/3L+IBCL Total N= 608   | 3L+ MCL and 2L/3L+LBCL Total N = 696   | 3L+ MCL 2L/3L+ LBCL and 2L+FL Total N= 826   |
|---------------------------------------------------|-----------------|-----------------|---------------------------|----------------------------------------|----------------------------------------------|
| TIME TO ONSET OF FIRST CRS (DAYS) (A)             |                 |                 |                           |                                        |                                              |
| N                                                 | 54              | 75              | 254                       | 308                                    | 383                                          |
| MEAN                                              | 4.7             | 5.7             | 5.2                       | 5.1                                    | 5.2                                          |
| STANDARD DEVIATION                                | 2.44            | 2.77            | 4.65                      | 4.35                                   | 4.09                                         |
| MEDIAN                                            | 4.0             | 6.0             | 4.0                       | 4.0                                    | 5.0                                          |
| Q1，Q3                                             | 3.0,7.0         | 4.0,7.0         | 3.0,7.0                   | 3.0,7.0                                | 3.0,7.0                                      |
| MIN， MAX                                          | 1,10            |                 | 1,63                      | 1,63                                   | 1,63                                         |
| TIME TO RESOLUTION OF FIRST CRS (DAYS)(B)         |                 |                 |                           |                                        |                                              |
| N                                                 | 53              | 75              | 250                       | 303                                    | 378                                          |
| MEAN                                              | 4.7             | 3.8             | 5.2                       | 5.1                                    | 4.9                                          |
| STANDARD DEVIATION                                | 2.55            | 2.18            | 3.47                      | 3.33                                   | 3.18                                         |
| MEDIAN                                            | 4.0             | 3.0             | 5.0                       | 4.0                                    | 4.0                                          |
| Q1、Q3                                             | 3.0,6.0         | 2.0,5.0         | 2.0,7.0                   | 3.0, 7.0                               | 2.0,6.0                                      |
| MIN，MAX                                           | 1 , 14          | 1,10            | 1, 17                     | 1,17                                   | 1, 17                                        |
| TIME TO ONSET OF FIRST GRADE >= 3 CRS (DAYS)(A)   |                 |                 |                           |                                        |                                              |
| N                                                 | 1               | 1               | 10                        | 11                                     | 12                                           |
| MEAN                                              | 11.0            | 5.0             | 6.8                       | 7.2                                    | 7.0                                          |
| STANDARD DEVIATION                                | N.A.            | N.A.            | 2.74                      | 2.89                                   | 2.83                                         |
| MEDIAN                                            | 11.0            | 5.0             | 6.5                       | 7.0                                    | 6.5                                          |
| Q1、Q3                                             | 11.0, 11.0      | 5.0 ，5.0        | 5.0,9.0                   | 5.0,9.0                                | 5.0,9.0                                      |
| MIN，MAX                                           | 11 ′ 11         | 5               | 3,12                      | 3,12                                   | 3,12                                         |
| TIME TORESOLUTION OF FIRST GRADE >=3 CRS(DAYS）(B) |                 |                 |                           |                                        |                                              |
| N                                                 | 0               | 1               | 8                         | 8                                      | 9                                            |
| MEAN                                              |                 | 2.0             | 6.6                       | 6.6                                    | 6.1                                          |
| STANMARD DEVIATION                                |                 | N.A.            | 3.96                      | 3.96                                   | 4.01                                         |
| MEDIAN                                            |                 | 2.0             | 5.5                       | 5.5                                    | 5.0                                          |
| Q1、Q3                                             |                 | 2.0,2.0         | 4.5,8.0                   | 4.5,8.0                                | 4.0, 7.0                                     |
| MIN ， MAX                                         |                 | 2               | 2,15                      | 2,15                                   | 2,15                                         |

(A) Time to onset was calculated from the latest liso-cel infusion date to the first onset of a CRS event.

(B)AnyCRSeventsstop/startwithin7days(start date-stopdate&lt;=7)wereconsideredinasingleepisode

TimetoresolutionofCRSwasdefinedasthenumberof daysfromonsettowhenthelastCRSeventofthefirstepisodeends.

Subjects with an unresolved event in the episode were excluded from the summary.

<div style=\"page-break-after: always\"></div>

The most common manifestations of CRS included pyrexia (60%), hypotension (22%), hypoxia (11%) tachycardia (10%), chills (8%), headache (8%), nausea (3%), and dyspnoea (2%).

In the TRANSCEND-MCL Cohort, 24 of 88 (27%) patients received tocilizumab and/or a corticosteroid for CRS after infusion of Breyanzi. 15 (17%) patients received tocilizumab only, 8 (9%) received tocilizumab and a corticosteroid and 1 (1%) patient received corticosteroids only

## Neurological Toxicity

In the R/R MCL Treated Set, iiNT occurred in 30.7% of subjects (vs 24.8% in the R/R LBCL Treated Set) and the majority of events were Grade 1-2 (21.6% vs 16.4%), with no Grade 5 events. SAEs of iiNT were similar between the R/R MCL and the R/R LBCL Treated Sets (12.5% in each). The most common (≥ 5%) iiNTs by NESI Group Term and the median time to onset are reported in the Table 58 .

Table 58. Treatment-emergent Investigator-identified Neurological Toxicity by NESI Group Term, Preferred Term and Grade in ≥ 5% of Subjects - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

|                         | 3L+MCL N=88   | 2L+L N = 130   | 2L/3L+ LBCL Total N=608   | 3L+MCL and 2L/3L+ IBCL Total N= 696   | 3L+ML 2L/3L+LBCL and 2L+ FL Total N = 826   |
|-------------------------|---------------|----------------|---------------------------|---------------------------------------|---------------------------------------------|
| Encephalopathy-ANYEVENT | 23 (26.1)     | ６３304 4.6)     | 103 16.9)                 | 126 18.1)                             | 132 16.0)                                   |
| GRADE 1-2               | 15 17.0)      | 3)             | 71 11.7)                  | 86 12.4)                              | 89 10.8)                                    |
| GRADE 3-4               | 9.1)          |                | 32 5.3)                   | 40 5.7)                               | 43 5.2)                                     |
| GRADE 5                 |               |                | 0                         | 0                                     | 0                                           |
| SAE                     | 9 (10.2)      | 3.1)           | 49 8.1)                   | 58 8.3)                               | 62 ( 7.5)                                   |
| Confusional state       | 14 15.9)      | 1.5)           | 52 8.6)                   | 66 9.5)                               | 68 8.2)                                     |
| GRADE 1-2               | 13.6)         | 0.8)           | 43 7.1)                   | 516 7.9)                              | 6.8)                                        |
| GRADE 3-4               | 2.3)          | 0.8)           | 1.5)                      | 1.6)                                  | 1.5)                                        |
| GRADE                   |               |                | 06                        |                                       |                                             |
| SAE                     | 5.7)          | ２１１０２ 1.5)     | 18 3.0)                   | 3.3)                                  | 0π5 3.0)                                    |
| Encephalopathy          | 5.7)          | 1 0.8)         | 29 4.8)                   | 4.9)                                  | 4.2)                                        |
| GRADE 1-2               | 2.3)          |                | 56 2.1)                   | 2.2)                                  | 1.8)                                        |
| GRADE 3-4               | 3.4)          | -0100 0.8)     | 2.6)                      | 2.7)                                  | 515:20 0 2.4)                               |
| GRADE 5                 |               |                |                           |                                       |                                             |
| SAE                     | ５２３０２ 2.3)    |                | 17 2.8)                   | 19 2.7)                               | 2.3)                                        |
| Tremor-ANYEVENT         | 6 6.8)        | 10 7.7)        | 53 8.7)                   | 59 8.5)                               | 69 8.4)                                     |
| GRADE 1-2               | 6 6.8)        | 10 7.7)        | 49 8.1)                   | 55 7.9)                               | 65 7.9)                                     |
| GRADE 3-4               |               | 003            | 0.7)                      | 4 0.6)                                | 0.5)                                        |
| GRADE 5                 | 0             |                | 40 2.5)                   | 0                                     | 40                                          |
| SAE                     | 0             | 2.3)           | 15                        | 15 2.2)                               | 18 2.2)                                     |
| Tremor                  | 6 6.8)        | 10 7.7)        | 52 8.6)                   | 58 8.3)                               | 68 8.2)                                     |
| GRADE 1-2               | 6 6.8)        | 10 7.7)        | 48 7.9)                   | 54 7.8)                               | 7.73                                        |
| GRADE 3-4               | 00            |                | 0.7)                      | 0.6)                                  | 0.5)                                        |
| GRADE 5                 |               | 003            | 40                        | 40                                    | 440                                         |
| SAE                     |               | 2.3)           | 14 2.3)                   | 14 2.0)                               | 17 2.1)                                     |
| Aphasia -ANY EVENT      | 5 5.7)        | 7.7)           | 7.2)                      | 49 7.0)                               | 红6G 7.1)                                    |
| GRADE 1-2 GRADE 3-4     | 50 5.7)       | 6.2 2          | 5.13 2.1)                 | 36 5.2) 13 1.9)                       | 5.3) 1.8)                                   |
| GRADE 5                 | 0             | 1.5)           | 0                         | 0                                     | 0                                           |
| SAE                     |               | 4.6)           |                           | 2.7)                                  | (                                           |
|                         | 1 1.1)        |                | 18 3.0)                   | 19                                    | 25 3.0)                                     |
| Aphasia                 | 3 3.4)        | 6.9)           | 36 5.9)                   | 39 5.6)                               | 48 5.8)                                     |
| GRADE 1-2               | 3 3.4)        | 6.2)           | 25 4.1)                   | 28 ( 4.0)                             | 36 ( 4.4) 12 1.5)                           |
| GRADE 3-4 GRADE 5       | 00            | 0.8)           | 11 1.8)                   | 11 ( 1.6) 0                           | 0                                           |
| SAE                     | 1 1.1)        | 9８１0５ 3.8)     | 0 17 2.8)                 | 18 （ 2.6)                             | 23 2.8)                                     |

|                     | 3L+MCL N= 88   | 2L+FL N = 130   | 2L/3L+IBCL Total N = 608   | 3L+ MCL and 2L/3L+IBCL Total N= 696   | 3L+MCL 2L/3L+LBCL and 2L+ FL Total N= 826   |
|---------------------|----------------|-----------------|----------------------------|---------------------------------------|---------------------------------------------|
| Delirium -ANY EVENT | 5 5.7)         | 3.8)            | 29 4.8)                    | 34 （ 4.9)                             | 39 （ 4.7)                                   |
| GRADE 1-2           | ３２0 3.4)       | 2.3)            | 19 3.1)                    | 22 ( 3.2)                             | 25 3.0)                                     |
| GRADE 3-4           | 2.3)           | ５3２0 1.5)       | 10 1.6)                    | 12 ( 1.7)                             | 14 1.7)                                     |
| GRADE 5             |                |                 | 0                          | 0                                     | 0                                           |
| SAE                 | 2 2.3)         | 3 2.3)          | 13 2.1)                    | 15 2.2)                               | 18 2.2)                                     |

NESI group terms were ordered by (1) 8 main NESI groups (Encephalopathy, Delirium, Aphasia, Tremor, Dizziness, Headache, Anxiety, Insomnia), and (2) all the other groups. Within (1) and (2), table was sorted by group term and preferred term in descending order of incidence in the Overall Total' column.

A subject was counted only once for multiple events within a preferred term/system organ class.

<div style=\"page-break-after: always\"></div>

|                                          | 3L+MCL N= 88   | 2L+FL N = 130   | 2L/3L+ LBCL Total N = 608   | 3L+ MCL and 2L/3L+LBCL Total N = 696   | 3L+MCL 2L/3L+ LBCL and 2L+ FL Total N= 826   |
|------------------------------------------|----------------|-----------------|-----------------------------|----------------------------------------|----------------------------------------------|
| TIME TO ONSET OF FIRST NT (DAYS）(A)      |                |                 |                             |                                        |                                              |
| N                                        | 27             | 21              | 151                         | 178                                    | 199                                          |
| MEAN                                     | 8.4            | 8.6             | 10.6                        | 10.2                                   | 10.1                                         |
| STANDARD DEVIATION                       | 5.34           | 2.56            | 9.15                        | 8.70                                   | 8.28                                         |
| MEDIAN                                   | 8.0            | 8.0             | 8.0                         | 8.0                                    | 8.0                                          |
| Q-Q3                                     | 5.0,11.0       | 7.0,9.0         | 6.0，12.0                    | 6.0,12.0                               | 6.0,11.0                                     |
| MIN， MAX                                 | 1,25           | 4,16            | 1,66                        | 1,66                                   | 1,66                                         |
| TIME TO RESOLUTION OF FIRST NT (DAYS)(B) |                |                 |                             |                                        |                                              |
| N                                        | 26             | 21              | 142                         | 168                                    | 189                                          |
| MEAN                                     | 11.0           | 4.5             | 14.4                        | 13.8                                   | 12.8                                         |
| STANDARD DEVIATION                       | 11.89          | 3.80            | 16.98                       | 16.31                                  | 15.70                                        |
| MEDIAN                                   | 5.0            | 3.0             | 8.0                         | 7.5                                    | 7.0                                          |
| Q-Q3                                     | 2.0,16.0       | 2.0, 5.0        | 4.0, 17.0                   | 3.0,17.0                               | 3.0,16.0                                     |
| MIN， MAX                                 | 1,45           |                 | 1,89                        | 1,89                                   | 1,89                                         |

|                                               | 3L+MCL N=88   | 2L+FL N = 130   | 2L/3L+ IBCL Total N= 608   | 3L+MCLand 2L/3L+LBCL Total N = 696   | 3L+MCL 2L/3L+ LBCL and 2L+ FL Total N = 826   |
|-----------------------------------------------|---------------|-----------------|----------------------------|--------------------------------------|-----------------------------------------------|
| TIME TO ONSET OF FIRST GRADE > 3 NT(DAYS) (A) |               |                 |                            |                                      |                                               |
| N                                             | 8             | 4               | 51                         | 59                                   | 63                                            |
| MEAN                                          | 10.0          | 10.3            | 11.4                       | 11.2                                 | 11.1                                          |
| STANDARDDEVIATION                             | 7.48          | 2.22            | 8.02                       | 7.90                                 | 7.66                                          |
| MEDIAN                                        | 8.5           | 10.0            | 9.0                        | 9.0                                  | 9.0                                           |
| Q1、Q3                                         | 6.5,10.5      | 8.5, 12.0       | 7.0,14.0                   | 7.0,14.0                             | 7.0,13.0                                      |
| MIN ，MX                                       | 2,27          | 8,13            | 2,44                       | 2，44                                 | 2，44                                          |
| TIMETORESOLUTIONOFFIRSTGRADE>=3NT (DAYS)(B)   |               |                 |                            |                                      |                                               |
| N                                             | 8             | 4               | 44                         | 52                                   | 56                                            |
| MEAN                                          | 11.3          | 5.5             | 18.2                       | 17.1                                 | 16.3                                          |
| STANDARDDEVIATION                             | 11.74         | 7.68            | 18.80                      | 17.98                                | 17.66                                         |
| MEDIAN                                        | 5.5           | 2.0             | 10.5                       | 10.0                                 | 9.5                                           |
| Q.3                                           | 2.5,19.0      | 1.5,9.5         | 5.0,23.5                   | 5.0,21.5                             | 4.0,21.0                                      |
| MIN，MAX                                       | 2,34          | 1, 17           | 3.83                       | 2,83                                 | 1,83                                          |

Table 59. Time to Onset and Time to Resolution of Treatment-emergent iiNT - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

<!-- image -->

(A) Time to onset was calculated from the liso-cel infusion date to the first onset of a NT event.

(B) Any NT events stop/start within 7 days (start date-stop date &lt;= 7) were considered in a single episode.

Time to resolution of NT was defined as the number of days from onset to when the last NT event of the first episode ends. Subjects with an unresolved event in the episode were excluded from the summary.

The most common neurologic toxicities included encephalopathy (26%), tremor (7%), delirium (6%), aphasia (6%), headache (5%), and dizziness (3%). Seizures (1%) have occurred in patients treated with Breyanzi.

## Macrophage Activation Syndrome

There were no MAS events reported in the R/R MCL Treated Set and 4 (0.7%) reported in the R/R LBCL Treated Set.

## Infusion Related Reaction (IRR)

The frequency of IRR was similar between the R/R MCL Treated Set (2.3%) and the R/R LBCL Treated Set (1.0%), and all IRR events were mild to moderate (Grade 1-2). There were no Grade ≥ 3 events reported. There was 1 SAE of IRR reported in the R/R MCL Treated Set, and none in the R/R LBCL Treated Set (see Table 54 ).

## Infections (Grade 3 and Higher)

The rate of Grade ≥ 3 infections and infestations was similar between the R/R MCL and the R/R LBCL Treated Sets, 14.8% vs 12.0%, respectively (see Table 54 ). The most common Grade ≥ 3 infections and infestations in the R/R MCL Treated Set by HLGT were unspecified pathogen (5.7%) and bacterial and viral  (4.5%,  each),  similar  to  the  R/R  LBCL  Treated  Set.  The  frequency  of  Grade  5  infections  and infestations was low in both R/R MCL and the R/R LBCL Treated Sets (2.3% vs 1.2%); in the R/R MCL Treated Set, 1 subject died due to COVID-19 pneumonia and 1 due to cryptococcal meningoencephalitis.

<div style=\"page-break-after: always\"></div>

The frequency of Grade ≥ 3 post-treatment-emergent period infection and infestation AEs was 7.3% and 5.0% in the R/R MCL and the R/R LBCL Treated Sets, respectively.

## Prolonged Cytopenia

The rate of prolonged cytopenia (defined as Grade ≥ 3 cytopenias not resolved by Study Day 29 visit, or  Day  35  for  BCM-003,  based  on  laboratory  results  of  low  hemoglobin,  absolute  neutrophil  count decreased and platelet count decreased) was similar between the R/R MCL and the R/R LBCL Treated Sets (39.8% and 35.7%, respectively). In the R/R MCL Treated Set, the majority of subjects with Grade ≥ 3 decreased hemoglobin, decreased absolute neutrophil count, or decreased platelet count at Day 29 visits (±2 days ) had recovered to Grade ≤ 2 by Month 2 ( Table 60 ).

Table 60. Recovery of Prolonged Cytopenia - Liso-cel 3L+ MCL, 2L+ FL, and 2L/3L+ LBCL

|                                                          | 3L+MCL N=88   | 2L+FL N = 130   | 2L/3L+ IBCL Total N= 608   | 3L+MCLand 2L/3L+ IBCL Total N= 696   | 3L+ MCL, 2L/3L+ LBCL and 2L+FL Total N= 826   |
|----------------------------------------------------------|---------------|-----------------|----------------------------|--------------------------------------|-----------------------------------------------|
| AT MONTH 1  (A)                                          | 4 (4.5)       | 6( 4.6)         | 43 (7.1)                   | 47（ 6.8)                             | 53 (6.4)                                      |
| HAD HEMOGLOBIN LAB RESULIS POST MONTH 1 (A)              | 4( 4.5)       | 6 4.6)          | 34( 5.6)                   | 38 5.5)                              | 44 (5.3)                                      |
| RECOVEREDTO GRADE <= 2 BY MONTH 2(B)                     | 4 4.5)        | 4 3.1)          | 25 4.1)                    | 29 4.2)                              | 4.0)                                          |
| RECOVERED TO GRADE <=2BY MONTH 3(C)                      | 4 4.5)        | 6 4.6)          | 30 4.9)                    | 34 4.9)                              | 40（ 4.8)                                      |
| RECOVEREDTOGRADE<=2BY EOS                                | 4 4.5)        | 6 4.6)          | 32( 5.3)                   | 36 5.2)                              | 42（ 5.1)                                      |
| GRADE>=3DECREASEDABSOLUTENEUTROPHILCOUNT AT MONTH 1  (A) | 21 (23.9)     | 20 (15.4)       | 131 ( 21.5)                | 152 ( 21.8)                          | 172 (20.8)                                    |
| HADABSOLUTENEUTROPHIL COUNT LAB RESUIIS FOST MONTH 1(A)  | 21 (23.9)     | 20 (15.4)       | 110 ( 18.1)                | 131 ( 18.8)                          | 151 (18.3)                                    |
| RECOVERED TO GRADE <=2BYMONTH2 (B)                       | 15 ( 17.0)    | 17 (13.1)       | 68 (11.2)                  | 83 (11.9)                            | 100 (12.1)                                    |
| RECOVERED TO GRADE <=2BYMONTH 3 (C)                      | 18 ( 20.5)    | 18 (13.8)       | 95 (15.6)                  | 113 (16.2)                           | 131 ( 15.9)                                   |
| RECOVEREDTOGRADE<=2BYEOS                                 | 19 ( 21.6)    | 19 (14.6)       | 105 ( 17.3)                | 124 (17.8)                           | 143 ( 17.3)                                   |
| AT MONTH 1 (A)                                           | 28 (31.8)     | 19 (14.6)       | 175 (28.8)                 | 203 (29.2)                           | 222 (26.9)                                    |
| HAD PLATELET LAB RESULIS POST MONIH 1(A)                 | 27 ( 30.7)    | 19 9 (14.6)     | 135 (22.2)                 | 162 (23.3)                           | 181 ( 21.9)                                   |
| RECOVERED TO GRADE <= 2 BY MONTH 2(B)                    | 20 (22.7)     | 10 7.7)         | 64 (10.5)                  | 84 (12.1)                            | 94 (11.4)                                     |
| RECOVERED TO GRADE <=2BYMONTH 3  (C)                     | 22 ( 25.0)    | 12 9.2)         | 95 (15.6)                  | 117 (16.8)                           | 129 ( 15.6)                                   |
| RECOVERED TO GRADE <=2BYEOS                              | 25 (28.4)     | 17 (13.1)       | 110 (18.1)                 | 135 (19.4)                           | 152 (18.4)                                    |

Prolonged cytopenia is defined as any grade ≥3 lab results of decreased hemoglobin, decreased neutrophil count or decreased platelets at Month 1 Visit. (A) Month 1 Visit is at Day 35 (+/- 6 days) after liso-cel infusion for BCM-003 and at Day 29 (+/- 2 days) after liso-cel infusion in other studies. Results after the initiation of subsequent anticancer therapy or product retreatment are excluded.

(B)Include subjects whorecovered tograde&lt;=2 after Month1 throughMonth 2(Day62(+6)forStudyBCM-003ArmB,and Day60[+14]forother studies).

(C) Include subjects who recovered to grade &lt;= 2 after Month 1 through Month 3 (Day 98 (+7) for Study BCM-003 Arm B, and Day 90[+14] for other studies).

## Tumor Lysis Syndrome

The frequency of TLS was similar between the R/R MCL and the R/R LBCL Treated Sets (2.3% vs 0.3%, respectively) (see Table 54 ). In the R/R MCL Treated Set, TLS occurred in 2 subjects: 1 subject had a Grade 3 event (related to liso-cel/LDC) which was ongoing at time of death from disease progression. Another subject with high tumor burden before infusion (SPD per IRC at 52.02 cm ² ) experienced a Grade 5 SAE of TLS (related to liso-cel). After infusion, on Day 10, the subject developed Grade 4 TLS, Grade 4 shock (related to liso-cel), and Grade 2 CRS which later worsened to Grade 4 (related to liso-cel). The subject died on Day 12, due to TLS (Grade 5).

## Second Primary Malignancy

Overall, the frequency of SPMs during the treatment-emergent period was 3.4% vs 1.3% in R/R MCL and the R/R LBCL Treated Sets, respectively (see Table 55 ).

In  the  treatment-emergent  period,  3  out  of  88  (3.4%)  subjects  had ≥ 1  SPM  one  each  of  Grade  3 squamous  cell  carcinoma,  Grade  3  acinar  cell  carcinoma  of  the  pancreas,  and  Grade  2  basal  cell carcinoma. None of them were of hematopoietic origin.

In the post-treatment-emergent period, 14 out of 82 (17.1%) subjects had ≥ 1 SPM. Among those, 2 subjects developed new a hematopoietic malignancy (myelodysplastic syndrome) which was considered related to LDC. The other 12 subjects developed solid tumors, the majority were non-melanomatous

<div style=\"page-break-after: always\"></div>

skin  cancer.  Submitted  samples  of  neoplastic  tissue  from  subjects  with  SPMs  in  Study  017001  MCL Cohort were tested for the presence of liso-cel transge. In total, 12 tumor samples from 11 subjects, were submitted for transgene testing by ISH and 8 results were negative for the detection of transgene, 4 were indeterminate due to insufficient RNA quality or no tumor present.

## Autoimmune Disorders

There were no incidences of autoimmune disorders in the R/R MCL Treated Set.

## Hypogammaglobulinemia

The frequency of hypogammaglobulinemia was similar between the R/R MCL and the R/R LBCL Treated Sets  during  the  treatment-emergent  period  (6.8%  vs  10.7%,  respectively)  and  post-treatmentemergent period (4.9% vs 4.8%, respectively) (see Table 55 ). All events were low grade (Grade 1-2).

## Other 017001 Study specific Adverse Events

GVHD in Subjects with Prior Allogeneic HSCT. In the R/R MCL Treated set, 29 subjects (33.0%) had prior HSCT, where 26 (29.5%) subjects received prior autologous HSCT, and 6 (6.8%) subjects received prior allogeneic HSCT. No AEs of GVHD were reported in the R/R MCL Treated Set in subjects with prior allogeneic HSCT, either in the treatment-emergent period, or in the post-treatment-emergent period.

Subjects with CNS Lymphoma Involvement. In the R/R MCL Treated Set, 7 subjects had secondary CNS lymphoma involvement at baseline and 4 of them received bridging therapy. Any grade iiNT occurred in 3 subjects (42.9%) and Grade 3 iiNT in 1 subject (14.3%, PT confusion) while in subjects with no secondary CNS disease any grade iiNT occurred in 24 subjects (29.6%) and Grade ≥ 3 in 7 subjects (8.6%).

Cardiac Events. In  the  R/R  MCL Treated Set, any grade TEAE within the SOC of Cardiac disorders occurred in 21 of 88 subjects (23.9%), and Grade ≥ 3 in 6/88 (6.8%). Similarly, in the R/R LBCL Treated Set, any grade cardiac TEAEs occurred in 21.2% of subjects and Grade ≥ 3 in 2.3%.

Overall,  in  the  R/R  MCL  Treated  Set,  cardiac  TEAEs  were  mostly  low  grade  (Grade  1-2)  rhythm abnormalities, as in the R/R LBCL Treated Set. The majority of cardiac events in R/R MCL resolved within 7 days. Grade ≥ 3 cardiac TEAEs occurred in 2 subjects with no CRS, in 2 subjects before or during CRS, or ≤ 7 days from CRS resolution, and in 2 subjects &gt;7 days after CRS resolution.

A description of the R/R MCL subjects who experienced cardiac TEAEs and their temporal relationship to CRS is provided:

- -Five of 21 subjects experienced at least one cardiac TEAE (any grade) without experiencing CRS. Among  these,  one  subject  experienced  Grade  5  cardio-respiratory  arrest  in  the  context  of treatment for a pancreatic carcinoma.
- -Twelve of 21 subjects developed at least one any grade cardiac TEAE before or during CRS, or ≤ 7 days from CRS resolution. Among these, 2 subjects had Grade ≥ 3 events;
- -Four of 21 subjects developed at least one any grade cardiac TEAE with onset date &gt;7 days after CRS resolution. Among these, 2 subjects had Grade ≥ 3 events.

In  the  post-treatment-emergent  period,  in  the  R/R  MCL  Treated  set,  any  grade  AEs  in  the  Cardiac Disorders SOC were experienced by 2 of 82 subjects (2.4%), and Grade ≥ 3 in 2/82 (2.4%).

Extra-nodal disease . A total of 46 of 88 subjects (52.3%) were identified with extra-nodal disease in the Liso-cel Treated Analysis Set. In R/R MCL with extra-nodal disease, the frequency of subjects with Grade 3 or higher TEAEs was 87.0%, versus 86.4% in the R/R MCL Liso-cel Treated Set. The most frequently occurring Grade ≥ 3 TEAEs by SOC were Blood and lymphatic disorders (69.6%), Metabolism

<div style=\"page-break-after: always\"></div>

and nutrition disorders (21.7%) and Infection and Infestations (19.6%). The most frequently occurring Grade ≥ 3 TEAEs by PT were neutropenia (47.8%), anemia (39.1%), and thrombocytopenia (21.7%). The most common AESIs in R/R MCL subjects with extra-nodal disease were CRS (67.4%), iiNT (30.4%) and Grade ≥ 3 infections (19.6%).

## Laboratory findings

## Haematology

In the R/R MCL Treated Set, changes in hematology laboratory results were consistent with the receipt of anticancer therapy for disease control and LDC prior to liso-cel treatment, followed by the expected recovery. The most common new or worsening haematological abnormalities (all grade) in the R/R MCL Treated set were neutrophil count decreased (77.3%), anemia (55.7%) and white blood cell decreased (53.4%) which were similar to the R/R LBCL Treated Set (79.4%, 51.5%, 59.5%, respectively).

## Clinical Chemistry

In the R/R MCL Treated Set, most chemistry parameters remained stable over time. The most frequent Grade  3-4  new  or  worsening  chemistry  laboratory  abnormality  was  hyperuricemia  in  10.2%, hyponatremia in 8.0%, and hypophosphatemia in 8.0% of subjects. In the R/R LBCL Treated Set the incidence of the same Grade 3-4 new or worsening chemistry laboratory abnormality were 2.0%, 5.3% and 10.4%, respectively.

## Coagulation

The  overall  proportions  of  subjects  with  Grade  3-4  new  or  worsening  abnormalities  in  fibrinogen (decreased) was generally similar between the R/R MCL and the R/R LBCL Treated Set, 2.3% and 7.9%, respectively.

## Safety in special populations

## Intrinsic Factors

There were no major differences in the frequency of TEAEs and Grade ≥ 3 TEAEs across subgroups (age, sex, ethnicity, race, anticancer treatment of disease control status [yes vs no], and region) in the R/R MCL Treated Set. However, some variability was observed due to the small size of some subgroups ( Table 61 ).

<div style=\"page-break-after: always\"></div>

Table 61. Summary of Intrinsic Factors in R/R MCL subjects in Study 017001

| Intrinsic Factor          | Results                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Age                       | Age (< 65 vs ≥ 65 and < 75 years vs ≥ 75 years): No clear differences (defined as difference of ≥ 20% between subgroups) were observed between subgroups in overall rates of subjects with any TEAEs, Grade ≥ 3 TEAEs, or AESIs. The 3 most frequently reported TEAEs were consistent between the subgroups.                                                           |
| Sex                       | Sex (male vs female): No clear differences were observed between subgroups in overall rates of subjects with any TEAEs, Grade >3 TEAEs, or AESIs.                                                                                                                                                                                                                      |
| Race                      | Race (white vs other races vs unknown or missing): No clear differences in rates of overall TEAEs, Grade ≥ 3 TEAEs, or AESIs were observed between subgroups. Because the subgroups other than white were small (for other races and unknown or missing n < 10) differences by PT may have been due to small sample size instead of actual differences between groups. |
| Ethnicity                 | The difference between the number of Hispanic (n = 4) and non-Hispanic (n = 81) subjects limits the interpretability of potential differences in safety by ethnicity.                                                                                                                                                                                                  |
| Pre-LDC LDH               | Liso-cel related G3-5 TEAEs had higher frequency (> 20%) in LDH ≥ ULN group compared to LDH < ULN group, 61.0% vs 38.3%, respectively. TEAEs, G3-4 TEAEs, G5 TEAEs, and SAEs rates were generally similar.                                                                                                                                                             |
| Pre-LDC SPD               | The difference between the number of pre-LDC SPD < 50 cm² (n = 73) and pre-LDC SPD ≥ 50 cm² (n = 7) subjects limits the interpretability of potential differences in safety by pre-LDC SPD.                                                                                                                                                                            |
| Baseline CRP              | Overall TEAE, Grade 3-5 TEAE, and SAE rates were generally similar by baseline CRP.                                                                                                                                                                                                                                                                                    |
| Screening ECOG            | Overall TEAE, SAE, Grade 3-4 TEAE, and AESI rates were generally similar by Screening ECOG of 0 and 1.                                                                                                                                                                                                                                                                 |
| CrC1                      | Overall TEAE, SAE, Grade 3-4 TEAE, and AESIrates were generally similar between subjects with CrCL < 60 mL/min and CrCl ≥ 60 mL/min although the limited sample size for the < 60 mL/min subgroup (n = 19) limits the interpretability of differences in safety.                                                                                                       |
| Screening LVEF            | The small sample size for the Screening LVEF < 50% subgroup (n = 5) limits the interpretability of differences in safety.                                                                                                                                                                                                                                              |
| Intrinsic Factor          | Results                                                                                                                                                                                                                                                                                                                                                                |
| Refractory Status         | Overall TEAE, SAE, Grade 3-4 TEAE, and AESI rates were generally similar by Refractory Status.                                                                                                                                                                                                                                                                         |
| Systemic Bridging Therapy | Overall TEAE, SAE, Grade 3-4 TEAE, and AESI rates were generally similar in the subgroup that received systemic bridging therapy.                                                                                                                                                                                                                                      |
| Region                    | Overall TEAE, SAE,Grade 3-4 TEAE, and AESIrates from North American MCL subjects were generally similar in the LBCL by Region.                                                                                                                                                                                                                                         |

## Safety to support the Product Information

The approved dose range of liso-cel in the SmPC is 44 to 120 × 10 6  CAR+ T cells. Thus, pooled safety analyses were performed for 779 subjects receiving liso-cel dose in the range of 44 to 120×10 6  CAR+ T cells. These analyses included subjects with R/R MCL (n= 88 from 017001 [MCL cohort], i.e. Liso-cel Treated Analysis Set), 2L LBCL (n= 177), 3L+ LBCL (n= 384) and 2L+ FL (n= 130). ADRs represent all reported TEAEs across all indications and are not restricted to AEs deemed related by the investigator. ADRs from time of infusion in subjects with R/R MCL from Study 017001, who received a dose of lisocel within the dose range of 44 to 120×10 6  CAR+ T cells, were integrated with data from the approved

<div style=\"page-break-after: always\"></div>

SmPC (n= 779). The results of this assessment do not impact heavily on the list of ADRs with, as included changes,  a  rearrangement  of Hypophosphatemia and tumour  lysis  syndrome under  a  new  SOC  of Metabolism and nutrition disorder and the increase in frequency from common to very common for Rush (see final SmPC).

## Safety related to drug-drug interactions and other interactions

Liso-cel  is  a  cellular  product  that  is  generally  administered  as  a  one-time  infusion.  Being  a  cellular product, liso-cel is not cleared by the usual mechanisms that apply to small molecules or antibodies. No controlled clinical studies have been performed to directly address drug interactions with liso-cel.

## Discontinuation due to adverse events

Given that liso-cel was administered as a single dose for all subjects in Study 017001 and follow-up continued for subjects regardless of AEs, this analysis is not applicable.

## Post marketing experience

Liso-cel was approved in the EU for the treatment of adult patients with 3L+ R/R LBCL on 04-Apr-2022. A  Type  II  variation  for  extension  of  indication  to  include  2L  LBCL  was  approved  on  28-Apr-2023. Additionally, a Type II variation for extension of indication to include 3L+ FL was approved on 12-Mar2025. Review of available post-marketing data presented in the Periodic Benefit-Risk Evaluation Report (reporting  period  05-Feb-2024  through  04-Aug-2024)  did  not  reveal  any  significant  safety/efficacy concerns that changed the existing benefit-risk profile of liso-cel.

## Indirect Comparison with Brexu-cel (Study CA0821138)

Study CA0821138   was a non-interventional MAIC study using indirect treatment comparison methods to estimate the comparative efficacy and safety of liso-cel vs brexu-cel and comparative efficacy of liso-cel vs pirtobrutinib in patients with 3L+ R/R MCL. Population-adjusted relative treatment effects associated with  liso-cel  in  Study  017001  MCL  Cohort  compared  to  brexu-cel  (ZUMA-2  study)  and  pirtobrutinib (BRUIN study) were estimated. For the safety outcomes, matching adjusted comparisons between lisocel and pirtobrutinib were not conducted due to differences in the type of the majority of the AESIs reported  for  the  two  medicinal  products  and  differences  in  the  monitoring  periods  for  AESIs.  When compared to brexu-cel, the results favored liso-cel over brexu-cel for most safety outcomes, both before and after the adjustment ( Table 62 ).

<div style=\"page-break-after: always\"></div>

Table 62. Naive and MAIC-adjusted Relative Treatment Effect Estimates - Safety Outcomes

|                                       | Liso-cel vs Brexu-cel OR (95% CI)   | Liso-cel vs Brexu-cel OR (95% CI)   |
|---------------------------------------|-------------------------------------|-------------------------------------|
|                                       | Naive (unadjusted)                  | MAIC-adjusted                       |
| CRS, any grade                        | 0.154 (0.060, 0.394)                | 0.123 (0.041, 0.367)                |
| CRS. Grade ≥3                         | 0.067 (0.008, 0.535)                | 0.045 (0.001, 2.541)                |
| Corticosteroid use for CRS management | 0.403 (0.164, 0.987)                | 0.161 (0.027, 0.973)                |
| Tocilizumab use for CRS management    | 0.248 (0.126, 0.488)                | 0.122 (0.041, 0.363)                |
| Vasopressor use for CRS management    | 0.121 (0.026, 0.564)                | 0.081 (0.005, 1.470)                |
| iiNT, any grade                       | 0.257 (0.132, 0.503)                | 0.221 (0.088, 0.556)                |
| iiNT, Grade ≥ 3                       | 0.224 (0.092, 0.545)                | 0.134 (0.027, 0.659)                |
| Corticosteroid use for iNT management | 0.306 (0.144, 0.648)                | 0.167 (0.046, 0.607)                |
| Tocilizumab use for iNT management    | 0.032 (0.004, 0.246)                | 0.033 (0.001, 0.869)                |
| Infections, any grade                 | 0.429 (0.225, 0.821)                | 0.333 (0.135, 0.818)                |
| Infections, Grade ≥ 3                 | 0.339 (0.156, 0.735)                | 0.245 (0.073, 0.826)                |
| Any prolonged cytopenia               | 0.517 (0.281, 0.951)                | 0.212 (0.077, 0.582)                |
| Any prolonged thrombocytopenia        | 0.423 (0.227, 0.790)                | 0.160 (0.052, 0.497)                |
| Any prolonged neutropenia             | 0.346 (0.180, 0.665)                | 0.142 (0.041, 0.496)                |

OR &lt; 1 indicates favorable results for liso-cel vs brexu-cel. Statistically significant results are bolded.

## 2.6.1. Discussion on clinical safety

Safety data for liso-cel from the MCL Cohort (3L+ MCL; referred to as the R/R MCL Treated Set) of Study 017001 (n= 88 [DL1S + DL2S]) were presented side-by-side and pooled (n= 826) with safety data for lisocel  in  2L/3L+  LBCL  and  2L+  FL.  This  allowed  comparison  of  the  safety  profile  of  liso-cel  in  R/R  MCL population (proposed indication) to the established safety profile of liso-cel in the approved SmPC.

Four subjects received nonconforming products. Although the efficacy and safety data in these 4 subjects are overall in line with those from patients receiving liso-cel (ORR of 50%, CRR of 50%, median DOR and PFS not reached), considering the small sample size, no definite conclusion is possible.

The proportion of subjects who received anticancer therapy for disease control (i.e., bridging therapy) in the R/R MCL Treated Set was similar to that in the R/R LBCL Treated Set (65.9% vs 60.9%, respectively), reflecting a population with high disease burden and rapid disease progression.

The exposure to liso-cel was adequate and in line with EU SmPC recommendations (i.e., 44 to 120 × 10 6 CAR+ T cells). All subjects in the R/R MCL Treated Set were dosed without delay or interruption, except 1 subject where dosing was delayed beyond the specified window of 7 days after the completion of LDC due to an AE of hyperbilirubinemia (Grade 2), which was resolved at the time of liso-cel infusion.

As of the data cut-off (16-May-2024) , with a median on-study follow-up time of 19.53 months (min, max: 0.4, 72.0) months , no new safety concerns with liso-cel were identified in subjects with R/R MCL.

<div style=\"page-break-after: always\"></div>

In the R/R MCL Treated Set (n= 88), TEAEs of any grade occurred in 88 (100%) of subjects.  Overall, the types and frequency of the most common TEAEs in ≥ 10% of subjects were consistent between the R/R MCL Liso-cel-treated Analysis Set and the R/R LBCL Treated Set.

Liso-cel-related  TEAEs occurred  in  77  (87.5%)  subjects  overall.  In  the  R/R  MCL  Treated  Set,  the  most frequently occurring liso-cel-related TEAEs were consistent with the R/R LBCL Treated Sets.

Deaths were mainly due to disease progression. 5 (5.7%) subjects died from AEs, versus 23 (3.8%) in the R/R LBCL Treated Set.

Treatment-emergent  Grade  5  AEs were  reported  in  4  (4.5%)  subjects  with  single  cases  of  COVID-19 pneumonia, cryptococcal meningoencephalitis (both assessed as related to liso-cel/LDC), TLS (assessed as related to liso-cel only), and cardio-respiratory arrest (assessed as not related to liso-cel/LDC).

In the R/R MCL Treated Set, 7 (8%) subjects died due to COVID-19 (1 in the treatment-emergent period and 6 in the post-treatment-emergent period) compared with 9 subjects (1.5%) in the R/R LBCL Treated Set.

COVID-19 could have had an impact on clinical safety/death in the immunocompromised R/R MCL patient population. Nevetheless, considering the limited and heterogeneous evidence available in the literature, differences  in  follow-up  durations  across  published  studies,  and  the  variable  timing  of  data  collection relative to the pandemic phases, the number of COVID-19-related deaths reported in the MCL Cohort (7 subjects)  as  of  the  data  cut-off  date  (16  May  2024)  is  consistent  with  findings  in  comparable  MCL populations ( Leuva et al., Seminars in Oncology, 2022; Tilch et al., HemaSphere, 2022; Vijenthira et al., Blood, 2020 ).

The profile of reported AESIs in the R/R MCL Liso-cel-treated Analysis Set was consistent with the known profile for R/R LBCL.

Most AESIs were  mild  to  moderate  in  severity  (Grade  1-2),  considered  to  be  liso-cel-related  by  the investigator, and manageable with protocol-specified guidelines and/or local standard of care. No subjects had AESIs of MAS or autoimmune disorders.

The frequency of all-grade CRS was higher in the R/R MCL Liso-cel-treated Analysis Set (61.4%) compared to the R/R LBCL Treated Set (41.8%), attributed primarily to disease biology of MCL ( Yang et al. Blood 2024; Lionel et al. Blood Adv. 2024; Hay et al. Blood 2017 ). This difference was largely due to the higher incidence of Grade 1-2 events (60.2%) within the R/R MCL population compared to the R/R LBCL population (40.1%), with no difference in Grade 3-4 events (1.1% vs. 1.6%, respectively). The increased incidence of Grade 1 CRS in the R/R MCL Treated Set - for which only supportive care (e.g., paracetamol) is typically required may account for the similar rates of tocilizumab and corticosteroid use observed between the R/R MCL and R/R LBCL Treated Sets, as these treatments are primarily used for managing higher-grade CRS.

Neurological  Toxicity  (iiNT) occurred  in  27  (30.7%)  subjects  with  R/R  MCL  (vs  24.8%  in  the  R/R  LBCL Treated Set). The percentage of subjects who received tocilizumab and/or corticosteroids for iiNT was similar in the R/R MCL Treated Set and the R/R LBCL Treated Set. ICANS-specific assessments were not implemented  in  the  MCL  Cohort  of  Study  017001.  Nevertheless,  the  SmPC  already  includes  relevant information on ICANS as an adverse drug reaction (ADR), including ICANS grading and the Immune Effector Cell-Associated Encephalopathy (ICE) score, which is considered sufficient for the characterization and management of this risk.

Infections (Grade 3 and higher). The rate of Grade ≥ 3 infections and infestations was similar between the R/R MCL and the R/R LBCL Treated Sets, 14.8% vs 12.0%, respectively. The frequency of Grade 5 infections and infestations was low (2.3%). The frequency of Grade ≥ 3 post-treatment-emergent period infection and infestation AEs was 7.3% and 5.0% in the R/R MCL and the R/R LBCL Treated Sets, respectively. The

<div style=\"page-break-after: always\"></div>

findings observed in the MCL Cohort are consistent with the established infectious risk profile of patients who have received multiple prior lines of therapy, including Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib. These data are also aligned with the findings reported by Varughese et al. ( Clin Infect Dis. 2018 ), in which 11.4% of patients with lymphoid malignancies treated with ibrutinib experienced serious infections  -  defined  as  those  requiring  hospitalization  or  parenteral  antimicrobial  therapy  from  the initiation of ibrutinib treatment until 30 days post-discontinuation - including 4.2% who developed invasive fungal infections (IFIs).

Infections are an important identified risk associated with liso-cel. Section 4.4 of the current SmPC already provides guidance on prophylaxis, monitoring, and management of infections. Furthermore, infections will continue to be closely monitored through ongoing pharmacovigilance activities.

Prolonged Cytopenia. The rate of prolonged cytopenia, defined as Grade ≥ 3 cytopenia at the Day 29 (± 2 days) visit based on local laboratory assessments of neutropenia, thrombocytopenia, or anaemia, was similar between the R/R MCL and the R/R LBCL Treated Sets (39.8% and 35.7%, respectively). Of the 88 total  patients  treated  in  the  MCL  Cohort,  Grade 3-4  thrombocytopenia  (n= 28,  31.8%),  Grade 3-4 neutropenia (n= 21, 23.9%) or Grade 3-4 anaemia (n= 4, 4.5%) had recovered to Grade ≤ 2 by Month 2.

The frequency of hypogammaglobulinemia was similar between the R/R MCL and the R/R LBCL Treated Sets during the treatment-emergent period (6.8% vs 10.7%, respectively) and post-treatment-emergent period (4.9% vs 4.8%, respectively).

Similar rates of Second Primary Malignancies (SPM )  were observed in the treatment-emergent period between the R/R MCL Liso-cel-treated Analysis Set and R/R LBCL Treated Set (3.4% and 1.3%, respectively). In the R/R MCL Liso-cel-treated Analysis Set, 3 SPMs were reported in 3 subjects. None of these SPMs were considered related to liso-cel.

During the post-treatment-emergent period, the frequency of SPMs was higher in the R/R MCL Liso-celtreated Analysis Set compared with the R/R LBCL Treated Set (17.1% vs 5.2%). In the R/R MCL Liso-celtreated Analysis Set, 14 SPMs were reported in 14 subjects. None of the SPMs were considered related to liso-cel.  MCL  subjects  have  an  increased  risk  of  SPMs,  particularly  if  treated  with  R-bendamustine, immunosuppressants or BTKi (i.e., skin cancers) ( Starace et al. Cancers 2024 ). The intensive treatments needed for long-term remissions are a concern ( Abalo et al. Eur J Cancer. 2023), and many studies highlight the  growing  recognition  of  SPMs  in  MCL,  reinforcing  the  necessity  for  continuous  vigilance  in  these patients ( Barista et al. Ann Oncol 2002 ; Shah et al, Anticancer Res. 2015; Rock et al. Advances in Radiation Oncology 2022; Bhanushali et al. Blood 2024; Zanelli et al.  Cancers 2023 ).

It is considered that comprehensive clinical and diagnostic evaluations already enable early assessment of patients' eligibility for treatment with Breyanzi. While current clinical practice tends to prioritize timely transplant or CAR-T cell therapy procedures, adjustments may be required to account for infections or other unresolved serious adverse events that, in the judgement of the treating physician, may increase patient risk. This consideration is reflected in section 4.4 of the SmPC.

Additionally, section 4.4 of the current SmPC recommends long-term, lifelong monitoring for secondary malignancies following treatment with Breyanzi. Further characterisation and monitoring SPMs in patients with MCL will continue through the ongoing GC-LTFU-001 long-term follow-up study and the BCM-005 post-authorisation safety study (PASS).

Cardiac Events. In  the  R/R  MCL Treated Set, any grade TEAE within the SOC of Cardiac disorders occurred in 21 of 88 subjects (23.9%), and Grade ≥ 3 in 6/88 (6.8%). Similarly, in the R/R LBCL Treated Set, any grade cardiac TEAEs occurred in 21.2% of subjects and Grade ≥ 3 in 2.3%. Overall, cardiac TEAEs were mostly low grade (Grade 1-2), rhythm abnormalities as in the R/R LBCL Treated Set, and the majority of cardiac events resolved within 7 days. In the post-treatment-emergent period, any grade AEs

<div style=\"page-break-after: always\"></div>

in the Cardiac Disorders SOC were experienced by 2 of 82 MCL subjects (2.4%), and Grade ≥ 3 in 2/82 (2.4%). Cardiovascular complications, likely associated with cytokine release syndrome (CRS) and systemic inflammation, have been reported to occur with CAR-T ( Camilli et al. Cardio-Oncology 2024; Gill J. Current Cardiology Reviews, 2023 ). It is noteworthy that all subjects in the MCL Cohort had received prior therapies with known or potential cardiotoxicity, including Bruton tyrosine kinase (BTK) inhibitors. Furthermore, section 4.4 of the current SmPC ( Special warnings and precautions for use ) already advises that patients who develop CRS should be closely monitored for cardiac and other organ function until resolution of symptoms.  Nevertheless,  the  MAH  acknowledges  the  clinical  importance  of  a  potential  association between  CRS  and  cardiac  events  and  remains  committed  to  continuous  pharmacovigilance.  Postmarketing  data  on  cardiac  events  in  patients  with  R/R  MCL  treated  with  liso-cel  will  continue  to  be monitored and will be included in forthcoming Periodic Safety Update Reports (PSURs).

In general, safety results in the extra-nodal disease subgroup were consistent with those of the overall population, but a definitive conclusion cannot be drawn considering the limitations in the adjudication of extra-nodal disease.

No  major  differences  were  observed  in  the  frequency  of TEAEs  and  Grade  ≥  3  TEAEs  across  other subgroups (age, sex, ethnicity, race, anticancer treatment of disease control status [yes vs no], and region). Some variability was noted, which may be attributed to the small sample size of some subgroups. No clear age-related differences in the frequency of TEAEs or AESIs were observed.

Moreover, considering that surface expression of EGFRt could serve as a target for selective depletion of chimeric antigen receptor (CAR) T cells using anti-EGFR medical products such as cetuximab as a strategy to mitigate severe adverse events associated with CAR T cells, an update of the clinical experience so far has been provided. To date, no subjects have received treatment with an anti-EGFR antibody for any of the currently approved indications in the European Union (EU), either in the parent studies or in the GCLTFU-001 long-term follow-up study.

Product Information . Pooled safety analyses were performed for 779 subjects receiving liso-cel dose in the range of 44 to 120 × 10 6 CAR+ T cells. These analyses included subjects with R/R MCL (n= 88 from 017001 [MCL cohort], i.e. Liso-cel Treated Analysis Set), 2L LBCL (n= 177), 3L+ LBCL (n= 384) and 2L+ FL (n= 130). ADRs represent all reported TEAEs across all indications and are not restricted to AEs deemed related by the investigator. Given the consistency between the safety profiles of R/R MCL and 2L/3L+ LBCL, the inclusion of the R/R MCL dataset in the Product Information is justified. This approach aligns with practices for other CAR-T products and supports a more comprehensive safety overview.

Furthermore, the MAH commits to collect safety information on the mantle cell lymphoma patients which will  be  included  in  the  ongoing  post-authorization  safety  study  (PASS)  JCAR017-BCM-005  through  the necessary adaptation of the protocol (in the RMP) to be submitted for assessment to the Agency within 2 months from receiving the commission decision on the current extension of indication.

## 2.6.2. Conclusions on clinical safety

Safety data for the R/R MCL Liso-cel-treated Analysis Set from Study 017001 were consistent with the known liso-cel safety profile for R/R LBCL Treated Set. With a median follow up of 19.53 months (min, max: 0.4, 72.0) months, no new safety concerns or new types of clinically important events with liso-cel were identified  in  subjects  with  R/R  MCL.  However,  while  this  period  is  enough  to  identify  the  earlier  and immediate AEs, there are potential risks for which conclusive data could not be obtained due to the limited sample size and a limited follow-up time, especially in terms of long-term safety. Long-term safety data for liso-cel in the mantle cell lymphoma (MCL) indication are being collected in Study GC-LTFU-001 and the ongoing post-authorization safety study (PASS) JCAR017-BCM-005. Safety concerns remain unchanged.

<div style=\"page-break-after: always\"></div>

## 2.6.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Risk management plan

The MAH submitted an updated RMP version (v 9.1) with this application.

The CAT-CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 9.1 is acceptable.

The CAT-CHMP endorsed the Risk Management Plan version 9.1 with the following content:

## Safety concerns

| Important identified risks   | Cytokine release syndrome Neurologic toxicity including ICANS Infections Hypogammaglobulinaemia Macrophage activation syndrome/haemophagocytic lymphohistiocytosis Tumour lysis syndrome Cytopenia, including bone marrow failure Secondary malignancy of T-cell origin                                 |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Autoimmune disorders Aggravation of graft versus host disease Secondary malignancies (except secondary malignancy of T-cell origin) Generation of replication competent lentivirus Immunogenicity Transmission of infectious agents Reduced viability of liso-cel due to inappropriate product handling |
| Missing information          | Impact on pregnancy and lactation Long-term safety Safety in patients < 18 years old Safety in patients ≥ 75 years                                                                                                                                                                                      |

## Pharmacovigilance plan

| Study / Status                                                                                                             | Summary of objectives                                                                                                      | Safety concerns addressed                                                                                                  | Milestone(s)                                                                                                               | Due Date(s)                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation |

<div style=\"page-break-after: always\"></div>

| Study / Status                    | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Safety concerns addressed                                                                                                                                                                                                                                                                                                                                      | Milestone(s)                                                                                                                                                                                       | Due Date(s)                                                                                                                                                                                                                                                                               |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PASS (JCAR017- BCM-005) / Ongoing | Primary Objective: To characterise the incidence and severity of selected ADRs, as outlined in the SmPC, in patients treated with liso-cel in the postmarketing setting, and to monitor for potential clinically important AEs that have not yet been identified as part of the liso-cel safety profile. Secondary Objectives: To assess long-term effectiveness in patients treated with liso-cel in the postmarketing setting. To assess the liso-cel safety and effectiveness profile in certain subgroups including but not limited to: 1) By large B-cell lymphoma subtypes (eg, FL3B, PMBCL, DLBCL not otherwise specified, high grade B-cell lymphoma). 2) According to geographical regions (eg, Europe). 3) Subjects aged ≥ 75 years. 4) Subjects with comorbid conditions (eg, renal impairment, reduced cardiac function). 5) Subjects with secondary CNS involvement. 6) Subjects with ECOG performance score ≥ 2. 7) By possible prognostic factors (eg, high-risk IPI). 8) Subjects previously | CRS/MAS a /HLH a NT including ICANS b Infections Hypogammaglobulinaemia TLS Cytopenia, including bone marrow failure Secondary malignancy of T-cell origin Secondary malignancies (except secondary malignancy of T-cell origin) Impact on pregnancy and lactation (for pregnancy events) Long-term safety Aggravation of GvHD a Safety in patients ≥ 75 years | Protocol Submission to EMA Date of protocol approval by PRAC Start of data collection c Safety reports d Interim reports e Date of Study Completion f Date of Final Study Report Submission to EMA | 14-Apr-2022 01-Dec-2022 Q1 2023 Safety reports every 6 months (eg, aligned with the reporting period of the PSURs); additional reports every 3 months if a new safety concern is identified At Year 5, 10, and 15 or when last patient is out of the registry-based study Q4 2042 Q4 2043 |

<div style=\"page-break-after: always\"></div>

| Study / Status                                                                                                                                                                                                             | Summary of objectives                                                                                                                                                                                                                                                                                                                                            | Safety concerns addressed                                                                                                                                                                                                                                                                                                | Milestone(s)                                                                                                                                                                                                                                                   | Due Date(s)                                                                                                                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                            | 10) Subjects treated with out-of-specification product.                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                            |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                                                                                       | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                                               | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                     | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| None.                                                                                                                                                                                                                      | None.                                                                                                                                                                                                                                                                                                                                                            | None.                                                                                                                                                                                                                                                                                                                    | None.                                                                                                                                                                                                                                                          | None.                                                                                                                                                                                                                      |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                            | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                  | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| LTFU study (GC-LTFU-001)/ Ongoing                                                                                                                                                                                          | Long-term follow-up of safety and efficacy for all paediatric and adult subjects exposed do a GM T-cell therapy in Bristol- Myers Squibb sponsored, or Bristol-Myers Squibb alliance partner sponsored, clinical trials in accordance with Health Authorities' guidance for long-term (up to 15 years) follow-up of subjects treated with gene therapy products. | Infections Cytopenia, including bone marrow failure Autoimmune disorders Secondary malignancy of T-cell origin Secondary malignancies (except secondary malignancy of T-cell origin) Impact on pregnancy and lactation Long-term safety Safety in patients < 18 years old Generation of replication competent lentivirus | Subjects to be followed up for 15 years. Interim reports (5 and 10 years from FSFV [Jul 2018]). LSLV Final database lock Final report of GC-LTFU- 001 follow-up of 3L+ large B- cell lymphoma liso-cel treated subjects Safety data will be reported in PSURs. | Q3 2023 and Q3 2028 Estimated Q3 2038 Q3 2038 Q3 2039 Submitted in accordance with the EURD list                                                                                                                           |
| Non-interventional cohort study of patients treated with liso-cel (lisocabtagene maraleucel) for relapsed/refractory follicular lymphoma in the postmarketing setting (CA082- 1175) / Ongoing                              | To characterize the incidence and severity of selected AEs, including secondary malignancy, and to assess the long-term effectiveness in patients receiving liso-cel to treat R/R FL.                                                                                                                                                                            | CRS/MAS a /HLH a NT including ICANS b Infections Hypogammaglobulinaemia TLS Cytopenia, including bone marrow failure Secondary malignancy of T-cell origin Secondary malignancies                                                                                                                                        | Start of data collection Progress updates Interim reports                                                                                                                                                                                                      | 31-Aug-2024 corresponds to the date from which data extraction starts. Aligned with the reporting period of the PSURs At Year 5 and 10                                                                                     |

<div style=\"page-break-after: always\"></div>

| Study / Status                                                                                       | Summary of objectives                                                          | Safety concerns addressed                                                                                                                                  | Milestone(s)                                                                           | Due Date(s)                                                                                                                                   |
|------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                      |                                                                                | malignancy of T-cell origin) Impact on pregnancy and lactation (for pregnancy events) Long-term safety Aggravation of GvHD a Safety in patients ≥ 75 years | Date of Study Completion                                                               | End of Q1 2044 (Study completion 15 years after reaching the defined patient number, no further data will be included in the study analyses.) |
|                                                                                                      |                                                                                |                                                                                                                                                            | Date of Final Study Report Submission to EMA                                           | Q4 2045                                                                                                                                       |
| Transgene assay service testing of secondary malignancies with insertion site analysis as applicable | Tumour tissue sample testing from patients that develop a secondary malignancy | Secondary malignancy of T-cell origin Secondary malignancies (except secondary malignancy of T-cell origin) g                                              | Safety data will be reported in PSURs. European Commission decision + 5 years European | Submitted in accordance with the EURD list. Q2 2026                                                                                           |
|                                                                                                      |                                                                                |                                                                                                                                                            | Commission decision + 10 years                                                         | Q2 2031                                                                                                                                       |
|                                                                                                      |                                                                                |                                                                                                                                                            | European Commission decision + 15 years                                                | Q2 2036                                                                                                                                       |

- a Included under the category of Other AEs considered related to liso-cel treatment in Study BCM-005.
- b NT is a primary endpoint in Study BCM-005, which comprises symptoms of NT, including cerebral oedema.
- c Based on the European Commission decision and protocol approval timeline. As the data collection in the EBMT Registry is independent of this study (secondary use of data), the start of data collection corresponds to the date from which data extraction starts. First data extraction for Study BCM-005 will take place 3 months after protocol approved by EMA.
- d 6-month safety reports will be provided with the PSUR submission (PSUR single assessment [PSUSA]) as determined by the EURD list.
- e Interim reports will be prepared at year 5, 10, and 15 after EC decision date or when last patient is out of the registry-based study.
- f Fifteen years after reaching the defined patient number, no further data will be included in the study analyses.
- g Only reported secondary malignancies where insertional oncogenesis is suspected and a sample is available

## Risk minimisation measures

Safety Concern

Important Identified Risks

Risk Minimisation Measures

Pharmacovigilance Activities

<div style=\"page-break-after: always\"></div>

| Safety Concern                      | Risk Minimisation Measures                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytokine release syndrome           | Routine risk minimisation measures: SmPC Sections 4.2 and 4.4, PL Sections 2 and 3 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: 11) Educational programme for HCPs and      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up questionnaire Additional pharmacovigilance |
| Neurologic toxicity including ICANS | Routine risk minimisation measures: SmPC Sections 4.2, 4.4 and 4.7, PL Sections 2 and 3 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: 13) Educational programme for HCPs and | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up questionnaire Additional pharmacovigilance |
| Infections                          | Routine risk minimisation measures: SmPC Section 4.4, PL Section 2 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: None                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities:                |
| Hypogammaglobulinaemia              | Routine risk minimisation measures: SmPC Section 4.4 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: None                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities:                |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                     | Risk Minimisation Measures                                                                                                                                                                                      | Pharmacovigilance Activities                                                                                                                                     |
|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Macrophage activation syndrome/haemophagocytic lymphohistiocytosis | Routine risk minimisation measures: SmPC Section 4.4 - warnings, advice and management discussed SmPC Section 4.8 - histiocytosis haematophagic listed as an ADR Additional risk minimisation measures: None    | US registry study (CA082- 1175) Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance |
| Tumour lysis syndrome                                              | Routine risk minimisation measures: SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures:                                                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional                                                   |
| Cytopenia, including bone marrow failure                           | Routine risk minimisation measures: SmPC Section 4.4, PL Section 2 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance                                 |
| Secondary malignancy of T- cell origin                             | Routine risk minimisation measures: SmPC Section 4.4, PL Section 2 - warnings, advice and management SmPC Section 4.8, PL Section 4 - listed as an ADR                                                          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up questionnaire                                   |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                        | Risk Minimisation Measures                                                                           | Pharmacovigilance Activities                                                                                                                        |
|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                                             |                                                                                                      |                                                                                                                                                     |
| Autoimmune disorders                                                  | Routine risk minimisation measures: None                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:                                                       |
| Aggravation of GvHD                                                   | Routine risk minimisation measures: SmPC Section 4.4, PL Section 2 - warnings, advice and management | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None.                                                 |
| Secondary malignancies (except secondary malignancy of T-cell origin) | Routine risk minimisation measures: SmPC Section 4.4 - warnings, advice and management               | and US registry study (CA082-1175) Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up |
| Secondary malignancies (except secondary malignancy of T-cell origin) | Additional risk minimisation measures: None                                                          | Additional pharmacovigilance activities: PASS (JCAR017-BCM-005)                                                                                     |
| Generation of replication competent lentivirus                        | Routine risk minimisation measures: None                                                             | Routine pharmacovigilance activities beyond adverse                                                                                                 |

Safety Concern

## Risk Minimisation Measures

Pharmacovigilance Activities

reactions reporting and

signal detection:

None.

## Additional risk minimisation measures:

None

Additional pharmacovigilance activities:

LTFU study (GC-LTFU-001).

Immunogenicity

## Routine risk minimisation measures:

SmPC Section 4.2 and PL Section 3 - premedication with paracetamol and diphenhydramine or another H1-antihistamine SmPC Section 4.8 - listed as an ADR

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:

None.

## Additional risk minimisation measures:

None

Additional pharmacovigilance activities:

None.

Transmission of infectious agents

## Routine risk minimisation measures:

SmPC Sections 4.2, 4.4 (Risk of transmission of infectious agents exists. Guidance on monitoring patients for signs and symptoms of infections), and 6.6, PL Section 2 and Labelling Section 10 - handling instructions

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:

None.

## Additional risk minimisation measures:

None

Additional pharmacovigilance activities:

None

Reduced viability of liso-cel due to inappropriate product handling

## Routine risk minimisation measures:

SmPC Sections 4.2, 6.3, 6.4, 6.5 and 6.6, PL Section 5 and Labelling Section 9 - handling instructions

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:

None.

## Additional risk minimisation measures:

15) Educational programme for HCPs

16) Controlled Distribution Programme

Additional pharmacovigilance activities:

None.

## Missing Information

Impact on pregnancy and lactation

## Routine risk minimisation measures:

SmPC Section 4.6, PL Section 2- warnings and advice

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:

None.

## Additional risk minimisation measures:

None

Additional pharmacovigilance activities:

PASS (JCAR017-BCM-005) and US registry study

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| Safety Concern                    | Risk Minimisation Measures                                                                                                           | Pharmacovigilance Activities                                                                                                                 |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
|                                   |                                                                                                                                      | (CA082-1175) for pregnancy events LTFU study (GC-LTFU-001).                                                                                  |
| Long-term safety                  | Routine risk minimisation measures: None Additional risk minimisation measures: None                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: |
| Safety in patients < 18 years old | Routine risk minimisation measures: SmPC Section 4.2, PL Section 2 - warnings and advice Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: |
| Safety in patients ≥ 75 years     | Routine risk minimisation measures: None                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None.                                          |

## 2.8. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI for editorial purposes and in addition, the list of local representatives in the PL has been revised to amend contact details for the representative of Iceland

## 2.8.1. User consultation

<div style=\"page-break-after: always\"></div>

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- -the readability of the PL (QRD template) of Breyanzi was assessed during the review of the initial MAA
- -the new indication in adults foresees the same route of administration and has a similar safety profile as the previously approved indication (i.e., key safety messages for the existing and new applied for indication are essentially the same).
- -Breyanzi is administered by HCP. The instructions for preparation, administration, storage and disposal that are currently reflected in the approved PL were also successfully tested as part of the user consultation performed for the initial MAA and remain unchanged.
- -the general design and layout of the proposed PL have not changed compared to the tested one.
- -the modifications now proposed in the PL (i.e., those relevant to the new indication) do not represent major changes

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Breyanzi is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.

## 3.1.2. Available therapies and unmet medical need

According to the current ESMO guidelines (M. Dreyling et al, Annals of Oncology 2017), covalent Brutontyrosine kinase inhibitors (BTKis) are the preferred option after failure of 1L treatment (immunochemotherapy, ASCT followed by rituximab). In particular, ibrutinib has been shown to improve outcomes in R/R MCL (Rule S et al, Br J Haematol 2017), but the occurrence of resistance or intolerance limits the long-term benefit with covalent BTKis.

There is no single standard-of-care for R/R MCL  in the post-BTKi setting and the optimal approach/sequence to treat R/R MCL is yet to be defined. Treatment choice is further complicated by the lack of data comparing the available treatment options in randomized controlled trials. Treatment choice in R/R MCL is guided by age, performance status, comorbidities, and prior therapy. It is noteworthy that temsirolimus, lenalidomide and bortezomib were all licensed before covalent BTKis, hence limited data are  available  on  their  efficacy  in  the  post-BTKi  setting,  especially  for  lenalidomide  and  bortezomib. Chemoimmunotherapy regimens (rituximab, bendamustine ± cytarabine) are additional options that have  been  associated  with  high  response  rates  (up  to  83%)  but  their  use  is  often  limited  by  the associated toxicity, often resulting in dose reduction/discontinuation.

Recently, brexucabtagene autoleucel (brexu-cel, autologous CD19-directed CAR T-cell therapy) has been approved in the EU under conditional approval (CMA) for the treatment of patients with R/R MCL after ≥ 2 prior lines of treatment, including BTKi and pirtobrutinib (a non-covalent BTKi) has been approved in the EU under conditional approval (CMA) for the treatment of patients with R/R MCL who have been previously treated with a BTKi. In both cases, the CMA was based on results from single-arm trials. As also highlighted by the systematic literature review submitted by the MAH, the ORR for the existing non-

<div style=\"page-break-after: always\"></div>

CAR-T therapies ranged between 27% and 83% (CRR 9.1-60%) yet the impact on survival was limited, with median OS ranging between 3.6 months and 14 months.

In the single-arm ZUMA-2 study, treatment with the anti-CD19 CAR T cell brexu-cel resulted in high rates of deep and durable responses (ORR 91% (95% CI, 81.8 to 96.7), CRR 68% (95% CI, 55.2 to 78.5), median DOR 28.2 (95% CI 13.5, 47.1) months) ( wang et al, 2022), yet non-negligible toxicity was also observed (Grade ≥ ≥ 3 AEs 98.5%;  Grade ≥ 3 CRS 13%, Grade ≥ 3 CART-related encephalopathy syndrome 32%, Grade ≥ 3 infections 30%).

Overall, subjects with R/R MCL in relapse or refractory after 2 or more lines of therapy, including a covalent  BTKi  treatment,  have  limited  therapeutic  options  and  generally  unsatisfying  outcomes.  An unmet medical need for effective and safe alternatives can be recognised.

## 3.1.3. Main clinical studies

Study 017001 is an open-label, multicentre, multicohort, seamless design, Phase 1 study to determine the safety, antitumor activity, and PK of liso-cel in adult subjects with R/R B-cell NHL; the Mantle Cell Lymphoma (MCL) cohort included subjects with R/R MCL who had received ≥ 2 prior lines of systemic therapy, including an alkylating agent, a BTKi, and rituximab (or other CD20-targeted agents).

The target dose of liso-cel used for MCL is consistent with the current posology recommendations in the Breyanzi SmPC for existing indications (i.e. 100 × 10 6  CAR+ viable T cells with a target 1:1 ratio of the CD4+ and CD8+ T cell components, within the acceptability range 44 to 120 × 10 6  CAR+ viable T cells).

The primary endpoint of this study was ORR by IRC according to the 2014 Lugano criteria; CRR by IRC was the key secondary endpoint.

A total  of  105  subjects  were  screened  for  the  MCL  cohort;  the  PAS  included  a  total  of  75  patients, corresponding to 72% of the Leukapheresed set (ITT; n=104 subjects).

## 3.2. Favourable effects

Liso- cell showed consistent efficacy results in the pre-specified final analyses ( data cut date 16 May2024, median follow up of 16.10 months ; ORR in the Leukapheresed set (n=104): 70.2% (95% CI: 60.4, 78.8), CRR Per Investigator assessment: 61.5% (95% CI: 51.5%, 70.9%), in the post-hoc defined 'Efficacy Set' (n=81),  ORR: 82.7% (95% CI: 72.7, 90.2), CRR: 71.6%, (95%CI 60.5%, 81.1%) and in subgroup analyses, including patients aged ≥75 years (N=15) and subjects with high risk factors such as refractoriness to their last therapy, Ki67≥30%, mutated TP53, blastoid morphology and high sMIPI score.

Treatment  with  liso-cel  also  resulted  in  durable  responses:  in  the  Leukapheresed  set  (mDoR  15.2 months, 95%CI 7.0, 24.0), in the analysis by Investigator assessment (mDoR 11.3 months, 95%CI 5.7, 23.3) and in the post-hoc defined 'Efficacy Set' (mDoR 11.5 months, 95%CI 6.2, 24.0).

Results from the primary (inferential) analysis from the MCL cohort of study 017001 (data cut date 19 Jan 2023, median follow up of 16.10 months) were overall consistent with those at the time of the final analysis.

## 3.3. Uncertainties and limitations about favourable effects

- The evidence supporting the efficacy of liso-cel in the target population comes from one single uncontrolled,  open-label  study,  which  limited  the  interpretation  of  time-to-event  endpoints. Significant  and  clinically  relevant  improvements  in  terms  of  PFS/OS  have  been  historically accepted as adequate basis to inform B/R decisions in NHLs, yet the interpretation of time-to-

<div style=\"page-break-after: always\"></div>

event endpoints in the absence of controls is hampered by the difficulties in disentangling the impact of the intervention from the effect of heterogeneity in tumour growth rates.

- The sample size was too limited to adequately characterize the efficacy of liso-cel in clinically relevant subgroups
- All subjects in the MCL cohort of study 017001 were screened at 14 sites in the US. Although the substantial uniformity in terms of guidelines and approved treatments between US and EU at the time study 017001 was conducted is acknowledged, uncertainties on results generalizability  to  the  EU  setting  remain,  due  to  possible  differences  in  treatment  access  or positioning (e.g. with respect to ASCT/alloHSCT). The MAH agreed on amending the ongoing PASS JCAR017 -BCM-005 study to include the collection of data on EU subjects with R/R MCL treated with liso-cel.

## 3.4. Unfavourable effects

The unfavorable effects with liso-cel are the generally known identified risks, i.e., CRS, neurotoxicity and prolonged cytopenias.

The most common adverse reactions of any grade were CRS (61.4%), neutropenia (59.1%), and anaemia (44.3%) fatigue (35%), thrombocytopenia (30%), and headache (23%).

The most common serious adverse reactions were CRS (23.9%), confusional state (5.7%), and pyrexia (3.4%)  mental  status  changes  (2%),  encephalopathy  (2%),  upper  respiratory  tract  infection  (2%),  and pleural effusion (2%).

The most common Grade 3 or higher adverse reactions included neutropenia (55.7%), anaemia (37.5%), and thrombocytopenia (25.0%), hypophosphataemia (9%), and leukopenia (7%).

CRS occurred in 61.4% of patients, 1.1% of whom experienced Grade 3 or 4 CRS (no fatal events). The median time to CRS onset from the time of liso-cel infusion was 4 days (range: 1 to 10 days) with a median time to resolution of 4 days (range: 1 to 14 days). The most common manifestations of CRS included pyrexia (60%), hypotension (22%), hypoxia (11%), tachycardia (10%), chills (8%), headache (8%), nausea (3%), and dyspnea (2%). In the TRANSCEND-MCL Cohort, 24 of 88 (27%) patients received tocilizumab and/or a corticosteroid for CRS after infusion of Breyanzi.

iiNT occurred in 30.7% of patients receiving Breyanzi, including Grade 3 or 4 in 9% of patients (no fatal events). The most common neurologic toxicities included encephalopathy (26.1%), tremor (6.8%), and aphasia and delirium (5.7%, each). Seizures (1%) have occurred in patients treated with Breyanzi. The median time to onset was 8 days (range: 1 to 25 days). Among the 27 subjects with first onset iiNT, 26 resolved (96.3%); the median time to resolution was 5 days (range: 1 to 45 days).

Grade 3 or higher cytopenias , present at Day 29 following Breyanzi administration, occurred in 39.8% of patients. Of the 88 total patients treated in the MCL Cohort, Grade 3-4 thrombocytopenia (n= 28, 31.8%), Grade 3-4 neutropenia (n= 21, 23.9%) or Grade 34 anaemia (n= 4, 4.5%) recovered to Grade ≤ 2 by Month 2.

Grade 3 infections occurred in 14.8% of patients.

## 3.5. Uncertainties and limitations about unfavourable effects

The  safety  database  included  88  R/R  MCL  patients  treated  with  liso-cel  in  pivotal  Study  017001 (TRANSCEND NHL-001). Generally, the spectrum of the unfavourable effects of liso-cel is known, and currently no major additional issues seem to arise. The safety profile of liso-cel in the intended target population appears manageable, and no new safety concerns have been identified.

<div style=\"page-break-after: always\"></div>

With a median follow up of 19.53 months (min, max: 0.4, 72.0) months, no new safety concerns with lisocel were identified in subjects in the R/R MCL Treated Set. However, while this period would be enough to identify the earlier and immediate AEs, there are some potential risks for which conclusive data could not be obtained due to the limited sample size and limited follow-up time, including the long-term safety profile. The MAH agreed to collect further long-term safety data in R/R MCL within the ongoing registrybased PASS JCAR017 -BCM-005 and in Study GC-LTFU-001.

## 3.6. Effects Table

Table 63. Effects Table for Liso-cel for the Treatment of Adult Patients with R/R MCL after 2 or More Lines of Systemic Therapy, including a BTKi (Study 017001 MCL Cohort) (Data cutoff 16 May-2024).

| Effect                               | Short description                                                                                         | Unit                                                                                      | Treatment                                                                                  | Uncertainties / Strength of evidence                                                                                 | References           |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects                   | Favourable Effects                                                                                        | Favourable Effects                                                                        | Favourable Effects                                                                         | Favourable Effects                                                                                                   | Favourable Effects   |
| Overall Response Rate                | Best Overall Response(CR or PR) per IRC based on the Lugano classification                                | %(n)                                                                                      | Efficacy Set: 82.7% (95% CI%=72.7, 90.2) (n=81) ITT Set: 70.2% (95% CI=60.4, 78.8) (n=104) | Unc: Single arm studySoE: consistent results across primary and sensitivity analyses, as well as secondary endpoints | Study 017001         |
| Duration of response                 | Median Time from first response (CR or PR) to PD or death from any cause (whichever occurs first) per IRC | Months Efficacy Set (n=81): 11.5 (95%CI 6.2- 24) ITT Set (n=104: 15.2 (95% CI: 7.0, 24.0) | Months Efficacy Set (n=81): 11.5 (95%CI 6.2- 24) ITT Set (n=104: 15.2 (95% CI: 7.0, 24.0)  | Unc: Single arm studySoE: consistent results across primary and sensitivity analyses, as well as secondary endpoints | Study 017001         |
| Unfavourable Effects                 | Unfavourable Effects                                                                                      | Unfavourable Effects                                                                      | Unfavourable Effects                                                                       | Unfavourable Effects                                                                                                 | Unfavourable Effects |
| CRS                                  | Cytokine- release syndrome                                                                                | N (%)                                                                                     | 54/88 (61.4%)                                                                              | Unc: Single-arm study Limited sample size Limited follow-up for long- term evaluations                               | Study 017001         |
| iiNT                                 | Investigator identified neuro-toxicity                                                                    | N (%)                                                                                     | 27/88 (30.7%)                                                                              | Unc: Single-arm study Limited sample size Limited follow-up for long- term evaluations                               | Study 017001         |
| Prolonged cytopenia                  | ≥ Grade 3                                                                                                 | N (%)                                                                                     | 35/88 (39.8%)                                                                              | Unc: Single-arm study Limited sample size Limited follow-up for long- term evaluations                               | Study 017001         |
| Infections                           | ≥ Grade 3                                                                                                 | N                                                                                         | 13/88 (14.8%)                                                                              | Unc: Single-arm study Limited sample size Limited follow-up for long- term evaluations                               | Study 017001         |
| SPM (treatment emergent period)      | Any grade                                                                                                 | (%)                                                                                       | 3/88 (3.4%)                                                                                | Unc: Single-arm study Limited sample size Limited follow-up for long- term evaluations                               | Study 017001         |
| SPM (post-treatment emergent period) | Any grade                                                                                                 | N (%)                                                                                     | 14/88 (17.1%)                                                                              | Unc: Single-arm study Limited sample size Limited follow-up for long- term evaluations                               | Study 017001         |
| Hypogammaglobulinaemia               |                                                                                                           | N (%)                                                                                     | 6/88 (6.8%)                                                                                | Unc: Single-arm study Limited sample size Limited follow-up for long- term evaluations                               | Study 017001         |

Abbreviation: SPM= secondary primary malignancies, CRS = cytokine release syndrome, iiNT = investigator- identified neurologic toxicity.

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

MCL is an aggressive form of NHL that is currently incurable with conventional treatment options. MCL is characterised by a relapsing/remitting disease course, with increasing resistance to treatment with each  relapse.  Despite  novel  medicinal  products  have  been  approved  (e.g.,  the  non-covalent  BTKi pirtobrutinib and the anti-CD19 CAR T cell therapy brexu-cel), the life-expectancy for patients with R/R MCL after at least 2 prior lines of therapy which included a BTKi is still reduced compared to the general population, and the unmet need for additional safe and effective treatment options can be recognised.

Results from the MCL cohort of pivotal study 017001 showed that treatment with liso-cel in a post-BTKi setting of R/R MCL was associated with a clinically relevant antitumoral effect, as highlighted by the high rates of ORR and CRR (a pre-requisite to experience prolonged disease control) in patients intended to be treated with liso-cel (70.2% and 61.5%, respectively). Responses with liso-cel were rapidly induced (mTTR 0.95 months) and a subgroup of patients in complete remission was able to achieve a long-lasting disease control  (24-month  DOR  rate  44.8%),  which  is  uncommon  with  conventional  treatments  in  such  an advanced setting of relapse.

The unfavourable effects observed with liso-cel were generally limited to the known identified risks with CARTs,  including  CRS,  neurotoxicity  and  prolonged  cytopenias.  The  low  rates  of  severe  CAR-T-related toxicity  compared  favourably  with  those  previously  observed  in  R/R  MCL,  although  the  limits  of  the uncontrolled study design hampered any reliable comparison across different studies, especially when the clinical heterogeneity of MCL is taken into consideration.

## 3.7.2. Balance of benefits and risks

Based on the available data, the overall B/R of liso-cel in the claimed indication is considered favourable. The clinically relevant rates of deep and durable responses observed in an advanced setting of R/R MCL balance the known risks associated to anti-CD19 CAR T cell therapy, especially considering the limited occurrence of severe CRS and iiNT events.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8. Conclusions

The overall B/R of Breyanzi is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CAT-CHMP considers the following group of variations acceptable and therefore recommends by consensus the variations to the terms of the Marketing Authorisation, concerning the following changes:

| Variations accepted   | Variations accepted                                                | Type              | Annexes affected   |
|-----------------------|--------------------------------------------------------------------|-------------------|--------------------|
| B.II.d.1.e            | B.II.d.1.e Change outside the approved specifications limits range | Variation type II |                    |

<div style=\"page-break-after: always\"></div>

| C.I.6.a   | C.I.6.a Addition of a new therapeutic indication or modification of an approved one   | Variation type II   | I and IIIB   |
|-----------|---------------------------------------------------------------------------------------|---------------------|--------------|

A grouped application comprised of two Type II variations, as follows:

- -Type II (C.I.6): Extension of indication to include the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor for BREYANZI, based on results from the pivotal Study 017001 MCL Cohort (TRANSCEND-NHL-001); this is a Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL). As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package leaflet is updated in accordance. Version 9.1 of the RMP was also submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to the Package Leaflet.
- -Type II (B.II.d.1.e): Change outside the approved specifications limits range

The group of variations leads to amendments to the annex(es) I and IIIB and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the group of variations, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CAT-CHMP by consensus is of the opinion that Breyanzi is not similar to Tecartus within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## 5. EPAR changes

The EPAR will be updated following the Commission Decision for this group of variations. In particular, the 'EPAR-Procedural steps taken and scientific information after authorisation' will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Breyanzi-H-C-4731EMA/VR/0000265024'